Document:

EX-10.2

 Exhibit 10.2 

REATA PHARMACEUTICALS, INC. 

AMENDED AND RESTATED 

2007 LONG TERM INCENTIVE PLAN 

1. Purpose. The purpose of the Reata Pharmaceuticals, Inc. Amended and Restated 2007 Long Term Incentive Plan (the
“Plan”) is to provide a means through which Reata Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and its Subsidiaries may attract and retain able persons as employees, directors and
consultants and to provide a means whereby those persons upon whom the responsibilities of the successful administration and management of the Company, and its Subsidiaries, rest, and whose present and potential contributions to the welfare of the
Company, and its Subsidiaries, are of importance, can acquire and maintain stock ownership, or awards the value of which is tied to the performance of the Company, thereby strengthening their concern for the welfare of the Company, and its
Subsidiaries, and their desire to remain employed. A further purpose of this Plan is to provide such employees, directors and consultants with additional incentive and reward opportunities designed to enhance the profitable growth of the Company.
Accordingly, this Plan primarily provides for the granting of Incentive Stock Options, Nonstatutory Stock Options, Restricted Stock Awards, Restricted Stock Units, Stock Appreciation Rights, Stock Awards, Dividend Equivalents, Other Stock-Based
Awards, Cash Awards, Performance Awards, Substitute Awards or any combination of the foregoing, as is best suited to the circumstances of the particular individual as provided herein. 

2. Definitions. For purposes of this Plan, the following terms shall be defined as set forth below: 

(a) “Affiliate” means any corporation, partnership, limited liability company, limited liability partnership,
association, trust or other organization which, directly or indirectly, controls, is controlled by, or is under common control with, the Company. For purposes of the preceding sentence, “control” (including, with correlative meanings, the
terms “controlled by” and “under common control with”), as used with respect to any entity or organization, shall mean the possession, directly or indirectly, of the power (i) to vote more than 50% of the securities having
ordinary voting power for the election of directors of the controlled entity or organization, or (ii) to direct or cause the direction of the management and policies of the controlled entity or organization, whether through the ownership of
voting securities, by contract, or otherwise. 
 (b) “Award” means any Option, SAR, Restricted Stock Award,
Restricted Stock Unit, Stock Awards, Dividend Equivalent, Other Stock-Based Award, Cash Award, Performance Award or Substitute Award, granted in isolation or combination, together with any other right or interest granted to a Participant under this
Plan. 
 (c) “Award Agreement” means any written instrument (including any employment, severance, or change of
control agreement) that establishes the terms, conditions, restrictions and/or limitations applicable to an Award in addition to those established by this Plan and by the Committee’s exercise of its administrative powers. 

(d) “Board” means the Board of Directors of the Company. 

  
 1 

 (e) “Cash Award” means an Award denominated in cash granted under
Section 6(i) hereof. 
 (f) “Change in Control” means the occurrence of any of the following events: 

(i) A “change in the ownership of the Company” which shall occur on the date that any one person, or more than one person acting as
a group, acquires ownership of stock in the Company that, together with stock held by such person or group, constitutes more than 50% of the total fair market value or total voting power of the stock of the Company; however, if any one person or
more than one person acting as a group is considered to own more than 50% of the total fair market value or total voting power of the stock of the Company, the acquisition of additional stock by the same person or persons will not be considered a
“change in the ownership of the Company” (or to cause a “change in the effective control of the Company” within the meaning of Section 2(f)(ii) below) and an increase of the effective percentage of stock owned by any one
person, or persons acting as a group, as a result of a transaction in which the Company acquires its stock in exchange for property will be treated as an acquisition of stock for purposes of this paragraph; provided, further, however, that for
purposes of this Section 2(f)(i), any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any entity controlled by the Company shall not constitute a Change in Control. This Section 2(f)(i)
applies only when there is a transfer of the stock of the Company (or issuance of stock) and stock in the Company remains outstanding after the transaction. 

(ii) A “change in the effective control of the Company” which shall occur on the date that either (A) any one person, or more
than one person acting as a group, acquires (or has acquired during the twelve month period ending on the date of the most recent acquisition by such person or persons) ownership of stock of the Company possessing 30% or more of the total voting
power of the stock of the Company, except for any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any entity controlled by the Company; or (B) a majority of the members of the Board are
replaced during any twelve-month period by directors whose appointment or election is not endorsed by a majority of the members of the Board prior to the date of the appointment or election. For purposes of a “change in the effective control of
the Company,” if any one person, or more than one person acting as a group, is considered to effectively control the Company within the meaning of this Section 2(f)(ii), the acquisition of additional control of the Company by the same
person or persons is not considered a “change in the effective control of the Company,” or to cause a “change in the ownership of the Company” within the meaning of Section 2(f)(i) above. 

(iii) A “change in the ownership of a substantial portion of the Company’s assets” which shall occur on the date that any one
person, or more than one person acting as a group, acquires (or has acquired during the twelve month period ending on the date of the most recent acquisition by such person or persons) assets of the Company that have a total gross fair market value
equal to or more than 40% of the total gross fair market value of all the assets of the Company immediately prior to such acquisition or acquisitions. For this purpose, gross fair market value means the value of the assets of the Company, or the
value of the assets being disposed of, determined without regard to any liabilities associated with such assets. Any transfer of assets to an entity that is controlled by the stockholders of the Company immediately after the transfer, as provided in
guidance issued pursuant to the Nonqualified Deferred Compensation Rules, shall not constitute a Change in Control. 

  
 2 

 For purposes of this Section 2(f), the provisions of section 318(a) of the Code regarding the constructive
ownership of stock will apply to determine stock ownership; provided, that, stock underlying unvested options (including options exercisable for stock that is not substantially vested) will not be treated as owned by the individual who holds the
option. In addition, for purposes of this Section 2(f) and except as otherwise provided in an Award Agreement, “Company” includes (x) the Company, (y) the entity for whom a Participant performs the services for which an
Award is granted, and (z) an entity that is a stockholder owning more than 50% of the total fair market value and total voting power (a “Majority Stockholder”) of the Company or the entity identified in (y) above, or any entity
in a chain of entities in which each entity is a Majority Stockholder of another entity in the chain, ending in the Company or the entity identified in (y) above. 

(g) “Code” means the United States Internal Revenue Code of 1986, as amended from time to time, including regulations
thereunder and successor provisions and regulations thereto. 
 (h) “Committee” means a committee of two or more
directors designated by the Board to administer this Plan; provided, however, that, unless otherwise determined by the Board, following a Qualifying Public Offering, the Committee shall consist solely of two or more directors, each of
whom shall be a Qualified Member. 
 (i) “Covered Employee” means an Eligible Person who is designated by the
Committee, at the time of grant of a Performance Award, as likely to be a “covered employee” within the meaning of section 162(m) of the Code for a specified fiscal year. 

(j) “Dividend Equivalent” means a right, granted to an Eligible Person under Section 6(g), to receive cash,
Stock, other Awards or other property equal in value to dividends paid with respect to a specified number of shares of Stock, or other periodic payments. 

(k) “Effective Date” of the Plan as amended and restated is September 23, 2015. 

(l) “Eligible Person” means all officers and employees of the Company or of any of its Subsidiaries, and other persons
who provide services to the Company or any of its Subsidiaries, including directors of the Company; provided, that, any such individual must be an “employee” of the Company or any of its parents or subsidiaries within the meaning of
General Instruction A.1(a) to Form S-8 if such individual will be granted an award that shall, or may, be settled in Stock. An employee on leave of absence may be considered as still in the employ of the Company or its Subsidiaries for purposes of
eligibility for participation in this Plan. 
 (m) “Exchange Act” means the Securities Exchange Act of 1934, as
amended from time to time, including rules thereunder and successor provisions and rules thereto. 
 (n) “Fair Market
Value” means, as of any specified date, (i) if the Stock is listed on a national securities exchange, the closing sales price of the Stock, as reported on the 

  
 3 

 
stock exchange composite tape on that date (or if no sales occur on that date, on the last preceding date on which such sales of the Stock are so reported); (ii) if the Stock is not traded
on a national securities exchange but is traded over the counter at the time a determination of its fair market value is required to be made under the Plan, the average between the reported high and low bid and asked prices of Stock on the most
recent date on which Stock was publicly traded; or (iii) in the event Stock is not publicly traded at the time a determination of its value is required to be made under the Plan, the amount determined by the Committee in its discretion in such
manner as it deems appropriate, taking into account all factors the Committee deems appropriate including, without limitation, the Nonqualified Deferred Compensation Rules. 

(o) “Incentive Stock Option” or “ISO” means any Option intended to be and designated as an
incentive stock option within the meaning of section 422 of the Code or any successor provision thereto. 
 (p) “Nonqualified
Deferred Compensation Rules” means the limitations or requirements of section 409A of the Code, as amended from time to time, including the guidance and regulations promulgated thereunder and successor provisions, guidance and
regulations thereto. 
 (q) “Nonstatutory Stock Option” means any Option that is not intended to be an
“incentive stock option” within the meaning of section 422 of the Code. 
 (r) “Option” means a right,
granted to an Eligible Person under Section 6(b) hereof, to purchase Stock or other Awards at a specified price during specified time periods. 

(s) “Other Stock-Based Awards” means Awards granted to an Eligible Person under Section 6(h) hereof. 

(t) “Outstanding Prior Awards” means Options and shares of Restricted Stock granted under the Plan prior to its
amendment and restatement that are outstanding immediately prior to the Effective Date. 
 (u) “Participant” means a
person who has been granted an Award under this Plan that remains outstanding, including a person who is no longer an Eligible Person. 

(v) “Performance Award” means a right, granted to an Eligible Person under Section 6(k) hereof, to receive Awards
based upon performance criteria specified by the Committee. 
 (w) “Person” means any person or entity of any nature
whatsoever, specifically including an individual, a firm, a company, a corporation, a partnership, a limited liability company, a trust or other entity; a Person, together with that Person’s Affiliates and Associates (as those terms are defined
in Rule 12b-2 under the Exchange Act, provided that “registrant” as used in Rule 12b-2 shall mean the Company), and any Persons acting as a partnership, limited partnership, joint venture, association, syndicate or other group (whether or
not formally organized), or otherwise acting jointly or in concert or in a coordinated or consciously parallel manner (whether or not pursuant to any express agreement), for the purpose of acquiring, holding, voting or disposing of securities of the
Company with such Person, shall be deemed a single “Person.” 

  
 4 

 (x) “Qualified Member” means a member of the Committee who is (i) a
“Non-Employee Director” within the meaning of Rule 16b-3(b)(3), (ii) following expiration of the Transition Period (as defined below), an “outside director” within the meaning of Treasury Regulation 1.162-27 under section
162(m) of the Code, and (iii) “independent” under the listing standards or rules of the securities exchange upon which the Stock is traded, but only to the extent such independence is required in order to take the action at issue
pursuant to such standards or rules. 
 (y) “Qualifying Public Offering” shall mean the first firm commitment
underwritten public offering of Stock for cash where the shares of Stock registered under the Securities Act are listed on a national securities exchange. 

(z) “Restricted Stock” means Stock granted to an Eligible Person under Section 6(d) hereof, that is subject to
certain restrictions and to a risk of forfeiture. 
 (aa) “Restricted Stock Unit” means a right, granted to an
Eligible Person under Section 6(e) hereof, to receive Stock, cash or a combination thereof at the end of a specified deferral period. 

(bb) “Rule 16b-3” means Rule 16b-3, promulgated by the Securities and Exchange Commission under section 16 of the
Exchange Act, as amended from time to time and applicable to this Plan and Participants. 
 (cc) “Section 162(m)
Award” means a Performance Award granted under Section 6(k)(i) hereof to a Covered Employee that is intended to satisfy the requirements for “performance-based compensation” within the meaning of section 162(m) of the
Code. 
 (dd) “Securities Act” means the Securities Act of 1933 and the rules and regulations promulgated
thereunder, or any successor law, as it may be amended from time to time. 
 (ee) “Stock” means the Company’s
Common Stock, par value $0.001 per share, such other securities as may be substituted (or re-substituted) for Stock pursuant to Section 8, and, if the Company has more than one class of Common Stock, then shares of any such class of Common
Stock as the Committee may designate with respect to any Award. 
 (ff) “Stock Award” means unrestricted shares of
Stock granted to an Eligible Person under Section 6(f) hereof. 
 (gg) “Stock Appreciation Rights” or
“SAR” means a right granted to an Eligible Person under Section 6(c) hereof. 
 (hh)
“Subsidiary” means with respect to the Company, any corporation or other entity of which a majority of the voting power of the voting equity securities or equity interest is owned, directly or indirectly, by the Company. 

  
 5 

 (ii) “Substitute Award” means an Award granted under Section 6(j)
hereof in substitution for a similar award as a result of certain business transactions. 
 3. Administration. 

(a) Authority of the Committee. The Plan shall be administered by the Committee except to the extent the Board elects to administer the
Plan, in which case references herein to the “Committee” shall be deemed to include references to the “Board.” Subject to the express provisions of the Plan, Rule 16b-3, if applicable, and other applicable laws, the Committee
shall have the authority, in its sole and absolute discretion, to: (i) designate Eligible Persons as Participants; (ii) determine the type or types of Awards to be granted to an Eligible Person; (iii) determine the number of shares of
Stock or amount of cash to be covered by Awards; (iv) determine the terms and conditions of any Award, consistent with the terms of the Plan, as well as the modification of such terms, which may include the acceleration of vesting, waiver of
forfeiture restrictions, modification of the form of settlement of the Award (for example, from cash to Stock or vice versa), or modification of any other condition or limitation regarding an Award, based on such factors as the Committee shall
determine, in its sole discretion; (v) determine whether, to what extent, and under what circumstances Awards may be vested, settled, exercised, canceled, or forfeited; (vi) interpret and administer the Plan and any instrument or agreement
relating to an Award made under the Plan; (vii) establish, amend, suspend, or waive rules and regulations used to administer the Plan; and (viii) make any other determination and take any other action that the Committee deems necessary or
desirable for the administration of the Plan. Subject to Rule 16b-3, section 162(m) of the Code, and the Nonqualified Deferred Compensation Rules, in each case, as applicable, the Committee may correct any defect, supply any omission, or reconcile
any inconsistency in the Plan, in any Award, or in any Award Agreement in the manner and to the extent it deems necessary or desirable to carry the Plan into effect, and the Committee shall be the sole and final judge of that necessity or
desirability. Notwithstanding the foregoing, the Committee shall not have any discretion to (A) accelerate, waive or modify any term or condition of an Award that is intended to qualify as “performance-based compensation” for purposes
of section 162(m) of the Code if such discretion would cause the Award to not so qualify, (B) accelerate the payment of any Award that provides for a deferral of compensation under the Nonqualified Deferred Compensation Rules if such
acceleration would subject a Participant to additional taxes under the Nonqualified Deferred Compensation Rules, or (C) take any action that would violate any applicable law. The express grant of any specific power to the Committee, and the
taking of any action by the Committee, shall not be construed as limiting any power or authority of the Committee. The determinations of the Committee on the matters referred to in this Section 3(a) shall be final and conclusive. 

(b) Manner of Exercise of Committee Authority. It is the intent of the Company that (i) Section 162(m) Awards shall qualify
as “performance-based compensation” within the meaning of section 162(m) of the Code and (ii) to the fullest extent possible, the grant of any Awards to, or other transaction by, a Participant who is subject to section 16 of the
Exchange Act shall be exempt from such section pursuant to an applicable exemption (except for transactions acknowledged in writing to be non-exempt by such Participant). Following a Qualifying Public Offering, at any time that a member of the
Committee is not a Qualified Member, any action of the Committee relating to (A) an Award granted or to be granted to an Eligible Person who is then subject to section 16 of the Exchange Act in respect of the Company

  
 6 

 
where such action is not taken by the full Board, or (B) a Section 162(m) Award, may be taken either (i) by a subcommittee, designated by the Committee, composed solely of two or
more Qualified Members, or (ii) by the Committee but with each such member who is not a Qualified Member abstaining or recusing himself or herself from such action; provided, however, that, upon such abstention or recusal, the
Committee remains composed solely of two or more Qualified Members. Such action, authorized by such a subcommittee or by the Committee upon the abstention or recusal of such non-Qualified Member(s), shall be the action of the Committee for purposes
of this Plan. Any action of the Committee shall be final, conclusive and binding on all Persons, including the Company, its Subsidiaries, stockholders, Participants, beneficiaries, and transferees under Section 7(a)(iii) and (iv) hereof or
other Persons claiming rights from or through a Participant. For the avoidance of doubt, following a Qualifying Public Offering, the full Board may take any action relating to an Award granted or to be granted to an Eligible Person who is then
subject to section 16 of the Exchange Act in respect of the Company, provided that such award is not a Section 162(m) Award. 
 (c)
Delegation of Authority. The Committee may delegate (A) to any officer of the Company, irrespective of whether or not the officer is also a member of the Board, the power to perform administrative functions and grant all types of Awards
under the Plan so long as the resolutions of the Board or Committee delegating such authority specifies (1) the total number of Awards that the officer may grant, and (2) with respect to Awards of Restricted Stock or Stock Awards, the time
period during which such Awards may be granted and a minimum amount of consideration for which the Awards may be issued and (B) to any individual member of the Board (including an officer of the Company that serves as a member of the Board),
any or all of the Committee’s powers and duties under the Plan, including the power to perform administrative functions and grant all types of Awards under the Plan, in the case of both (A) and (B), subject to such additional terms or
limitations as the Committee shall provide and only to the extent that such delegation will not (i) violate state or corporate law, (ii) following a Qualifying Public Offering, result in the loss of an exemption under Rule 16b-3(d)(1) for
Awards granted to Participants subject to section 16 of the Exchange Act in respect of the Company, or (iii) following a Qualifying Public Offering, cause Section 162(m) Awards to fail to so qualify. Upon any such delegation, all
references in the Plan to the “Committee,” other than in Section 8, shall be deemed to include any officer of the Company or member of the Board to whom such powers have been delegated by the Committee. Any such delegation shall not
limit such officer or director’s right to receive Awards under the Plan; provided, however, the officer or director may not grant Awards to himself or herself, a member of the Board, or any executive officer of the Company or an
Affiliate, or take any action with respect to any Award previously granted to himself or herself, a member of the Board, or an individual who is an executive officer of the Company or an Affiliate. The Committee may also appoint agents to assist it
in administering the Plan that are not executive officers of the Company or members of the Board, provided that such individuals may not be delegated the authority to (i) grant or modify any Awards that will, or may, be settled in Stock or
(ii) take any action that would cause Section 162(m) Awards to fail to so qualify, if applicable. 
 (d) Limitation of
Liability. The Committee and each member thereof shall be entitled to, in good faith, rely or act upon any report or other information furnished to him or her by any officer or employee of the Company or any of its Subsidiaries, the
Company’s legal counsel, independent auditors, consultants or any other agents assisting in the administration of this Plan. Members of the Committee and any officer or employee of the Company or any of its Subsidiaries

  
 7 

 
acting at the direction or on behalf of the Committee shall not be personally liable for any action or determination taken or made in good faith with respect to this Plan, and shall, to the
fullest extent permitted by law, be indemnified and held harmless by the Company with respect to any such action or determination. 
 (e)
Participants in Non-U.S. Jurisdictions. Notwithstanding any provision of the Plan to the contrary, to comply with applicable laws in countries other than the United States in which the Company or any of its Affiliates operates or has
employees, directors or other service providers from time to time, or to ensure that the Company complies with any applicable requirements of foreign securities exchanges, the Committee, in its sole discretion, shall have the power and authority to:
(i) determine which of its Affiliates shall be covered by the Plan; (ii) determine which Eligible Persons outside the United States are eligible to participate in the Plan; (iii) modify the terms and conditions of any Award granted to
Eligible Persons outside the United States to comply with applicable foreign laws or listing requirements of any foreign exchange; (iv) establish sub-plans and modify exercise procedures and other terms and procedures, to the extent such
actions may be necessary or advisable (any such sub-plans and/or modifications shall be attached to the Plan as appendices), provided, however, that no such sub-plans and/or modifications shall increase the share limitations contained
in Section 4(a); and (v) take any action, before or after an Award is granted, that it deems advisable to comply with any applicable governmental regulatory exemptions or approval or listing requirements of any such foreign securities
exchange. For purposes of the Plan, all references to foreign laws, rules, regulations or taxes shall be references to the laws, rules, regulations and taxes of any applicable jurisdiction other than the United States or a political subdivision
thereof. 
 4. Stock Subject to Plan. 

(a) Overall Number of Shares Available for Delivery. Subject to adjustment in a manner consistent with any adjustment made pursuant to
Section 8, the total number of shares of Stock reserved and available for issuance in connection with Awards under this Plan as of the Effective Date shall be 17,600,000 shares (“the Share Pool”); provided, however, that the shares of
Stock reserved and available for issuance in connection with Awards under this Plan shall be available for issuance only in connection with shares of Stock issued in connection with Outstanding Prior Awards and shares of Stock issued in connection
with Awards granted on or after the Effective Date. On January 1 of 2017 and January 1 of each calendar year occurring thereafter and prior to the expiration of the Plan, the Share Pool will automatically be increased by an amount equal to
three percent (3%) of the number of shares of Stock outstanding on a fully diluted basis as of the close of business on the immediately preceding December 31 (calculated by adding to the number of shares of Stock outstanding (of all
classes of Common Stock), all outstanding securities convertible into Stock (of all classes of Common Stock) on such date on an as converted basis). Notwithstanding the foregoing, the Committee may act prior to January 1 of a given year to
provide that there will be no such automatic increase in the Share Pool for such year or that the increase in the Share Pool for such year will be lesser number of shares of Stock than would otherwise occur pursuant to the preceding sentence, For
purposes of clarity, the only shares of Stock that will count against the share limit calculated pursuant to this Section 4(a) are shares of Stock issued in connection with Awards granted on or after the Effective Date and shares of Stock
issued in connection with Outstanding Prior Awards. Notwithstanding the number of shares of Stock available in the Share Pool, no more than 17,600,000 shares of Stock will be available for issuance in connection with Incentive Stock Options under
the Plan. 

  
 8 

 (b) Application of Limitation to Grants of Awards. Subject to Section 4(c), no Award
may be granted if the number of shares of Stock to be delivered in connection with such Award exceeds the number of shares of Stock remaining available under this Plan and not subject to Awards. The Committee may adopt reasonable counting procedures
to ensure appropriate counting, avoid double counting (as, for example, in the case of tandem or Substitute Awards) and make adjustments if the number of shares of Stock actually delivered differs from the number of shares previously counted in
connection with an Award. 
 (c) Availability of Shares Not Issued under Awards. Shares of Stock subject to an Award under this Plan
(including any Outstanding Prior Award) that expires or is canceled, forfeited, exchanged, settled in cash or otherwise terminated, including (i) shares forfeited with respect to Restricted Stock, and (ii) the number of shares withheld or
surrendered to the Company in payment of any exercise or purchase price of an Award or taxes relating to Awards, will again be deemed reserved and available for issuance under this Plan, except that if any such shares could not again be available
for Awards to a particular Participant under any applicable law or regulation, such shares shall be available exclusively for Awards to Participants who are not subject to such limitation. 

(d) Stock Offered. The shares to be delivered under the Plan shall be made available from (i) authorized but unissued shares of
Stock, (ii) Stock held in the treasury of the Company, or (iii) previously issued shares of Stock reacquired by the Company, including shares purchased on the open market. 

5. Eligibility; Per Person Award Limitations. Awards may be granted under this Plan only to Persons who are Eligible Persons at the
time of grant thereof. Following a Qualifying Public Offering, in each calendar year during any part of which this Plan is in effect and the Transition Period expires or has previously expired, a Covered Employee may not be granted (a) Awards
(other than Awards designated to be paid only in cash or the settlement of which is not based on a number of shares of Stock) relating to more than 1,000,000 shares of Stock, subject to adjustment in a manner consistent with any adjustment made
pursuant to Section 8 or (b) Awards designated to be paid only in cash, or the settlement of which is not based on a number of shares of Stock, having a value determined on the date of grant in excess of $20,000,000; in each case,
multiplied by the number of full or partial calendar years in any performance period established with respect to the Award, if applicable. In each calendar year during any part of which this Plan is in effect, an Eligible Person who is serving as a
member of the Board and who is not an employee of the Company may not be granted Awards having a value, determined, if applicable, pursuant to Financial Accounting Standards Board Accounting Standards Codification Topic 718, on the date of grant in
excess of $1,000,000 multiplied by the number of full or partial calendar years in any performance period established with respect to an Award, if applicable. 

6. Specific Terms of Awards. 

(a) General. Awards may be granted on the terms and conditions set forth in this Section 6. Awards granted under this Plan may, in
the discretion of the Committee, be granted 

  
 9 

 
either alone, in addition to, or in tandem with any other Award. In addition, the Committee may impose on any Award or the exercise thereof, at the date of grant or thereafter (subject to
Section 8(a)), such additional terms and conditions, not inconsistent with the provisions of this Plan, as the Committee shall determine. The Committee may provide in an Award Agreement terms and conditions that are more beneficial to a
Participant than are otherwise provided by the Plan if the Committee determines that such terms and conditions (i) are not expressly prohibited by the Plan, (ii) will not prevent the qualification of a Section 162(m) Award as
“performance-based compensation” within the meaning of section 162(m) of the Code, (iii) will not invalidate an exemption from section 16 of the Exchange Act with respect to the grant, settlement or exercise of an Award,
(iv) will not subject a Participant to additional taxes under the Nonqualified Deferred Compensation Rules, (v) will not prevent the qualification of an Incentive Stock Option as such within the meaning of section 422 of the Code, and
(vi) will neither violate nor require stockholder approval under any applicable law or the standards or rules of the securities exchange upon which the Stock is traded. Further, notwithstanding any provision of the Plan or an Award Agreement, a
Participant can consent to terms under or with respect to an Award or the Stock issuable pursuant to an Award that are less beneficial to the Participant than the terms of the Plan or an Award Agreement. 

(b) Options. The Committee is authorized to grant Options, which may be designated as either ISOs or Nonstatutory Stock Options, to
Eligible Persons on the following terms and conditions: 
 (i) Exercise Price. Each Award Agreement evidencing an Option shall state
the exercise price per share of Stock (the “Exercise Price”); provided, however, that, except as provided in Section 6(j), the Exercise Price per share of Stock subject to an Option shall not be less than
the greater of (A) the par value per share of the Stock or (B) 100% of the Fair Market Value per share of the Stock as of the date of grant of the Option (or in the case of an ISO granted to an individual who owns stock possessing more
than 10% of the total combined voting power of all classes of stock of the Company or its parent or any Subsidiary, 110% of the Fair Market Value per share of the Stock on the date of grant). 

(ii) Time and Method of Exercise. The Committee shall determine the time or times at which or the circumstances under which an Option
may be exercised in whole or in part (including based on achievement of performance goals pursuant to Section 6(k) hereof and/or future service requirements), the methods by which such Exercise Price may be paid or deemed to be paid, the form
of such payment, including without limitation, cash or cash equivalents, Stock (including previously owned shares or through a cashless or broker-assisted exercise or other reduction of the amount of shares otherwise issuable pursuant to the
Option), other Awards or awards granted under other plans of the Company or any Subsidiary, other property, or any other legal consideration the Committee deems appropriate (including notes or other contractual obligations of Participants to make
payment on a deferred basis), and the methods by or forms in which Stock will be delivered or deemed to be delivered to Participants, including, but not limited to, the delivery of Restricted Stock subject to Section 6(d). In the case of an
exercise whereby the Exercise Price is paid with Stock, such Stock shall be valued as of the date of exercise. No Option may be exercisable for a period of more than ten (10) years following the date of grant of the Option (or in the case of an
ISO granted to an individual who owns stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or its parent or any Subsidiary, for a period of no more than five (5) years following the date of
grant of the ISO). 

  
 10 

 (iii) ISOs. The terms of any ISO granted under this Plan shall comply in all respects
with the provisions of section 422 of the Code. ISOs may only be granted to Eligible Persons who are employees of the Company or employees of a parent or Subsidiary corporation of the Company. Except as otherwise provided in Section 8, no term
of this Plan relating to ISOs (including any SAR in tandem therewith) shall be interpreted, amended or altered, nor shall any discretion or authority granted under this Plan be exercised, so as to disqualify either this Plan or any ISO under section
422 of the Code, unless the Participant has first requested the change that will result in such disqualification. ISOs shall not be granted more than ten years after the earlier of the adoption of this Plan or the approval of this Plan by the
Company’s stockholders. Notwithstanding the foregoing, the Fair Market Value of shares of Stock subject to an ISO and the aggregate Fair Market Value of shares of stock of any parent or subsidiary corporation (within the meaning of sections
424(e) and (f) of the Code) subject to any other ISO (within the meaning of section 422 of the Code) of the Company or a parent or subsidiary corporation (within the meaning of sections 424(e) and (f) of the Code) that first becomes
purchasable by a Participant in any calendar year may not (with respect to that Participant) exceed $100,000, or such other amount as may be prescribed under section 422 of the Code or applicable regulations or rulings from time to time. As used in
the previous sentence, Fair Market Value shall be determined as of the date the ISOs are granted. Failure to comply with this provision shall not impair the enforceability or exercisability of any Option, but shall cause the excess amount of shares
to be reclassified in accordance with the Code. 
 (c) Stock Appreciation Rights. The Committee is authorized to grant SARs to
Eligible Persons on the following terms and conditions: 
 (i) Right to Payment. An SAR shall confer on the Participant to whom it
is granted a right to receive, upon exercise thereof, the excess of (A) the Fair Market Value of one share of Stock on the date of exercise over (B) the grant price of the SAR as determined by the Committee. 

(ii) Grant Price. Each Award Agreement evidencing an SAR shall state the grant price per share of Stock; provided,
however, that the grant price per share of Stock subject to an SAR shall not be less than the greater of (A) the par value per share of the Stock or (B) 100% of the Fair Market Value per share of the Stock as of the date of grant of
the SAR. 
 (iii) Time and Method of Exercise and Settlement. Except as otherwise provided herein, the Committee shall determine, at
the date of grant or thereafter, the number of shares of Stock to which the SAR relates, the time or times at which and the circumstances under which an SAR may be vested and/or exercised in whole or in part (including based on achievement of
performance goals pursuant to Section 6(k) hereof and/or future service requirements), the method of exercise, method of settlement, form of consideration payable upon settlement, method by or forms in which Stock (if any) will be delivered to
Participants, and any other terms and conditions of any SAR. SARs may be either free-standing or in tandem with other Awards. No SAR may be exercisable for a period of more than ten (10) years following the date of grant of the SAR. 

  
 11 

 (iv) Rights Related to Options. An SAR granted in connection with an Option shall entitle
a Participant, upon exercise, to surrender that Option or any portion thereof, to the extent unexercised, and to receive payment of an amount determined by multiplying (A) the difference obtained by subtracting the Exercise Price with respect
to a share of Stock specified in the related Option from the Fair Market Value of a share of Stock on the date of exercise of the SAR, by (B) the number of shares as to which that SAR has been exercised. The Option shall then cease to be
exercisable to the extent surrendered. SARs granted in connection with an Option shall be subject to the terms and conditions of the Award Agreement governing the Option, which shall provide that the SAR is exercisable only at such time or times and
only to the extent that the related Option is exercisable and shall not be transferable except to the extent that the related Option is transferrable. 

(d) Restricted Stock. The Committee is authorized to grant Restricted Stock to Eligible Persons on the following terms and conditions:

 (i) Grant and Restrictions. Restricted Stock shall be subject to such restrictions on transferability, risk of forfeiture and
other restrictions, if any, as the Committee may impose, which restrictions may lapse separately or in combination at such times, under such circumstances (including based on achievement of performance goals pursuant to Section 6(k) hereof
and/or future service requirements), in such installments or otherwise, as the Committee may determine at the date of grant or thereafter. During the restricted period applicable to the Restricted Stock, the Restricted Stock may not be sold,
transferred, pledged, hypothecated, margined or otherwise encumbered by the Participant. 
 (ii) Dividends and Splits. As a
condition to the grant of an Award of Restricted Stock, the Committee may allow a Participant to elect, or may require, that any cash dividends paid on a share of Restricted Stock be automatically reinvested in additional shares of Restricted Stock,
applied to the purchase of additional Awards under this Plan or deferred without interest to the date of vesting of the associated Award of Restricted Stock; provided, that, to the extent applicable, any such election is intended to comply
with the Nonqualified Deferred Compensation Rules. Unless otherwise determined by the Committee and specified in the applicable Award Agreement, Stock distributed in connection with a Stock split or Stock dividend, and other property (other than
cash) distributed as a dividend, shall be subject to restrictions and a risk of forfeiture to the same extent as the Restricted Stock with respect to which such Stock or other property has been distributed. 

(e) Restricted Stock Units. The Committee is authorized to grant Restricted Stock Units to Eligible Persons, subject to the following
terms and conditions: 
 (i) Award and Restrictions. Restricted Stock Units shall be subject to such restrictions (which may include
a risk of forfeiture) as the Committee may impose, if any, which restrictions may lapse at the expiration of the deferral period or at earlier specified times (including based on achievement of performance goals and/or future service requirements),
separately or in combination, in installments or otherwise, as the Committee may determine. 
 (ii) Settlement. Settlement of
Restricted Stock Units shall occur upon expiration of the deferral period specified for such Restricted Stock Unit by the Committee (or, if 

  
 12 

 
permitted by the Committee, as elected by the Participant). Restricted Stock Units shall be satisfied by the delivery of (A) a number of shares of Stock equal to the number of RSUs vesting
on such date, or (B) cash in an amount equal to the Fair Market Value of the specified number of shares of Stock covered by the vesting Restricted Stock Units, or a combination thereof, as determined by the Committee at the date of grant or
thereafter. 
 (f) Stock Awards. The Committee is authorized to grant a Stock Award under the Plan to any Eligible Person as a bonus,
as additional compensation, or in lieu of cash compensation the individual is otherwise entitled to receive, in such amounts and subject to such other terms as the Committee in its discretion determines to be appropriate. 

(g) Dividend Equivalents. The Committee is authorized to grant Dividend Equivalents to an Eligible Person, entitling the Eligible
Person to receive cash, Stock, other Awards, or other property equal in value to dividends or other distributions paid with respect to a specified number of shares of Stock, or other periodic payments. Dividend Equivalents may be awarded on a
free-standing basis or in connection with another Award (other than an Award of Restricted Stock or a Stock Award). The Committee may provide that Dividend Equivalents shall be paid or distributed when accrued or at a later specified date, and if
distributed at a later date may be deemed to have been reinvested in additional Stock, Awards, or other investment vehicles or accrued in a bookkeeping account without interest, and subject to such restrictions on transferability and risks of
forfeiture, as the Committee may specify. With respect to Dividend Equivalents granted in connection with another Award, absent a contrary provision in the Award Agreement, such Dividend Equivalents shall be subject to the same restrictions and risk
of forfeiture as the Award with respect to which the dividends accrue and shall not be paid unless and until such Award has vested and been earned. Notwithstanding the foregoing, Dividend Equivalents shall only be paid in a manner that is either
exempt from or in compliance with the Nonqualified Deferred Compensation Rules. 
 (h) Other Stock-Based Awards. The Committee is
authorized, subject to limitations under applicable law, to grant to Eligible Persons such other Awards that may be denominated or payable in, valued in whole or in part by reference to, or otherwise based on, or related to, Stock, as deemed by the
Committee to be consistent with the purposes of this Plan, including without limitation convertible or exchangeable debt securities, other rights convertible or exchangeable into Stock, purchase rights for Stock, Awards with value and payment
contingent upon performance of the Company or any other factors designated by the Committee, and Awards valued by reference to the book value of Stock or the value of securities of or the performance of specified Subsidiaries of the Company. The
Committee shall determine the terms and conditions of such Other Stock-Based Awards. Stock delivered pursuant to an Other-Stock Based Award in the nature of a purchase right granted under this Section 6(h) shall be purchased for such
consideration, paid for at such times, by such methods, and in such forms, including, without limitation, cash, Stock, other Awards, or other property, as the Committee shall determine. 

(i) Cash Awards. The Committee is authorized to grant Cash Awards, on a free-standing basis or as an element of or supplement to, or in
lieu of, any other Award under this Plan to Eligible Persons in such amounts and subject to such other terms (including the achievement of performance goals pursuant to Section 6(k) hereof and/or future service requirements) as the Committee in
its discretion determines to be appropriate. 

  
 13 

 (j) Substitute Awards; No Repricing. Awards may be granted in substitution or exchange for
any other Award granted under the Plan or under another plan of the Company or any other right of an Eligible Person to receive payment from the Company. Awards may be also be granted under the Plan in substitution for similar awards held by
individuals who become Eligible Persons as a result of a merger, consolidation or acquisition of another entity or the assets of another entity by or with the Company or an Affiliate of the Company. Such Substitute Awards referred to in the
immediately preceding sentence that are Options or Stock Appreciation Rights may have an exercise price that is less than the Fair Market Value of a share of Stock on the date of the substitution if such substitution complies with the Nonqualified
Deferred Compensation Rules and other applicable laws and exchange rules. Except as provided in this Section 6(j) or in Section 8 hereof, the terms of outstanding Awards may not be amended to reduce the Exercise Price or grant price of
outstanding Options or SARs or to cancel outstanding Options and SARs in exchange for cash, other Awards or Options or SARs with an Exercise Price or grant price that is less than the Exercise Price or grant price of the original Options or SARs
without the approval of the stockholders of the Company. 
 (k) Performance Awards. The Committee is authorized to designate any of
the Awards granted under the foregoing provisions of this Section 6 as Performance Awards. The Committee may use such business criteria and other measures of performance as it may deem appropriate in establishing any performance conditions
applicable to a Performance Award, and may exercise its discretion to reduce or increase the amounts payable under any Performance Award, except as limited under Section 6(k)(i) hereof in the case of a Section 162(m) Award. Performance
conditions may differ for Performance Awards granted to any one Participant or to different Participants. The performance period applicable to any Performance Award shall be set by the Committee in its discretion but shall not exceed ten years. 

(i) Section 162(m) Awards. If the Committee determines that a Performance Award granted to a Covered Employee is intended to
qualify as a Section 162(m) Award, the grant, exercise, vesting and/or settlement of such Performance Award shall be contingent upon achievement of a pre-established performance goal or goals and other terms set forth in this
Section 6(k)(i); provided, however, that nothing in this Section 6(k) or elsewhere in the Plan shall be interpreted as preventing the Committee from granting Awards to Covered Employees that are not intended to constitute
Section 162(m) Awards or from determining that it is no longer necessary or appropriate for a Section 162(m) Award to qualify as such. 

(A) Performance Goals Generally. The performance goals for Section 162(m) Awards shall consist of one or more business criteria
and a targeted level or levels of performance with respect to each of such criteria as specified by the Committee. Performance goals shall be objective and shall otherwise meet the requirements of section 162(m) of the Code and regulations
thereunder (including Treasury Regulation §1.162-27 and successor regulations thereto), including the requirement that the level or levels of performance targeted by the Committee must be “substantially uncertain” at the time the
Committee actually establishes the performance goal or goals. 

  
 14 

 (B) Performance Criteria. 

(1) Business Criteria. One or more of the following business criteria for the Company, on a consolidated basis, and/or for specified
Subsidiaries or business or geographical units of the Company (except with respect to the total stockholder return and earnings per share criteria), shall be used by the Committee in establishing performance goals for Section 162(m) Awards:
(1) earnings (including earnings per share and net earnings); (2) earnings before interest, taxes, and depreciation; (3) earnings before interest, taxes, depreciation, and amortization; (4) earnings before interest, taxes,
depreciation, amortization, and legal settlements; (5) earnings before interest, taxes, depreciation, amortization, legal settlements, and other income (expense); (6) earnings before interest, taxes, depreciation, amortization, legal
settlements, other income (expense), and stock-based compensation; (7) earnings before interest, taxes, depreciation, amortization, legal settlements, other income (expense), stock-based compensation, and changes in deferred revenue;
(8) total stockholder return; (9) return on equity or average stockholder’s equity; (10) return on assets, investment, or capital employed; (11) Stock price; (12) margin (including gross margin); (13) income
(before or after taxes); (14) operating income; (15) operating income after taxes; (16) pre-tax profit; (17) operating cash flow; (18) sales or revenue targets; (19) increases in revenue or product revenue;
(20) expenses, cost reduction, and balance sheet goals; (21) improvement in or attainment of working capital levels; (22) economic value added (or an equivalent metric); (23) debt or equity financings; (24) market share;
(25) cash flow; (26) cash flow per share of Stock; (27) share price performance of the Stock; (28) debt reduction; (29) implementation or completion of projects or processes; (30) employee retention;
(31) stockholders’ equity; (32) capital expenditures; (33) debt levels; (34) operating profit or net operating profit; (35) workforce diversity; (36) growth of net income or operating income; (37) billings;
(38) bookings; (39) clinical development milestones such as obtaining effective or optimal dose, achieving proof of concept, and initiation of phases of clinical studies and studies by specified dates; (40) timely completion of
clinical studies; (41) patient enrollment rates; (42) budget management; (43) regulatory body approval (including, but not limited to the U.S. Food and Drug Administration) with respect to an applicable filing, products, studies, and
studies; (44) commercial launch of products; (45) regulatory milestones; (46) progress of internal research or development programs, including, but not limited to, advancing new molecules out of discovery and into early toxicology and
selecting and creating strategy for new indications for a product or the life cycle of a class of products; (47) progress of partnered programs; (48) partner satisfaction; (49) submission of 510(k)s or pre-market approvals and other
regulatory achievements; (50) milestones related to samples received and tests or panels run; (51) strategic partnerships or transactions (including in-licensing and out-licensing of intellectual property); (52) geographic business
expansion; (53) corporate development (including, without limitation, licenses, innovation, research or establishment of third party collaborations); (54) manufacturing or process development; (55) legal compliance or risk reduction;
(56) patent application or issuance goals; (57) goals relating to acquisitions or divestitures (in whole or in part), joint ventures or strategic alliances; and (58) any of the above goals determined pre-tax or post-tax, on an
absolute or relative basis, as a ratio with other business criteria, or as compared to the performance of a published or special index deemed applicable by the Committee including, but not limited to, the Standard & Poor’s 500 Stock
Index or a group of comparable companies. The terms above are used as applied under generally accepted accounting principles, as applicable. 

(2) Effect of Certain Events. The Committee may, at the time the performance goals in respect of a Section 162(m) Award are
established, provide for the manner in which actual performance and performance goals with regard to the business criteria 

  
 15 

 
selected will reflect the impact of specified events during the relevant performance period, which may mean excluding the impact of any or all of the following events or occurrences for such
performance period: (a) asset write-downs or impairments to assets; (b) litigation, claims, judgments or settlements; (c) the effect of changes in tax law or other such laws or regulations affecting reported results; (d) accruals
for reorganization and restructuring programs; (e) any unusual or infrequent items as described in the Accounting Standards Codification Topic 225, as amended by Accounting Standards Update 2015-01, and as the same may be further amended or
superseded from time to time; (f) any change in accounting principles as defined in the Accounting Standards Codification Topic 250, as the same may be amended or superseded from time to time; (g) any loss from a discontinued operation as
described in the Accounting Standards Codification Topic 360, as the same may be amended or superseded from time to time; (h) goodwill impairment charges; (i) operating results for any business acquired during the calendar year;
(j) third party expenses associated with any investment or acquisition by the Company or any Subsidiary; (k) any amounts accrued by the Company or its Subsidiaries pursuant to management bonus plans or cash profit sharing plans and related
employer payroll taxes for the fiscal year; (l) any discretionary or matching contributions made to a savings and deferred profit-sharing plan or deferred compensation plan for the fiscal year; (m) interest, expenses, taxes, depreciation
and depletion, amortization and accretion charges; (n) marked-to-market adjustments for financial instruments; and (o) changes in business strategy impacting timing and magnitude of financial operating goals, including, but not limited to,
expenses, operating cash flow, and balance sheet goals. In addition, Section 162(m) Awards may be adjusted by the Committee in accordance with the provisions of Section 8(b) through 8(h) of the Plan. The adjustments described in this
paragraph shall only be made, in each case, to the extent that such adjustments in respect of a Section 162(m) Award would not cause the Award to fail to qualify as “performance-based compensation” under section 162(m) of the Code.

 (C) Timing for Establishing Performance Goals. No later than 90 days after the beginning of any performance period applicable to
a Section 162(m) Award, or at such other date as may be required or permitted for “performance-based compensation” under section 162(m) of the Code, the Committee shall establish (i) the Eligible Persons who will be granted
Section 162(m) Awards, and (ii) the objective formula used to calculate the amount of cash or stock payable, if any, under such Section 162(m) Awards, based upon the level of achievement of a performance goal or goals with respect to
one or more of the business criteria selected by the Committee from the list set forth in Section 6(k)(i)(B) hereof. 
 (D)
Performance Award Pool. The Committee may establish an unfunded pool, with the amount of such pool calculated using an objective formula based upon the level of achievement of a performance goal or goals with respect to one or more of the
business criteria selected from the list set forth in Section 6(k)(i)(B) hereof during the given performance period, as specified by the Committee in accordance with Section 6(k)(i)(C) hereof. The Committee may specify the amount of the
pool as a percentage of any of such business criteria, a percentage in excess of a threshold amount with respect to such business criteria, or as another amount which need not bear a direct relationship to such business criteria but shall be
objectively determinable and calculated based upon the level of achievement of pre-established goals with regard to the business criteria. 

  
 16 

 (E) Settlement or Payout of Awards; Other Terms. Except as otherwise
permitted under section 162(m) of the Code, after the end of each performance period and before any Section 162(m) Award is settled or paid, the Committee shall certify the level of performance achieved with regard to each business
criteria established with respect to each Section 162(m) Award and shall determine the amount of cash or Stock, if any, payable to each Participant with respect to each Section 162(m) Award. The Committee may, in its discretion, reduce the amount of
a payment or settlement otherwise to be made in connection with a Section 162(m) Award, but may not exercise discretion to increase any such amount payable to a Covered Employee in respect of a Section 162(m) Award. 

(F) Written Determinations. With respect to each Section 162(m) Award, all determinations by the Committee as to (A) the
establishment of performance goals and performance period with respect to the selected business criteria, (B) the establishment of the objective formula used to calculate the amount of cash or stock payable, if any, based on the level of
achievement of such performance goals, and (C) the certification of the level of performance achieved during the performance period with regard to each business criteria selected, shall each be made in writing. Consistent with the terms of
Section 3(b) hereof, when taking any action with respect to Section 162(m) Awards, the Committee shall be made up entirely of Qualified Members. Further, the Committee may not delegate any responsibility relating to a Section 162(m)
Award that would cause the Award to fail to so qualify. 
 (G) Options and SARs. Notwithstanding the foregoing provisions of this
Section 6(k)(i), Options and SARs with an Exercise Price or grant price not less than the Fair Market Value on the date of grant awarded to Covered Employees are intended to be Section 162(m) Awards even if not otherwise contingent upon
achievement of a pre-established performance goal or goals with respect to the business criteria listed above. 
 (ii) Status of
Section 162(m) Awards. The terms governing Section 162(m) Awards shall be interpreted in a manner consistent with section 162(m) of the Code and the regulations thereunder, in particular the prerequisites for qualification as
“performance-based compensation,” and, if any provision of this Plan as in effect on the date of adoption of any Award Agreements relating to Performance Awards that are designated as Section 162(m) Awards does not comply or is
inconsistent with the requirements of section 162(m) of the Code and the regulations thereunder, such provision shall be construed or deemed amended to the extent necessary to conform to such requirements. Notwithstanding anything to the contrary in
this Section 6(k) or elsewhere in this Plan, following a Qualifying Public Offering, the Company intends to rely on the transition relief set forth in Treasury Regulation §1.162-27(f), and hence the deduction limitation imposed by section
162(m) of the Code will not be applicable to the Company until the earliest to occur of (i) following a Qualifying Public Offering, the material modification of the Plan within the meaning of Treasury Regulation §1.162-27(h)(1)(iii);
(ii) following a Qualifying Public Offering the issuance of the number of shares of Stock set forth in Section 4(a); or (iii) the first meeting of stockholders of the Company at which directors are to be elected that occurs after the
close of the third calendar year following the calendar year in which a Qualifying Public Offering occurs (the “Transition Period”), and during the Transition Period, Awards to Covered Employees shall only be required to
comply with the transition relief described in Treasury Regulation §1.162-27(f). For the avoidance of doubt, the deduction limitation imposed by section 162(m) of the Code will not be applicable to the Company prior to a Qualifying Public
Offering. 

  
 17 

 7. Certain Provisions Applicable to Awards. 

(a) Limit on Transfer of Awards. 

(i) Except as provided in Section 7(a)(iii) and (iv) below, each Option and SAR shall be exercisable only by the Participant during
the Participant’s lifetime, or by the Person to whom the Participant’s rights shall pass by will or the laws of descent and distribution. Notwithstanding the foregoing, an ISO shall not be transferable other than by will or the laws of
descent and distribution. 
 (ii) Except as provided in Section 7(a)(iii) and (iv) below, no Award other than a Stock Award, and
no right under any such Award, may be assigned, alienated, pledged, attached, sold or otherwise transferred or encumbered by a Participant and any such purported assignment, alienation, pledge, attachment, sale, transfer or encumbrance shall be void
and unenforceable against the Company or any Affiliate. 
 (iii) To the extent specifically provided by the Committee, an Award may be
transferred by a Participant without consideration to immediate family members or related family trusts, limited partnerships or similar entities or on such terms and conditions as the Committee may from time to time establish. 

(iv) An Award may be transferred pursuant to a domestic relations order entered or approved by a court of competent jurisdiction upon
delivery to the Company of a written request for such transfer and a certified copy of such order. 
 (b) Form and Timing of Payment
under Awards; Deferrals. Subject to the terms of this Plan and any applicable Award Agreement, payments to be made by the Company or any of its Subsidiaries upon the exercise or settlement of an Award may be made in such forms as the Committee
shall determine in its discretion, including without limitation cash, Stock, other Awards or other property, and may be made in a single payment or transfer, in installments, or on a deferred basis (which may be required by the Committee or
permitted at the election of the Participant on terms and conditions established by the Committee); provided, however, that any such deferred or installment payments will be set forth in the Award Agreement and/or otherwise made in a
manner that will not result in additional taxes under the Nonqualified Deferred Compensation Rules. Payments may include, without limitation, provisions for the payment or crediting of reasonable interest on installment or deferred payments or the
grant or crediting of Dividend Equivalents or other amounts in respect of installment or deferred payments denominated in Stock. This Plan shall not constitute an “employee benefit plan” for purposes of section 3(3) of the Employee
Retirement Income Security Act of 1974, as amended. 
 (c) Evidencing Stock. The Stock or other securities of the Company delivered
pursuant to an Award may be evidenced in any manner deemed appropriate by the Committee in its sole discretion, including, but not limited to, in the form of a certificate issued in the name of the Participant or by book entry, electronic or
otherwise and shall be subject to such stop transfer orders and other restrictions as the Committee may deem advisable under the Plan or the rules, 

  
 18 

 
regulations, and other requirements of the Securities and Exchange Commission, any stock exchange upon which such Stock or other securities are then listed, and any applicable federal, state or
other laws, and the Committee may cause a legend or legends to be inscribed on any such certificates to make appropriate reference to such restrictions. If certificates representing Restricted Stock are registered in the name of the Participant, the
Committee may require that such certificates bear an appropriate legend referring to the terms, conditions and restrictions applicable to such Restricted Stock, that the Company retain physical possession of the certificates, and that the
Participant deliver a stock power to the Company, endorsed in blank, related to the Restricted Stock 
 (d) Consideration for Grants.
Awards may be granted for such consideration, including services, as the Committee shall determine, but shall not be granted for less than the minimum lawful consideration. 

(e) Additional Agreements. Each Eligible Person to whom an Award is granted under this Plan may be required to agree in writing, as a
condition to the grant of such Award or otherwise, to subject an Award that is exercised or settled following such Eligible Person’s termination of employment or service to a general release of claims and/or a noncompetition or other restricted
covenant agreement in favor of the Company and its Affiliates, with the terms and conditions of such agreement(s) to be determined in good faith by the Committee. 

(f) Termination of Service. Except as provided herein, the treatment of an Award upon a termination of employment or any other service
relationship by and between a Participant and the Company or any Affiliate shall be specified in the applicable Award Agreement. 
 8.
Amendment; Subdivision or Consolidation; Recapitalization; Change in Control; Reorganization. 
 (a) Amendments to the Plan and
Awards. The Board may amend, alter, suspend, discontinue or terminate this Plan or the Committee’s authority to grant Awards under this Plan without the consent of stockholders or Participants, except that any amendment or alteration to
this Plan, including any increase in any share limitation, shall be subject to the approval of the Company’s stockholders not later than the annual meeting next following such Board action if such stockholder approval is required by any federal
or state law or regulation or the rules of any stock exchange or automated quotation system on which the Stock may then be listed or quoted, and the Board may otherwise, in its discretion, determine to submit other such changes to this Plan to
stockholders for approval; provided, that, without the consent of an affected Participant, no such Board action may materially and adversely affect the rights of such Participant under any previously granted and outstanding Award. The
Committee may waive any conditions or rights under, or amend, alter, suspend, discontinue or terminate any Award theretofore granted and any Award Agreement relating thereto, except as otherwise provided in this Plan; provided,
however, that, without the consent of an affected Participant, no such Committee action may materially and adversely affect the rights of such Participant under such Award. For purposes of clarity, any adjustments made to Awards pursuant to
Section 8(b) through 8(h) will be deemed not to materially and adversely affect the rights of any Participant under any previously granted and outstanding Award and therefore may be made without the consent of affected Participants. 

  
 19 

 (b) Existence of Plans and Awards. The existence of this Plan and the Awards granted
hereunder shall not affect in any way the right or power of the Company, the Board or the stockholders of the Company to make or authorize any adjustment, recapitalization, reorganization or other change in the Company’s capital structure or
its business, any merger or consolidation of the Company, any issue of debt or equity securities ahead of or affecting Stock or the rights thereof, the dissolution or liquidation of the Company or any sale, lease, exchange or other disposition of
all or any part of its assets or business or any other corporate act or proceeding. In no event will any action taken by the Committee pursuant to this Section 8 result in the creation of deferred compensation within the meaning of the
Nonqualified Deferred Compensation Rules. 
 (c) Subdivision or Consolidation of Shares. The terms of an Award and the share
limitations under the Plan shall be subject to adjustment by the Committee from time to time, in accordance with the following provisions: 

(i) If at any time, or from time to time, the Company shall subdivide as a whole (by reclassification, by a Stock split, by the issuance of a
distribution on Stock payable in Stock, or otherwise) the number of shares of Stock then outstanding into a greater number of shares of Stock or in the event the Company distributes an extraordinary cash dividend, then, as appropriate (A) the
maximum number of shares of Stock available for the Plan or in connection with Awards as provided in Section 4 (including the annual increase in such share limit) and Section 5 shall be increased proportionately, and the kind of shares or
other securities available for the Plan shall be appropriately adjusted, (B) the number of shares of Stock (or other kind of shares or securities) that may be acquired under any then outstanding Award shall be increased proportionately, and
(C) the price (including the Exercise Price or grant price) for each share of Stock (or other kind of shares or securities) subject to then outstanding Awards shall be reduced proportionately, without changing the aggregate purchase price or
value as to which outstanding Awards remain exercisable or subject to restrictions. 
 (ii) If at any time, or from time to time, the
Company shall consolidate as a whole (by reclassification, by reverse Stock split, or otherwise) the number of shares of Stock then outstanding into a lesser number of shares of Stock, then, as appropriate (A) the maximum number of shares of
Stock available for the Plan or in connection with Awards as provided in Section 4 (including the annual increase in such share limit) and Section 5 shall be decreased proportionately, and the kind of shares or other securities available
for the Plan shall be appropriately adjusted, (B) the number of shares of Stock (or other kind of shares or securities) that may be acquired under any then outstanding Award shall be decreased proportionately, and (C) the price (including
the exercise price) for each share of Stock (or other kind of shares or securities) subject to then outstanding Awards shall be increased proportionately, without changing the aggregate purchase price or value as to which outstanding Awards remain
exercisable or subject to restrictions. 
 (iii) Whenever the number of shares of Stock subject to outstanding Awards and the price for
each share of Stock subject to outstanding Awards are required to be adjusted as provided in this Section 8(c), the Committee shall promptly prepare a notice setting 

  
 20 

 
forth, in reasonable detail, the event requiring adjustment, the amount of the adjustment, the method by which such adjustment was calculated, and the change in price and the number of shares of
Stock, other securities, cash, or property purchasable subject to each Award after giving effect to the adjustments. The Committee shall promptly provide each affected Participant with such notice. 

(d) Recapitalization. If the Company recapitalizes, reclassifies its capital stock, or otherwise changes its capital structure (a
“recapitalization”) without the occurrence of a Change in Control, the number and class of shares of Stock covered by an Award theretofore granted shall be adjusted so that such Award shall thereafter cover the number and
class of shares of Stock and securities to which the holder would have been entitled pursuant to the terms of the recapitalization if, immediately prior to the recapitalization, the holder had been the holder of record of the number of shares of
Stock then covered by such Award and the share limitations provided in Sections 4 and 5 shall be adjusted in a manner consistent with the recapitalization. 

(e) Additional Issuances. Except as expressly provided herein, the issuance by the Company of shares of stock of any class or
securities convertible into shares of stock of any class, for cash, property, labor or services, upon direct sale, upon the exercise of rights or warrants to subscribe therefor, or upon conversion of shares or obligations of the Company convertible
into such shares or other securities, and in any case whether or not for fair value, shall not affect, and no adjustment by reason thereof shall be made with respect to, the number of shares of Stock subject to Awards theretofore granted or the
purchase price per share of Stock, if applicable. 
 (f) Change in Control and Other Events. Notwithstanding any other provisions of
the Plan or an Award Agreement to the contrary, upon a Change in Control or changes in the outstanding Stock by reason of a recapitalization, reorganization, merger, consolidation, combination, exchange or other relevant change in capitalization
occurring after the date of the grant of any Award and not otherwise provided for by this Section 8, the Committee, acting in its sole discretion without the consent or approval of any holder, may effect one or more of the following
alternatives, which may vary among individual holders and which may vary among Options, SARs or other Awards held by any individual holder: (i) remove any applicable forfeiture restrictions on any Award; (ii) accelerate the time of
exercisability of an Award so that such Award may be exercised in full or in part for a limited period of time on or before a date specified by the Committee, before or after such Change in Control, after which specified date all unexercised Awards
and all rights of holders thereunder shall terminate; (iii) provide for a cash payment with respect to outstanding Awards by requiring the mandatory surrender to the Company by selected holders of some or all of the outstanding Awards held by
such holders (irrespective of whether such Awards are then vested or exercisable pursuant to the Plan) as of a date, before or after such Change in Control, specified by the Committee, in which event the Committee shall thereupon cancel such Awards
(with respect to all shares subject to such Awards) and pay to each holder an amount of cash (or other consideration including securities or other property) per Award (other than a Dividend Equivalent or Cash Award) equal to the Change in Control
Price (as defined below), less the Exercise Price with respect to an Option and less the grant price with respect to a SAR, as applicable to such Awards; provided, however, that to the extent the exercise price of an Option or an SAR
exceeds the Change in Control Price, such award may be canceled for no consideration; or (iv) make such other adjustments to Awards then outstanding as the Committee deems appropriate to reflect such Change in Control, provided, that such
adjustment may not 

  
 21 

 
materially and adversely affect the rights of a Participant, as determined in the sole discretion of the Committee, without the consent of such Participant (including, but not limited to,
(x) the substitution, assumption, or continuation of Awards by the successor company or a parent or subsidiary thereof for new awards, and (y) the adjustment as to the number and price of shares of Stock or other consideration subject to
such Awards); provided, however, that the Committee may determine in its sole discretion that no adjustment is necessary to Awards then outstanding. 

(g) Change in Control Price. The “Change in Control Price” shall equal the amount determined in the following
clause (i), (ii), (iii), (iv) or (v), whichever is applicable, as follows: (i) the price per share offered to holders of Stock in any merger or consolidation, (ii) the per share Fair Market Value of the Stock immediately before the
Change in Control without regard to assets sold in the Change in Control and assuming the Company has received the consideration paid for the assets in the case of a sale of the assets, (iii) the amount distributed per share of Stock in a
dissolution transaction, (iv) the price per share offered to holders of Stock in any tender offer or exchange offer whereby a Change in Control takes place, or (v) if such Change in Control occurs other than pursuant to a transaction
described in clauses (i), (ii), (iii), or (iv) of this Section 8(g), the Fair Market Value per share of the Stock that may otherwise be obtained with respect to such Awards or to which such Awards track, as determined by the Committee as
of the date determined by the Committee to be the date of cancellation and surrender of such Awards. In the event that the consideration offered to stockholders of the Company in any transaction described in this Section 8(g) or in
Section 8(f) consists of anything other than cash, the Committee shall determine the fair cash equivalent of the portion of the consideration offered which is other than cash and such determination shall be binding on all affected Participants
to the extent applicable to Awards held by such Participants. 
 9. General Provisions. 

(a) Restricted Securities. Prior to a Qualifying Public Offering, the Stock to be issued under this Plan, which may be issued in
reliance on any available exemption under the Securities Act, shall be deemed to be “restricted securities” as defined in Rule 144, promulgated by the Securities and Exchange Commission under the Securities Act as from time to time in
effect and applicable to the Plan and Participants. Resales of such Stock by the holder thereof shall be in compliance with the Securities Act or an exemption therefrom. Such Stock may bear a legend if determined necessary by the Committee in
substantially the following form: 
 “THE SHARES OF STOCK REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. THE SHARES MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, TRANSFERRED, OR OTHERWISE DISPOSED OF UNTIL THE HOLDER HEREOF PROVIDES EVIDENCE SATISFACTORY TO REATA PHARMACEUTICALS, INC. (WHICH, IN THE
DISCRETION OF REATA PHARMACEUTICALS, INC., MAY INCLUDE AN OPINION OF COUNSEL SATISFACTORY TO REATA PHARMACEUTICALS, INC.) THAT SUCH OFFER, SALE, PLEDGE, TRANSFER, OR OTHER DISPOSITION WILL NOT VIOLATE APPLICABLE FEDERAL OR STATE LAWS.” 

  
 22 

 (b) Right of First Refusal. Except as otherwise expressly provided in any particular Award
Agreement, if any Participant (“Transferor”), regardless of whether such Participant is the original holder of the Award contemplated in this Section 9(b), proposes to sell, transfer, assign, hypothecate, make gifts of
or in any manner dispose of, encumber, or alienate (each individually constituting a “Transfer”) to a transferee, any Stock, obtained in connection with any Award held by such Transferor, either pursuant to a bona fide offer
(“Offer”) from a potential transferee (“Offeror”) or by effecting a gift of the Stock (“Gift”) to a donee (“Donee”) without consideration, then the
Transferor must comply with the provisions of this Section 9(b), including, without limitation, acknowledging and allowing the applicable time periods to lapse with respect to the rights of the Company as provided herein, before accepting any
such Offer or otherwise affecting the Transfer of any Stock pursuant to such Offer, or affecting any such Gift. 
 (i) Statement of
Offer. Before accepting any Offer or affecting any Gift, the Transferor shall obtain from the Offeror or Donee, as the case may be, a statement (“Statement”) in writing addressed to the Transferor and signed by the
Offeror or Donee, setting forth: (A) the date of the Statement (the “Statement Date”); (B) the number of shares of Stock covered by the Offer or Gift and, in the case of an Offer, the price per share to be paid by
the Offeror and the terms of payment of such price; (C) the Offeror’s or Donee’s willingness to be bound by the terms of this Section 9(b) and execute and deliver to the Company such documentation as required under this
Section 9(b); (D) the Offeror’s or Donee’s name, address and telephone number; and (E) the Offeror’s or Donee’s willingness to supply any additional information about himself or herself as may be reasonably
requested by the Company. Promptly upon receipt of a Statement, and before accepting the Offer or affecting the Gift to which the Statement relates, the Transferor shall deliver to the Company (1) a copy of the Statement, and (2) in the
case of an Offer, evidence reasonably satisfactory to the Company as to the Offeror’s financial ability to consummate the proposed purchase. 

(ii) Company Rights. Subject to the provisions of Section 9(b)(i), upon receipt of a copy of the Statement, the Company shall
have the exclusive right and option (the “Right”), but not the obligation, to purchase all of the shares of Stock that the Offeror proposes to purchase from the Transferor or, in the case of a Gift, that the Transferor
proposes to give to the Donee (collectively, “Subject Securities”) (A) in the case of an Offer, for the per share price and on the terms as set forth in the Statement; provided, however, that if the
purchase price is payable in whole or in part in property (which term shall include the securities of any issuer other than the Company) other than cash, the Company may pay, in lieu of such property, a sum of cash equal to the fair market value of
such property as determined by the Transferor and the Company in good faith or, if the Transferor and the Company do not agree on the fair market value of such property within five days after the Company delivers written notice (as described below)
of its intention to exercise the Right, then the Transferor and the Company shall select one independent appraiser (with each of the Transferor and the Company jointly bearing one-half of the expense of the appraiser) to determine the fair market
value of that property and the appraised fair market value of that property as determined by such appraiser shall be deemed the fair market value of that property for purposes of this Section 9(b)(ii), or (B) in the case of a Gift, the
Fair Market Value of the Subject Securities, as determined in good faith by the Company; provided that the Transferor 

  
 23 

 
may elect to retain the Subject Securities rather than sell the Subject Securities at the Fair Market Value as determined by the Company by giving written notice thereof to the Company within
five days after such determination by the Company is received in writing by the Transferor. The Company shall exercise the Right by giving written notice thereof to the Transferor. Upon exercising the Right, the Company shall have the obligation, to
the extent it lawfully may do so, to purchase the Subject Securities within 30 days after the date of the Company’s receipt of its copy of the Statement on and subject to the terms and conditions hereof. If the terms of the purchase include the
Transferor’s release of any pledge or encumbrance on the Subject Securities and the Transferor shall have failed to obtain the release of the pledge or encumbrance by the purchase date, at the Company’s option the purchase shall occur on
the scheduled date with the purchase price reduced to the extent of all unpaid indebtedness for which the Subject Securities are then pledged or encumbered. Failure by the Company to exercise the Right, or failure by the Company to otherwise perform
its obligations under this Section 9(b)(ii), within the 30 day period herein prescribed shall be deemed an election by the Company not to exercise the Right. If the Company exercises the Right and is unable for any reason to perform its
obligations thereunder in accordance with this Section 9(b), the Company may assign all or a portion of its rights under the Right to any one or more of the Company’s stockholders (other than the Transferor) (“Assignee
Stockholder”), as the Board shall determine, in its sole and absolute discretion. 
 (iii) Purchase of Less Than All
Shares. Anything in Section 9(b) to the contrary notwithstanding, the Company and any Assignee Stockholder individually may, pursuant to the exercise of the Right, purchase fewer than all of the Subject Securities provided that such Persons
in the aggregate purchase all, and not less than all, of the Subject Securities, and it shall be a condition precedent to the obligation of any of such Persons to purchase any Subject Securities, that all, and not less than all, of the Subject
Securities have been elected to be purchased pursuant to the exercise of the Right. 
 (iv) Failure to Exercise Right or Consummate
Transaction. If the Company elects not to exercise the Right, or if the Right is exercised and the obligations to be performed thereunder by the Company are not performed in accordance with this Section 9(b), or if the Company’s rights
are assigned to an Assignee Stockholder and such Assignee Stockholder fails to perform his or her obligations under the assigned Right in accordance with this Section 9(b), then, subject to the application of any applicable state or federal
securities laws, the Transferor may dispose of all of the Subject Securities within 90 days after the date of the Statement at the per share price and on the terms, if any, as set forth in the Statement free and clear of the terms of this
Section 9(b); provided, however, that (A) any subsequent transfer by the Offeror or Donee, as applicable, shall once again be subject to this Section 9(b) and (B) if the sale or gift of the Subject Securities is not
consummated within such 90-day period, then the Transfer of any such Stock shall once again be subject to the terms of this Section 9(b). 

(v) Legend. To assure the enforceability of the Company’s rights under this Section 9(b), until the date of a Qualifying
Public Offering, each certificate or instrument representing Stock or an Award held by him, her, or it may, in the Committee’s discretion, bear a conspicuous legend in substantially the following form: 

“THE SHARES [REPRESENTED BY THIS CERTIFICATE] [ISSUABLE PURSUANT TO THIS AGREEMENT] ARE 

  
 24 

 
SUBJECT TO THE COMPANY’S RIGHT OF FIRST REFUSAL IN THE CASE OF A TRANSFER AS PROVIDED UNDER THE REATA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2007 LONG TERM INCENTIVE PLAN AND/OR AN AWARD
AGREEMENT ENTERED INTO PURSUANT THERETO. COPIES OF SUCH PLAN AND AWARD AGREEMENT ARE AVAILABLE UPON WRITTEN REQUEST TO THE COMPANY AT ITS PRINCIPAL EXECUTIVE OFFICES.” 

(vi) Expiration. The rights and obligations pursuant to this Section 9(b) hereof will terminate upon the date of a Qualifying
Public Offering. 
 (c) Purchase Option. 

(i) Except as otherwise expressly provided in any particular Award Agreement, (A) if a Participant ceases to be employed by or perform
services for the Company or its Subsidiaries for any reason at any time or (B) upon the occurrence of a Change in Control, the Company (and/or its designee(s)) shall have the option (the “Purchase Option”) to purchase,
and the Participant (or the Participant’s executor or the administrator of the Participant’s estate in the event of the Participant’s death, or the transferee of the Stock or Award in the case of any disposition, or the
Participant’s legal representative in the event of the Participant’s incapacity) (hereinafter, collectively with such Participant, the “Grantor”) shall sell to the Company and/or its designee(s), all or any portion
(at the Company’s option) of the shares of Stock issued pursuant to this Plan and held by the Grantor (such shares of Stock herein referred to as the “Purchasable Shares”). 

(ii) The Company shall give notice in writing to the Grantor of the exercise of the Purchase Option within eighteen months of the date of the
termination of the Participant’s employment or service relationship or the date of the Change in Control. Such notice shall state the number of Purchasable Shares to be purchased and the determination of the Board of the Fair Market Value per
share of such Purchasable Shares, or the Change in Control Price, if applicable. If no notice is given within the time limit specified above, the Purchase Option shall terminate. 

(iii) The purchase price to be paid for the Purchasable Shares purchased pursuant to the Purchase Option shall be the Change in Control
Price, if applicable, or Fair Market Value per share, as of the date of the notice of exercise of the Purchase Option times the number of shares being purchased or, to the extent approved by the Company in its sole discretion, such other amount
mutually agreeable to the Company and the Grantor. The purchase price shall be paid in cash. The closing of such purchase shall take place at the Company’s principal executive offices within ten (10) days after the purchase price has been
determined. At such closing, the Grantor shall deliver to the purchasers the certificates or instruments evidencing the Purchasable Shares being purchased free and clear of all liens and encumbrances (if any), duly endorsed (or accompanied by duly
executed stock powers) and otherwise in good form for delivery, against payment of the purchase price by check of the purchasers. In the event that, notwithstanding the foregoing, the Grantor shall have failed to obtain the release of any pledge or
other encumbrance 

  
 25 

 
on any Purchasable Shares by the scheduled closing date, at the option of the purchasers, the closing shall nevertheless occur on such scheduled closing date, with the cash purchase price being
reduced to the extent of all unpaid indebtedness for which such Purchasable Shares are then pledged or encumbered. 
 (iv) To assure the
enforceability of the Company’s rights under this Section 9(c), until the date of a Qualifying Public Offering, each certificate or instrument representing Stock or an Award held by him, her, or it may, in the Committee’s discretion,
bear a conspicuous legend in substantially the following form: 
 “THE SHARES [REPRESENTED BY THIS CERTIFICATE] [ISSUABLE PURSUANT TO
THIS AGREEMENT] ARE SUBJECT TO AN OPTION TO REPURCHASE PROVIDED UNDER THE PROVISIONS OF THE REATA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2007 LONG TERM INCENTIVE PLAN AND/OR AN AWARD AGREEMENT ENTERED INTO PURSUANT THERETO. COPIES OF SUCH PLAN
AND AWARD AGREEMENT ARE AVAILABLE UPON WRITTEN REQUEST TO THE COMPANY AT ITS PRINCIPAL EXECUTIVE OFFICES.” 
 (v) The Company’s
rights under this Section 9(c) shall terminate upon the date of a Qualifying Public Offering. 
 (d) Lock-Up Period. If so
requested by the Company or any representative of the underwriters (the “Managing Underwriter”) in connection with any registration of the offering of any securities of the Company under the Securities Act, a Participant or
transferee will not sell or otherwise transfer any Stock or other securities of the Company during the 180-day period (or such other period as may be requested in writing by the Managing Underwriter and agreed to in writing by the Company) (the
“Market Standoff Period”) following the effective date of a Qualifying Public Offering. The Company may impose stop-transfer instructions with respect to securities subject to the foregoing restrictions until the end of such
Market Standoff Period. 
 (e) Investors’ Rights Agreement. Prior to a Qualifying Public Offering, any Stock that may be
acquired pursuant to the Plan is subject to the Eighth Amended and Restated Investors’ Rights Agreement, dated December 6, 2011, as amended from time-to-time, by and among the Company and certain other individuals listed therein (the
“Investors’ Rights Agreement”) and, as a condition to the issuance or retention of such Stock, a Participant may be required to take such action as may be necessary to subject such Stock to the Investors’ Rights
Agreement. 
 (f) Tax Withholding. The Company and any of its Subsidiaries are authorized to withhold from any Award granted, or any
payment relating to an Award under this Plan, including from a distribution of Stock, amounts of withholding and other taxes due or potentially payable in connection with any transaction involving an Award, and to take such other action as the
Committee may deem advisable to enable the Company, its Subsidiaries and Participants to satisfy obligations for the payment of withholding taxes and other tax obligations relating to any 

  
 26 

 
Award. The Committee shall determine, in its sole discretion, the form of payment acceptable for such tax withholding obligations, including, without limitation, the delivery of cash or cash
equivalents, Stock (including previously owned shares, net settlement, a broker-assisted sale, or other cashless withholding or reduction of the amount of shares otherwise issuable or delivered pursuant to the Award), other property, or any other
legal consideration the Committee deems appropriate. Following a Qualifying Public Offering, any determination made by the Committee to allow a Participant who is subject to Rule 16b-3 to pay taxes with shares of Stock through net settlement or
previously owned shares shall be approved by a committee made up of two or more Qualified Members or the full Board. If such tax obligations are satisfied through the withholding of shares of Stock that are otherwise issuable to the Participant
pursuant to an Award (or through the surrender of shares of Stock by the Participant to the Company), the maximum number of shares of Stock that may be so withheld (or surrendered) shall be the number of shares of Stock that have an aggregate Fair
Market Value on the date of withholding or repurchase equal to the aggregate amount of such tax liabilities determined based on the greatest withholding rates for federal, state, foreign and/or local tax purposes, including payroll taxes, that may
be utilized without creating adverse accounting treatment with respect to such Award, as determined by the Committee. 
 (g) Limitation
on Rights Conferred under Plan. Neither this Plan nor any action taken hereunder shall be construed as (i) giving any Eligible Person or Participant the right to continue as an Eligible Person or Participant or in the employ or service of
the Company or any of its Subsidiaries, (ii) interfering in any way with the right of the Company or any of its Subsidiaries to terminate any Eligible Person’s or Participant’s employment or service relationship at any time,
(iii) giving an Eligible Person or Participant any claim to be granted any Award under this Plan or to be treated uniformly with other Participants and/or employees and/or other service providers, or (iv) conferring on a Participant any of
the rights of a stockholder of the Company unless and until the Participant is duly issued or transferred shares of Stock in accordance with the terms of an Award. 

(h) Governing Law; Submission to Jurisdiction. All questions arising with respect to the provisions of the Plan and Awards shall be
determined by application of the laws of the State of Delaware, without giving effect to any conflict of law provisions thereof, except to the extent Delaware law is preempted by federal law. The obligation of the Company to sell and deliver Stock
hereunder is subject to applicable federal and state laws and to the approval of any governmental authority required in connection with the authorization, issuance, sale, or delivery of such Stock. With respect to any claim or dispute related to or
arising under this Plan, the Company and the Participants consent to the exclusive jurisdiction, forum and venue of the state and federal courts located in Dallas County, Texas. 

(i) Severability and Reformation. If any provision of the Plan or any Award is or becomes or is deemed to be invalid, illegal, or
unenforceable in any jurisdiction or as to any Person or Award, or would disqualify the Plan or any Award under any law deemed applicable by the Committee, such provision shall be construed or deemed amended to conform to the applicable law or, if
it cannot be construed or deemed amended without, in the determination of the Committee, materially altering the intent of the Plan or the Award, such provision shall be stricken as to such jurisdiction, Person or Award and the remainder of the Plan
and any such Award shall remain in full force and effect. If any of the terms or provisions of this Plan or any Award 

  
 27 

 
Agreement conflict with the requirements of Rule 16b-3 (as those terms or provisions are applied to Eligible Persons who are subject to section 16(b) of the Exchange Act) or section 422 of the
Code (with respect to Incentive Stock Options), then those conflicting terms or provisions shall be deemed inoperative to the extent they so conflict with the requirements of Rule 16b-3 (unless the Board or the Committee, as appropriate, has
expressly determined that the Plan or such Award should not comply with Rule 16b-3) or section 422 of the Code, in each case, only to the extent such sections of the Code are applicable. With respect to Incentive Stock Options, if this Plan does not
contain any provision required to be included herein under section 422 of the Code, that provision shall be deemed to be incorporated herein with the same force and effect as if that provision had been set out at length herein; provided,
further, that, to the extent any Option that is intended to qualify as an Incentive Stock Option cannot so qualify, that Option (to that extent) shall be deemed a Nonstatutory Stock Option for all purposes of the Plan. 

(j) Unfunded Status of Awards; No Trust or Fund Created. This Plan is intended to constitute an “unfunded” plan for certain
incentive awards. Neither the Plan nor any Award shall create or be construed to create a trust or separate fund of any kind or a fiduciary relationship between the Company or any Affiliate and a Participant or any other Person. To the extent that
any Person acquires a right to receive payments from the Company or any Affiliate pursuant to an Award, such right shall be no greater than the right of any general unsecured creditor of the Company or such Affiliate. 

(k) Nonexclusivity of this Plan. Neither the adoption of this Plan by the Board nor its submission to the stockholders of the Company
for approval shall be construed as creating any limitations on the power of the Board or a committee thereof to adopt such other incentive arrangements as it may deem desirable, including, following a Qualifying Public Offering, incentive
arrangements and awards which do not constitute “performance-based compensation” under section 162(m) of the Code. Nothing contained in this Plan shall be construed to prevent the Company or any of its Subsidiaries from taking any
corporate action which is deemed by the Company or such Subsidiary to be appropriate or in its best interest, whether or not such action would have an adverse effect on this Plan or any Award made under this Plan. No employee, beneficiary or other
Person shall have any claim against the Company or any of its Subsidiaries as a result of any such action. 
 (l) Fractional Shares.
No fractional shares of Stock shall be issued or delivered pursuant to the Plan or any Award, and the Committee shall determine in its sole discretion whether cash, other securities, or other property shall be paid or transferred in lieu of any
fractional shares of Stock or whether such fractional shares of Stock or any rights thereto shall be canceled, terminated, or otherwise eliminated with or without consideration. 

(m) Headings. Headings are given to the Sections and subsections of the Plan solely as a convenience to facilitate reference. Such
headings shall not be deemed in any way material or relevant to the construction or interpretation of the Plan or any provision thereof. 

(n) Facility of Payment. Any amounts payable hereunder to any individual under legal disability or who, in the judgment of the
Committee, is unable to manage properly his financial affairs, may be paid to the legal representative of such individual, or may be applied for the benefit of such individual in any manner that the Committee may select, and the Company shall be
relieved of any further liability for payment of such amounts. 

  
 28 

 (o) Gender and Number. Words in the masculine gender shall include the feminine gender,
the plural shall include the singular and the singular shall include the plural. 
 (p) Conditions to Delivery of Stock. Nothing
herein or in any Award Agreement shall require the Company to issue any shares with respect to any Award if that issuance would, in the opinion of counsel for the Company, constitute a violation of the Securities Act or any similar or superseding
statute or statutes, any other applicable statute or regulation, or the rules of any applicable securities exchange or securities association, as then in effect. In addition, each Participant who receives an Award under this Plan shall not sell or
otherwise dispose of Stock that is acquired upon grant or vesting of an Award in any manner that would constitute a violation of any applicable federal or state securities laws, the Plan or the rules, regulations or other requirements of the
Securities and Exchange Commission or any stock exchange upon which the Stock is then listed. At the time of any exercise of an Option or Stock Appreciation Right, or at the time of any grant of any other Award the Company may, as a condition
precedent to the exercise of such Option or Stock Appreciation Right or settlement of any other Award, require from the Participant (or in the event of his or her death, his or her legal representatives, heirs, legatees, or distributees) such
written representations, if any, concerning the holder’s intentions with regard to the retention or disposition of the shares of Stock being acquired pursuant to the Award and such written covenants and agreements, if any, as to the manner of
disposal of such shares as, in the opinion of counsel to the Company, may be necessary to ensure that any disposition by that holder (or in the event of the holder’s death, his or her legal representatives, heirs, legatees, or distributees)
will not involve a violation of the Securities Act or any similar or superseding statute or statutes, any other applicable state or federal statute or regulation, or any rule of any applicable securities exchange or securities association, as then
in effect. Stock or other securities shall not be delivered pursuant to any Award until payment in full of any amount required to be paid pursuant to the Plan or the applicable Award Agreement (including, without limitation, any Exercise Price,
grant price, or tax withholding) is received by the Company. 
 (q) Section 409A of the Code. It is the general intention, but
not the obligation, of the Committee to design Awards to comply with or to be exempt from the Nonqualified Deferred Compensation Rules, and Awards will be operated and construed accordingly. Neither this Section 9(q) nor any other provision of
the Plan is or contains a representation to any Participant regarding the tax consequences of the grant, vesting, exercise, settlement, or sale of any Award (or the Stock underlying such Award) granted hereunder, and should not be interpreted as
such. In no event shall the Company be liable for all or any portion of any taxes, penalties, interest or other expenses that may be incurred by the Employee on account of non-compliance with the Nonqualified Deferred Compensation Rules.
Notwithstanding any provision in this Plan or an Award Agreement to the contrary, in the event that a “specified employee” (as defined under the Nonqualified Deferred Compensation Rules) becomes entitled to a payment under an Award that
would be subject to additional taxes and interest under the Nonqualified Deferred Compensation Rules if the Participant’s receipt of such payment or benefits is not delayed until the earlier of (i) the date of the Participant’s death,
or (ii) the date that is six months after the Participant’s “separation from service,” as defined under the Nonqualified Deferred Compensation Rules (such 

  
 29 

 
date, the “Section 409A Payment Date”), then such payment or benefit shall not be provided to the Participant until the Section 409A Payment Date. Any amounts subject
to the preceding sentence that would otherwise be payable prior to the Section 409A Payment Date will be aggregated and paid in a lump sum without interest on the Section 409A Payment Date. The applicable provisions of the Nonqualified
Deferred Compensation Rules are hereby incorporated by reference and shall control over any Plan or Award Agreement provision in conflict therewith. 

(r) Clawback. This Plan is subject to any written clawback policies that the Company, with the approval of the Board, may adopt. Any
such policy may subject a Participant’s Awards and amounts paid or realized with respect to Awards under this Plan to reduction, cancelation, forfeiture or recoupment if certain specified events or wrongful conduct occur, including but not
limited to an accounting restatement due to the Company’s material noncompliance with financial reporting regulations or other events or wrongful conduct specified in any such clawback policy adopted to conform to the Dodd-Frank Wall Street
Reform and Consumer Protection Act of 2010 and rules promulgated thereunder by the Securities and Exchange Commission and that the Company determines should apply to this Plan. 

(s) Amendment and Restatement. As of the Effective Date, this amendment and restatement of the Plan supersedes and replaces in all
respects the Reata Pharmaceuticals, Inc. 2007 Long Term Incentive Plan, as in effect immediately prior to the Effective Date. 
 (t) Plan
Effective Date and Term. This Plan, as amended and restated, was adopted by the Board on the Effective Date, to be effective on the Effective Date. No Awards may be granted under this Plan on and after the tenth anniversary of the Effective
Date. However, any Award granted prior to such termination, and the authority of the Board or Committee to amend, alter, adjust, suspend, discontinue, or terminate any such Award or to waive any conditions or rights under such Award in accordance
with the terms of this Plan, shall extend beyond such termination date until the final disposition of such Award. 

  
 30 

 Exhibit 10.2a 

<Date> 
 <Name> 

<Address> 
 <Address> 

NOTICE OF GRANT OF STOCK OPTION 

(Director/Consultant) 

Pursuant to the terms and conditions of the Reata Pharmaceuticals, Inc. Amended and Restated 2007 Long Term Incentive Plan, attached as
Appendix A (the “Plan”), and the associated Stock Option Agreement, attached as Appendix B (the “Agreement”), you are hereby granted an option (this “Option”) to
purchase shares of Stock under the conditions set forth in this Notice of Grant of Stock Option (the “Notice of Grant”), in the Agreement, and in the Plan. Capitalized terms used but not defined herein shall have the meanings
set forth in the Plan. 
  

			
	Type of Option:	  	Nonstatutory Stock Option (This Option is not intended to be an Incentive Stock Option (as defined in the Plan).)
		
	Optionee:	  	<Name>
		
	Date of Grant:	  	<Date> (“Date of Grant”)
		
	Number of Shares:	  	<Number of shares> (“Option Shares”)
		
	Option Price:	  	$[            ] per share
		
	Expiration Date:	  	<Expiration Date>
		
	Vesting Schedule:	  	 The Option Shares shall be deemed “Nonvested Shares” unless and until they have become “Vested Shares,”
as defined below. The Option Shares will become “Vested Shares” as follows: [                ]; provided, however, that,
except as otherwise provided in the Agreement, such Nonvested Shares will become Vested Shares on such dates only if you remain a director or employee of or a service provider to the Company or its Subsidiaries continuously from the Date of Grant
through the applicable vesting date.
  
 Notwithstanding the foregoing, in the event of
(i) a Change in Control, (ii) a separation from service by reason of death, or (iii) a separation from service by reason of Disability (as defined in the Agreement), any Option Shares that are Nonvested Shares on the date of such event shall become
Vested Shares on such date.

 <Name> 

Page 2 
 <Date> 

 

 By your signature and the signature of the Company’s representative below, you and the
Company hereby acknowledge your receipt of this Option granted on the Date of Grant indicated above, which has been issued to you under the terms and conditions of this Notice of Grant, the Plan and the Agreement, including the vesting and risk of
forfeiture provisions set forth therein. 
 You understand and acknowledge that if the purchase price of the Stock under this Option is less
than the Fair Market Value of such Stock on the date of grant of this Option, then you may incur adverse tax consequences under sections 409A and/or 422 of the Code. You acknowledge and agree that (a) you are not relying upon any determination
by the Company, its affiliates, or any of their respective employees, directors, officers, attorneys or agents (collectively, the “Company Parties”) of the Fair Market Value of the Stock on the Date of Grant, (b) you are
not relying upon any written or oral statement or representation of the Company Parties regarding the tax effects associated with your execution of this Notice of Grant and your receipt, holding and exercise of this Option, and (c) in deciding
to enter into this Notice of Grant, you are relying on your own judgment and the judgment of the professionals of your choice with whom you have consulted. You hereby release, acquit and forever discharge the Company Parties from all actions, causes
of actions, suits, debts, obligations, liabilities, claims, damages, losses, costs and expenses of any nature whatsoever, known or unknown, on account of, arising out of, or in any way related to the tax effects associated with your execution of
this Notice of Grant and your receipt, holding and exercise of this Option. In addition, you are consenting to receive documents from the Company and any plan administrator by means of electronic delivery, provided that such delivery complies with
applicable law. This consent shall be effective for the entire time that you are a participant in the Plan. 
 By signing this Notice you
will become a party to the Eighth Amended and Restated Investors’ Rights Agreement, dated December 6, 2011, as it may be amended from time-to-time (the “Investors’ Rights Agreement”), attached as Appendix C.
You further acknowledge receipt of a copy of the Plan, the Agreement and the Investors’ Rights Agreement and agree to all of the terms and conditions of this Notice of Grant and of the Plan, the Agreement and the Investors’ Rights
Agreement, which are incorporated in this Notice of Grant by reference. 
 Note: To accept the grant of this Option, you must execute this form and
return an executed copy to [                    ] (the “Designated Recipient”) by <Expiration Date>. Failure to return the executed
copy to the Designated Recipient by such date will render this Option invalid. 

 <Name> 

Page 3 
 <Date> 

 

			
	REATA PHARMACEUTICALS, INC.,
	a Delaware corporation
		
	By:	 	  

	Name:	 	[                                ]
	Title:	 	[                                
]

			
	
	Accepted by:
	
	  

	<Name>	 	
		
	Date:	 	  

			
	
	  

	[                                ]
		
	 Date Received:
	 	  

 Attachments: 

Appendix A – Reata Pharmaceuticals, Inc. Amended and Restated 2007 Long Term Incentive Plan 

Appendix B – Stock Option Agreement 

Appendix C – Investors’ Rights Agreement 

 Appendix A 

Reata Pharmaceuticals, Inc. 

Amended and Restated 

2007 Long Term Incentive Plan 

 Appendix B 

Stock Option Agreement 

 Appendix C 

Eighth Amended and Restated Investors’ 

Rights Agreement, dated December 6, 2011 

 Exhibit 10.2b 

<Date> 
 <Name> 

<Address> 
 <Address> 

NOTICE OF GRANT OF STOCK OPTION 

(Employee) 
 Pursuant to
the terms and conditions of the Reata Pharmaceuticals, Inc. Amended and Restated 2007 Long Term Incentive Plan, attached as Appendix A (the “Plan”), and the associated Stock Option Agreement, attached as Appendix
B (the “Agreement”), you are hereby granted an option (this “Option”) to purchase shares of Stock under the conditions set forth in this Notice of Grant of Stock Option (the “Notice of
Grant”), in the Agreement, and in the Plan. Capitalized terms used but not defined herein shall have the meanings set forth in the Plan. 
  

					
	Type of Option:	  	Check one (and only one) of the following:
			
		  	 ̈	  	Incentive Stock Option (This Option is intended to be an Incentive Stock Option (as defined in the Plan).)
			
		  	 ̈	  	Nonstatutory Stock Option (This Option is not intended to be an Incentive Stock Option (as defined in the Plan).)
		
	Optionee:	  	<Name>
		
	Date of Grant:	  	<Date> (“Date of Grant”)
		
	Number of Shares:	  	<Number of shares> (“Option Shares”)
		
	Option Price:	  	 $[            ] per share

 
 Note: In the case of an Incentive Stock Option, the Option Price must be at least
100% (or, in the case of a 10% shareholder of the Company, 110%) of the Fair Market Value (as defined in the Plan) of a share of Stock on the Date of Grant.

		
	Expiration Date:	  	<Expiration Date>
		
		  	Note: In the case of an Incentive Stock Option, this date cannot be more than ten years (or in the case of a 10% shareholder of the Company, more than five years) from the Date of Grant.

 <Name> 

Page 2 
 <Date> 

 

			
	Vesting Schedule:	 	 The Option Shares shall be deemed “Nonvested Shares” unless and until they have become “Vested Shares,”
as defined below. The Option Shares will become “Vested Shares” as follows: [                ] of the Nonvested Shares will become Vested Shares
on the date that is the one year anniversary of the Date of Grant, following which [                    ] of the Nonvested Shares will become Vested
Shares every three months, such that 100% of the Nonvested Shares will be Vested Shares as of the [                    ] year anniversary of the Date
of Grant; provided, however, that, except as otherwise provided in the Agreement, such Nonvested Shares will become Vested Shares on such dates only if you remain in the employ of or a service provider to the Company or its
Subsidiaries continuously from the Date of Grant through the applicable vesting date.
  

Notwithstanding the foregoing, following a Change in Control, any Option Shares that are Nonvested Shares on the date of the Change in Control shall become
Vested Shares with respect to [                    ] of all such Nonvested Shares on the one month anniversary of the Change in Control and
thereafter with respect to an additional [                    ] of all such Nonvested Shares at the time of the Change in Control on each subsequent
month anniversary of the Change in Control such that the Option Shares will be 100% Vested Shares on the [                    ] month anniversary of
the Change in Control, in each case, so long as you remain in the employ of or a service provider to the Company or its Subsidiaries continuously from the Date of Grant through the applicable vesting date; provided, however, that if
100% of the Option Shares would otherwise become Vested Shares pursuant to the vesting rules set forth in the preceding paragraph prior to the
[                    ] month anniversary of the date of the Change in Control, then the Option Shares will become Vested Shares in accordance with
such vesting rules.

 By your signature and the signature of the Company’s representative below, you and the Company hereby
acknowledge your receipt of this Option granted on the Date of Grant indicated above, which has been issued to you under the terms and conditions of this Notice of Grant, the Plan and the Agreement, including the vesting and risk of forfeiture
provisions set forth therein. 
 You understand and acknowledge that if the purchase price of the Stock under this Option is less than the
Fair Market Value of such Stock on the date of grant of this Option, then you may incur adverse tax consequences under sections 409A and/or 422 of the Code. You acknowledge and agree that (a) you are not relying upon any determination by the
Company, its affiliates, or any of their respective employees, directors, officers, attorneys or agents (collectively, the “Company Parties”) of the Fair Market Value of the Stock on the Date of Grant, (b) you are not
relying upon any written or oral statement or representation of the Company Parties regarding the tax effects associated with your execution of this Notice of Grant and your receipt, holding and exercise of this Option, and (c) in deciding to
enter into this Notice of Grant, you are relying on your own judgment and the judgment of the professionals of your choice with whom you have consulted. You hereby release, acquit and forever discharge the Company Parties from all actions, causes of
actions, suits, debts, obligations, liabilities, claims, 

 <Name> 

Page 3 
 <Date> 

 

 
damages, losses, costs and expenses of any nature whatsoever, known or unknown, on account of, arising out of, or in any way related to the tax effects associated with your execution of this
Notice of Grant and your receipt, holding and exercise of this Option. In addition, you are consenting to receive documents from the Company and any plan administrator by means of electronic delivery, provided that such delivery complies with
applicable law. This consent shall be effective for the entire time that you are a participant in the Plan. 
 By signing this Notice you
will become a party to the Eighth Amended and Restated Investors’ Rights Agreement, dated December 6, 2011, as it may be amended from time-to-time (the “Investors’ Rights Agreement”), attached as Appendix C.
You further acknowledge receipt of a copy of the Plan, the Agreement and the Investors’ Rights Agreement and agree to all of the terms and conditions of this Notice of Grant and of the Plan, the Agreement and the Investors’ Rights
Agreement, which are incorporated in this Notice of Grant by reference. 
 Note: To accept the grant of this Option, you must execute this form and
return an executed copy to [                    ] (the “Designated Recipient”) by <Expiration Date>. Failure to return the executed
copy to the Designated Recipient by such date will render this Option invalid.  

 <Name> 

Page 4 
 <Date> 

 

			
	REATA PHARMACEUTICALS, INC.,
	a Delaware corporation
		
	By:	 	  

	Name:	 	[                                ]
	Title:	 	[                                
]

			
	
	Accepted by:
	
	  

	<Name>	 	

			
		
	Date:	 	  

			
	
	  

	[                                
]

			
		
	Date Received:	 	  

 Attachments: 

Appendix A – Reata Pharmaceuticals, Inc. Amended and Restated 2007 Long Term Incentive Plan 

Appendix B – Stock Option Agreement 

Appendix C – Investors’ Rights Agreement 

 Appendix A 

Reata Pharmaceuticals, Inc. 

Amended and Restated 

2007 Long Term Incentive Plan 

 Appendix B 

Stock Option Agreement 

 Appendix C 

Eighth Amended and Restated Investors’ 

Rights Agreement, dated December 6, 2011 

Exhibit 10.2c 
 <Date>

 <Name> 
 <Address> 

<Address> 
 NOTICE OF GRANT OF STOCK
OPTION 
 (Employee) 

Pursuant to the terms and conditions of the Reata Pharmaceuticals, Inc. Amended and Restated 2007 Long Term Incentive Plan, attached as
Appendix A (the “Plan”), and the associated Stock Option Agreement, attached as Appendix B (the “Agreement”), you are hereby granted an option (this “Option”) to
purchase shares of Stock under the conditions set forth in this Notice of Grant of Stock Option (the “Notice of Grant”), in the Agreement, and in the Plan. Capitalized terms used but not defined herein shall have the meanings
set forth in the Plan. 
  

			
		
	 Type of Option:
	  	Check one (and only one) of the following:
		
		  	  ̈    Incentive Stock Option (This Option is intended to
be an Incentive Stock Option (as defined in the Plan).)

		
		  	  ̈    Nonstatutory Stock Option (This Option is not
intended to be an Incentive Stock Option (as defined in the Plan).)

		
	 Optionee:
	  	<Name>
		
	 Date of Grant:
	  	<Date> (“Date of Grant”)
		
	 Number of Shares:
	  	<Number of shares> (“Option Shares”)
		
	 Option Price:
	  	$[        ] per share
		
		  	Note: In the case of an Incentive Stock Option, the Option Price must be at least 100% (or, in the case of a 10% shareholder of the Company, 110%) of the Fair Market Value (as defined in the Plan) of a share of Stock on
the Date of Grant.
		
	 Expiration Date:
	  	<Expiration Date>
		
		  	Note: In the case of an Incentive Stock Option, this date cannot be more than ten years (or in the case of a 10% shareholder of the Company, more than five years) from the Date of
Grant.

 <Name> 

 Page
 44
 
 <Date> 
  

			
		
	 Vesting Schedule:
	  	The Option Shares shall be deemed “Nonvested Shares” unless and until they have become “Vested Shares,” as defined below. The Option Shares will become “Vested Shares” as
follows: [            ] of the Nonvested Shares will become Vested Shares on the date that is the three month anniversary of the Date of Grant, following which
[            ] of the Nonvested Shares will become Vested Shares every three months, such that 100% of the Nonvested Shares will be Vested Shares as of the
[            ] year anniversary of the Date of Grant; provided, however, that, except as otherwise provided in the Agreement, such Nonvested Shares will become Vested Shares
on such dates only if you remain in the employ of or a service provider to the Company or its Subsidiaries continuously from the Date of Grant through the applicable vesting date.
		
		  	Notwithstanding the foregoing, following a Change in Control, any Option Shares that are Nonvested Shares on the date of the Change in Control shall become Vested Shares with respect to
[            ] of all such Nonvested Shares on the one month anniversary of the Change in Control and thereafter with respect to an additional
[            ] of all such Nonvested Shares at the time of the Change in Control on each subsequent month anniversary of the Change in Control such that the Option Shares will be 100%
Vested Shares on the [             ] month anniversary of the Change in Control, in each case, so long as you remain in the employ of or a service provider to the Company or its
Subsidiaries continuously from the Date of Grant through the applicable vesting date; provided, however, that if 100% of the Option Shares would otherwise become Vested Shares pursuant to the vesting rules set forth in the preceding
paragraph prior to the [            ] month anniversary of the date of the Change in Control, then the Option Shares will become Vested Shares in accordance with such vesting
rules.

 By your signature and the signature of the Company’s representative below, you and the Company hereby
acknowledge your receipt of this Option granted on the Date of Grant indicated above, which has been issued to you under the terms and conditions of this Notice of Grant, the Plan and the Agreement, including the vesting and risk of forfeiture
provisions set forth therein. 
 You understand and acknowledge that if the purchase price of the Stock under this Option is less than the
Fair Market Value of such Stock on the date of grant of this Option, then you may incur adverse tax consequences under sections 409A and/or 422 of the Code. You acknowledge and agree that (a) you are not relying upon any determination by the
Company, its affiliates, or any of their respective employees, directors, officers, attorneys or agents (collectively, the “Company Parties”) of the Fair Market Value of the Stock on the Date of Grant, (b) you are not
relying upon any written or oral statement or representation of the Company Parties regarding the tax effects associated with your execution of this Notice of Grant and your receipt, holding and exercise of this Option, and (c) in deciding to
enter into this Notice of Grant, you are relying on your own judgment and the judgment of the professionals of your 

 <Name> 

 Page
 45
 
 <Date> 
  

 
choice with whom you have consulted. You hereby release, acquit and forever discharge the Company Parties from all actions, causes of actions, suits, debts, obligations, liabilities, claims,
damages, losses, costs and expenses of any nature whatsoever, known or unknown, on account of, arising out of, or in any way related to the tax effects associated with your execution of this Notice of Grant and your receipt, holding and exercise of
this Option. In addition, you are consenting to receive documents from the Company and any plan administrator by means of electronic delivery, provided that such delivery complies with applicable law. This consent shall be effective for the entire
time that you are a participant in the Plan. 
 By signing this Notice of Grant you will become a party to the Investors’ Rights
Agreement. You further acknowledge receipt of a copy of the Plan, the Agreement and the Investors’ Rights Agreement and agree to all of the terms and conditions of this Notice of Grant and of the Plan, the Agreement and the Investors’
Rights Agreement, which are incorporated in this Notice of Grant by reference. 
 Note: To accept the grant of this Option, you must execute this form
and return an executed copy to [            ] (the “Designated Recipient”) by <Expiration Date>. Failure to return the executed copy to the Designated Recipient by such date
will render this Option invalid.  

 <Name> 

Page 4 
 <Date> 

 

			
	 REATA PHARMACEUTICALS, INC.,
 a
Delaware corporation

			
		
	By:	 	  

			
		
	Name:	 	[                    ]
	Title:	 	[                    ]

  

			
	Accepted by:
	
	 
	<Name>
		
	Date:	 	  

			
		
	 	 	 
	[                    ]

			
		
	Date Received:	 	  

 Attachments: 

Appendix A – Reata Pharmaceuticals, Inc. Amended and Restated 2007 Long Term Incentive Plan 

Appendix B – Stock Option Agreement 

 Appendix A 

Reata Pharmaceuticals, Inc. 

Amended and Restated 

2007 Long Term Incentive Plan 

 Appendix B 

Stock Option Agreement 

 Exhibit 10.2d 

[TO BE PLACED ON REATA LETTERHEAD] 

NOTICE OF GRANT OF RESTRICTED STOCK 

(Director/Consultant) 

Pursuant to the terms and conditions of the Reata Pharmaceuticals, Inc. Amended and Restated 2007 Long Term Incentive Plan, attached as
Appendix A (the “Plan”), and the associated Restricted Stock Agreement, attached as Appendix B (the “Agreement”), you are hereby issued shares of Stock subject to certain restrictions
thereon and under the terms and conditions set forth below, in the Agreement, and in the Plan (the “Restricted Shares”). Capitalized terms used but not defined herein shall have the meanings set forth in the Plan. 

 

			
	Grantee:	  	
		
	Date of Grant:	  	             ,          (“Date of Grant”)
		
	Number of Shares:	  	
		
	Fair Market Value of Shares on Date of Grant:	  	
		
	 Vesting Schedule:
	  	 The restrictions on all of the Restricted Shares granted pursuant to the Agreement will expire and the Restricted Shares will become
transferable, except to the extent provided in Section 14 of the Agreement, and nonforfeitable as follows: [                    ]; provided,
however, that, except as otherwise provided in the Agreement, such Restricted Shares will vest on such dates only if you remain a director or employee of or a service provider to the Company or its Subsidiaries continuously from the Date of
Grant through the applicable vesting date.
  
 Notwithstanding the foregoing, in the event
of (i) a Change in Control, (ii) a separation from service by reason of death, or (iii) a separation from service by reason of Disability (as defined below), any Restricted Shares that are unvested on the date of such event shall become vested on
such date.
  
 “Disability” means, as determined by the Board or
the Committee, in its sole discretion exercised in good faith, a physical or mental impairment of sufficient severity that you are either unable to perform the essential functions of your position, with or without a reasonable accommodation for your
disability, or to perform the essential functions of your position without an accommodation that would be an undue hardship for the Company or a Subsidiary to provide.

 <Name> 

Page 2 
 <Date> 

 

 By your signature and the signature of the Company’s representative below, you and the
Company hereby acknowledge receipt of the Restricted Shares issued on the Date of Grant indicated above, which have been issued under the terms and conditions of this Notice of Grant of Restricted Stock (the “Notice of
Grant”), the Plan and the Agreement. 
 You acknowledge and agree that (a) you are not relying upon any determination by
the Company, its affiliates, or any of their respective employees, directors, officers, attorneys or agents (collectively, the “Company Parties”) of the Fair Market Value of the Stock on the Date of Grant, (b) you are
not relying upon any written or oral statement or representation of the Company Parties regarding the tax effects associated with your execution of this Notice of Grant and your receipt, holding and vesting of the Restricted Shares, and (c) in
deciding to enter into this Agreement, you are relying on your own judgment and the judgment of the professionals of your choice with whom you have consulted. You hereby release, acquit and forever discharge the Company Parties from all actions,
causes of actions, suits, debts, obligations, liabilities, claims, damages, losses, costs and expenses of any nature whatsoever, known or unknown, on account of, arising out of, or in any way related to the tax effects associated with your execution
of the Agreement and your receipt, holding and vesting of the Restricted Shares. 
 Furthermore, you understand and acknowledge that you
should consult with your tax advisor regarding the advisability of filing with the Internal Revenue Service an election under section 83(b) of the Code with respect to the Restricted Shares for which the restrictions have not lapsed. A form of a
Section 83(b) Election has been attached to this Agreement as Appendix C for your convenience. This election must be filed no later than 30 days after Date of Grant set forth in this Notice of Grant. This time period cannot be extended.
You acknowledge (a) that you have been advised to consult with a tax advisor regarding the tax consequences of the award of the Restricted Shares and (b) that timely filing of a section 83(b) election is your sole responsibility, even if
you request the Company or its representative to file such election on your behalf. 
 In addition, you are consenting to receive documents
from the Company and any plan administrator by means of electronic delivery, provided that such delivery complies with applicable law. This consent shall be effective for the entire time that you are a participant in the Plan. 

By signing this Notice you will become a party to the Eighth Amended and Restated Investors’ Rights Agreement, dated December 6,
2011, as it may be amended from time-to-time (the “Investors’ Rights Agreement”), attached as Appendix D. You further acknowledge receipt of a copy of the Plan, the Agreement and the Investors’ Rights Agreement and
agree to all of the terms and conditions of this Notice of Grant and of the Plan, the Agreement and the Investors’ Rights Agreement, which are incorporated in this Notice of Grant by reference. 

Note: To accept the grant of these Restricted Shares, you must execute this form and return an executed copy to
[                    ] (the “Designated Recipient”) by
[                    ]. Failure to return the executed copy to the Designated Recipient by such date will render this grant of Restricted Stock
invalid.  

 <Name> 

Page 3 
 <Date> 

 

			
	REATA PHARMACEUTICALS, INC.,
	a Delaware corporation
		
	By:	 	  

	Name:	 	[                                ]
	Title:	 	[                                ]
	
	Accepted by:
	
	  

	[GRANTEE]
		
	Date:	 	  

	
	  

	[                                
]

			
		
	Date Received:	 	  

 Attachments: 

Appendix A – Reata Pharmaceuticals, Inc. Amended and Restated 2007 Long Term Incentive Plan 

Appendix B – Restricted Stock Agreement 

Appendix C – Section 83(b) Election 

Appendix D – Investors’ Rights Agreement 

 Appendix A 

Reata Pharmaceuticals, Inc. 

Amended and Restated 

2007 Long Term Incentive Plan 

 Appendix B 

Restricted Stock Agreement 

 Appendix C 

Section 83(b) Election 

 INSTRUCTIONS FOR FILING 

YOUR SECTION 83(b) ELECTION 
  

	1.	Not later than 30 days after the date of grant, mail one executed copy of the election by certified mail, return receipt requested, to the IRS Service Center where your federal tax returns are filed. Attached is a
sample cover letter to the Internal Revenue Service to be used in connection with filing the Section 83(b) election. In addition, below is a chart that lists the address for each IRS service center. 

 

			
	 Taxpayer’s State of Residence
	  	 IRS Service Center

	Alabama, Georgia, North Carolina, South Carolina	  	 Department of the Treasury
 Internal Revenue
Service
 Kansas City, MO 64999-0002

		
	Florida, Louisiana, Mississippi, Texas	  	 Department of the Treasury
 Internal Revenue
Service
 Austin, TX 73301-0002

		
	Alaska, Arizona, California, Colorado, Hawaii, Nevada, Oregon, Washington	  	 Department of the Treasury
 Internal Revenue
Service
 Fresno, CA 93888-0002

		
	Arkansas, Idaho, Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Montana, Nebraska, New Mexico, North Dakota, Ohio, Oklahoma, South Dakota, Utah, Wisconsin, Wyoming	  	 Department of the Treasury
 Internal Revenue
Service
 Fresno, CA 93888-0002

		
	Kentucky, Tennessee, Missouri, New Jersey, Virginia, West Virginia	  	 Department of the Treasury
 Internal Revenue
Service
 Kansas City, MO 64999-0002

		
	Connecticut, Delaware, District of Columbia, Maine, Maryland, Massachusetts, New Hampshire, New York, Pennsylvania, Rhode Island, Vermont	  	 Department of the Treasury
 Internal Revenue
Service
 Kansas City, MO 64999-0002

		
	A foreign country, U.S. possession or territory*, or use an APO or FPO address, or file Form 2555, 2555-EZ, or 4563, or are a dual-status alien	  	 Department of the Treasury
 Internal Revenue
Service
 Austin, TX 73301-0215

  

	*	If you live in American Samoa, Puerto Rico, Guam, the U.S. Virgin Islands, or the Northern Mariana Islands, see IRS Publication 570. 

 

	1.	Mail one copy of the executed election by certified mail, return receipt requested, to: 

 Reata
Pharmaceuticals, Inc. 
 Attn: Legal Department 

2801 Gateway Drive, Suite 150 

Irving, TX 75063 
  

	2.	Attach a copy of the election to your federal income tax return for the year in which the grant and election were made. 

Note: It is your sole responsibility, and not the responsibility of Reata Pharmaceuticals, Inc. (the “Company”) or any of its
affiliates, to timely file your Section 83(b) election even if you request the Company or any of its affiliates or any of their respective managers, directors, officers, employees or authorized representatives (including attorneys, accountants,
consultants, bankers, lenders, prospective lenders and financial representatives) of the Company to assist in making such filing. In addition, the Company and its affiliates cannot provide you with tax advice. The information provided in these
instructions is general in nature and if you have any specific questions about your individual tax circumstances, you should consult with your tax adviser. 

  
 2 

 SUGGESTED FORM OF SECTION 83(b) 

ELECTION TRANSMITTAL LETTER 
 [DATE]

 VIA CERTIFIED MAIL 
 Return Receipt Requested

 Department of the Treasury 
 Internal Revenue Service Center

 [Insert applicable IRS service center address] 
  

	Re:	Election Under Section 83(b) of the Internal Revenue Code 

 Ladies and Gentlemen: 

Pursuant to Treasury Regulation Section 1.83-2(c) promulgated under Section 83 of the Internal Revenue Code of 1986, as amended (the
“Code”), enclosed please find a copy of an executed election under Section 83(b) of the Code relating to the issuance of common stock of Reata Pharmaceuticals, Inc., a Delaware corporation. 

 

	
	Very truly yours,
	
	[TAXPAYER NAME]

 Enclosure 

  
 3 

 SECTION 83(b) ELECTION 

The undersigned taxpayer hereby elects, pursuant to Section 83(b) of the Internal Revenue Code of 1986, as amended, to include in gross
income as compensation for services the excess (if any) of the fair market value of the property described below over the amount paid for such property. 
  

							
	1.	  	The name, taxpayer identification number and address of the undersigned (the “Taxpayer”), and the taxable year for which this election is being made are:
				
		  	Taxpayer’s Name:	  	  
	 	
				
		  	Taxpayer’s Social	  		 	
		  	Security/Employer Identification Number:
                                         
                -        -            
				
		  	Taxpayer’s Address:	  	  
	 	
		  		  	  
	 	
				
		  	Taxable Year:	  	         Calendar Year	 	
		
	2.	  	The property that is the subject of this election (the “Property”) is                     
common shares, par value $0.01 per share, in Reata Pharmaceuticals, Inc.
		
	3.	  	The Property was transferred to the Taxpayer on                     .
		
	4.	  	The Property is subject to the following restrictions: Pursuant to the terms of the Reata Pharmaceuticals, Inc. Amended and Restated 2007 Long Term Incentive Plan and the Restricted Stock Agreement and related Notice
of Grant of Restricted Sock (the “Agreement”) between Reata Pharmaceuticals, Inc. and the Taxpayer, the common stock will not be transferable and will be subject to a substantial risk of forfeiture as set forth in the Agreement and the
Reata Pharmaceuticals, Inc. Amended and Restated 2007 Long Term Incentive Plan. The restrictions on the common stock will expire and the shares will become transferable and non-forfeitable according to the following schedule:
                                        ;
provided, however, that such restrictions will expire on such dates only if the Taxpayer continues to provide services to Reata Pharmaceuticals, Inc. or its subsidiaries continuously from the Date of Grant through the vesting date. All unvested
common stock shall be forfeited upon the termination of the Taxpayer’s employment or service relationship with the Company or its subsidiaries for any reason except as otherwise provided in the Taxpayer’s employment agreement.
		
	5.	  	The fair market value of the Property at the time of transfer (determined without regard to any restriction other than a nonlapse restriction as defined in Section 1.83-3(h) of the Income Tax Regulations) is
$             per common share ×                  shares =
$            .
		
	6.	  	The amount paid by the Taxpayer for the Property is $             per common share ×
                 shares = $            .
		
	7.	  	The amount to include in gross income is $            .

 The undersigned taxpayer will file this election with the Internal Revenue Service office with which the taxpayer files his
or her annual income tax return not later than 30 days after the date of transfer of the 

  
 4 

 
Property. A copy of the election also will be furnished to the person for whom the services were performed. Additionally, the undersigned will include a copy of the election with his or her
income tax return for the taxable year in which the Property is transferred. The undersigned is the person performing the services in connection with which the Property was transferred. 

 

							
	Dated:	 	  
	 		 	  

		 		 		 	Taxpayer’s Signature

  
 5 

 Appendix D 

Eighth Amended and Restated Investors’ 

Rights Agreement, dated December 6, 2011 

 Exhibit 10.2e 

[TO BE PLACED ON REATA LETTERHEAD] 

NOTICE OF GRANT OF RESTRICTED STOCK 

(Employee) 
 Pursuant to
the terms and conditions of the Reata Pharmaceuticals, Inc. Amended and Restated 2007 Long Term Incentive Plan, attached as Appendix A (the “Plan”), and the associated Restricted Stock Agreement, attached
as Appendix B (the “Agreement”), you are hereby issued shares of Stock subject to certain restrictions thereon and under the terms and conditions set forth below, in the Agreement, and in the Plan (the
“Restricted Shares”). Capitalized terms used but not defined herein shall have the meanings set forth in the Plan. 
  

			
	Grantee:	  	
		
	Date of Grant:	  	             ,          (“Date of Grant”)
		
	Number of Shares:	  	
		
	Fair Market Value of Shares on Date of Grant:	  	
		
	Vesting Schedule:	  	 The restrictions on all of the Restricted Shares granted pursuant to the Agreement will expire and the Restricted Shares will become
transferable, except to the extent provided in Section 14 of the Agreement, and nonforfeitable as follows: [                    ] Restricted Shares
will vest on the date that is the one year anniversary of the Date of Grant, following which [                    ] Restricted Shares will vest every
three months, such that 100% of the Restricted Shares will be vested as of the [                    ] year anniversary of the Date of Grant;
provided, however, that, except as otherwise provided in the Agreement, such Restricted Shares will vest on such dates only if you remain in the employ of or a service provider to the Company or its Subsidiaries continuously from the
Date of Grant through the applicable vesting date.
  
 Notwithstanding the foregoing,
following a Change in Control, any Restricted Shares that are unvested on the date of the Change in Control shall vest with respect to
[                    ] of all such unvested Restricted Shares on the one month anniversary of the Change in Control and thereafter with respect to an
additional [                    ] of all such unvested Restricted Shares at the time of the Change in Control on each subsequent month anniversary of
the Change in Control such that the Restricted Shares will be 100% vested on the [                    ] month anniversary of the Change in Control,
in each case, so long as you remain in the employ of or a service provider to the Company or its Subsidiaries continuously from the Date of Grant

 <Name> 

Page 2 
 <Date> 

 

			
		
		  	through the applicable vesting date; provided, however, that if 100% of the Restricted Shares would otherwise become vested pursuant to the vesting rules set forth in the preceding paragraph prior to the
[                    ] month anniversary of the date of the Change in Control, then the Restricted Shares will become vested in accordance with such
vesting rules.

 By your signature and the signature of the Company’s representative below, you and the Company hereby
acknowledge receipt of the Restricted Shares issued on the Date of Grant indicated above, which have been issued under the terms and conditions of this Notice of Grant of Restricted Stock (the “Notice of Grant”), the Plan and
the Agreement. 
 You acknowledge and agree that (a) you are not relying upon any determination by the Company, its affiliates, or any
of their respective employees, directors, officers, attorneys or agents (collectively, the “Company Parties”) of the Fair Market Value of the Stock on the Date of Grant, (b) you are not relying upon any written or oral
statement or representation of the Company Parties regarding the tax effects associated with your execution of this Notice of Grant and your receipt, holding and vesting of the Restricted Shares, and (c) in deciding to enter into this
Agreement, you are relying on your own judgment and the judgment of the professionals of your choice with whom you have consulted. You hereby release, acquit and forever discharge the Company Parties from all actions, causes of actions, suits,
debts, obligations, liabilities, claims, damages, losses, costs and expenses of any nature whatsoever, known or unknown, on account of, arising out of, or in any way related to the tax effects associated with your execution of the Agreement and your
receipt, holding and vesting of the Restricted Shares. 
 Furthermore, you understand and acknowledge that you should consult with your tax
advisor regarding the advisability of filing with the Internal Revenue Service an election under section 83(b) of the Code with respect to the Restricted Shares for which the restrictions have not lapsed. A form of a Section 83(b) Election has
been attached to this Agreement as Appendix C for your convenience. This election must be filed no later than 30 days after Date of Grant set forth in this Notice of Grant. This time period cannot be extended. You acknowledge (a) that
you have been advised to consult with a tax advisor regarding the tax consequences of the award of the Restricted Shares and (b) that timely filing of a section 83(b) election is your sole responsibility, even if you request the Company or its
representative to file such election on your behalf. 
 In addition, you are consenting to receive documents from the Company and any plan
administrator by means of electronic delivery, provided that such delivery complies with applicable law. This consent shall be effective for the entire time that you are a participant in the Plan. 

By signing this Notice you will become a party to the Eighth Amended and Restated Investors’ Rights Agreement, dated December 6,
2011, as it may be amended from time-to-time (the “Investors’ Rights Agreement”), attached as Appendix D. You further acknowledge receipt of a copy of the Plan, the Agreement and the Investors’ Rights Agreement and
agree to all of the terms and conditions of this Notice of Grant and of the Plan, the Agreement and the Investors’ Rights Agreement, which are incorporated in this Notice of Grant by reference. 

 <Name> 

Page 3 
 <Date> 

 

 Note: To accept the grant of these Restricted Shares, you must execute this form and return an executed
copy to [                    ] (the “Designated Recipient”) by
[                    ]. Failure to return the executed copy to the Designated Recipient by such date will render this grant of Restricted Stock
invalid. 

 <Name> 

Page 4 
 <Date> 

 

			
	REATA PHARMACEUTICALS, INC.,
	a Delaware corporation
		
	By:	 	  

	Name:	 	[                                ]
	Title:	 	[                                
]

			
	
	Accepted by:
	
	  

	[GRANTEE]

			
		
	Date:	 	  

			
	
	  

	[                                
]

			
		
	Date Received:	 	  

 Attachments: 

Appendix A – Reata Pharmaceuticals, Inc. Amended and Restated 2007 Long Term Incentive Plan 

Appendix B – Restricted Stock Agreement 

Appendix C – Section 83(b) Election 

Appendix D – Investors’ Rights Agreement 

 Appendix A 

Reata Pharmaceuticals, Inc. 

Amended and Restated 

2007 Long Term Incentive Plan 

 Appendix B 

Restricted Stock Agreement 

 Appendix C 

Section 83(b) Election 

 INSTRUCTIONS FOR FILING 

YOUR SECTION 83(b) ELECTION 
  

	1.	Not later than 30 days after the date of grant, mail one executed copy of the election by certified mail, return receipt requested, to the IRS Service Center where your federal tax returns are filed. Attached is a
sample cover letter to the Internal Revenue Service to be used in connection with filing the Section 83(b) election. In addition, below is a chart that lists the address for each IRS service center. 

 

			
	 Taxpayer’s State of Residence
	  	 IRS Service Center

	Alabama, Georgia, North Carolina, South Carolina	  	 Department of the Treasury
 Internal Revenue
Service
 Kansas City, MO 64999-0002

		
	Florida, Louisiana, Mississippi, Texas	  	 Department of the Treasury
 Internal Revenue
Service
 Austin, TX 73301-0002

		
	Alaska, Arizona, California, Colorado, Hawaii, Nevada, Oregon, Washington	  	 Department of the Treasury
 Internal Revenue
Service
 Fresno, CA 93888-0002

		
	Arkansas, Idaho, Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Montana, Nebraska, New Mexico, North Dakota, Ohio, Oklahoma, South Dakota, Utah, Wisconsin, Wyoming	  	 Department of the Treasury
 Internal Revenue
Service
 Fresno, CA 93888-0002

		
	Kentucky, Tennessee, Missouri, New Jersey, Virginia, West Virginia	  	 Department of the Treasury
 Internal Revenue
Service
 Kansas City, MO 64999-0002

		
	Connecticut, Delaware, District of Columbia, Maine, Maryland, Massachusetts, New Hampshire, New York, Pennsylvania, Rhode Island, Vermont	  	 Department of the Treasury
 Internal Revenue
Service
 Kansas City, MO 64999-0002

		
	A foreign country, U.S. possession or territory*, or use an APO or FPO address, or file Form 2555, 2555-EZ, or 4563, or are a dual-status alien	  	 Department of the Treasury
 Internal Revenue
Service
 Austin, TX 73301-0215

  

	*	If you live in American Samoa, Puerto Rico, Guam, the U.S. Virgin Islands, or the Northern Mariana Islands, see IRS Publication 570. 

 

	1.	Mail one copy of the executed election by certified mail, return receipt requested, to: 

 Reata
Pharmaceuticals, Inc. 
 Attn: Legal Department 

2801 Gateway Drive, Suite 150 

Irving, TX 75063 
  

	2.	Attach a copy of the election to your federal income tax return for the year in which the grant and election were made. 

Note: It is your sole responsibility, and not the responsibility of Reata Pharmaceuticals, Inc. (the “Company”) or any of its
affiliates, to timely file your Section 83(b) election even if you request the Company or any of its affiliates or any of their respective managers, directors, officers, employees or authorized representatives (including attorneys, accountants,
consultants, bankers, lenders, prospective lenders and financial representatives) of the Company to assist in making such filing. In addition, the Company and its affiliates cannot provide you with tax advice. The information provided in these
instructions is general in nature and if you have any specific questions about your individual tax circumstances, you should consult with your tax adviser. 

  
 2 

 SUGGESTED FORM OF SECTION 83(b) 

ELECTION TRANSMITTAL LETTER 
 [DATE]

 VIA CERTIFIED MAIL 
 Return Receipt
Requested 
 Department of the Treasury 
 Internal Revenue
Service Center 
 [Insert applicable IRS service center address] 
  

	Re:	Election Under Section 83(b) of the Internal Revenue Code 

 Ladies and Gentlemen: 

Pursuant to Treasury Regulation Section 1.83-2(c) promulgated under Section 83 of the Internal Revenue Code of 1986, as amended (the
“Code”), enclosed please find a copy of an executed election under Section 83(b) of the Code relating to the issuance of common stock of Reata Pharmaceuticals, Inc., a Delaware corporation. 

 

	
	Very truly yours,
	
	[TAXPAYER NAME]

 Enclosure 

  
 3 

 SECTION 83(b) ELECTION 

The undersigned taxpayer hereby elects, pursuant to Section 83(b) of the Internal Revenue Code of 1986, as amended, to include in gross
income as compensation for services the excess (if any) of the fair market value of the property described below over the amount paid for such property. 
  

							
	1.	  	The name, taxpayer identification number and address of the undersigned (the “Taxpayer”), and the taxable year for which this election is being made are:
				
		  	Taxpayer’s Name: 	  	  
	  	
				
		  	Taxpayer’s Social	  		  	
		  	Security/Employer Identification Number:
                                         
                -        -            
				
		  	Taxpayer’s Address:	  	  
	  	
		  		  	  
	  	
				
		  	Taxable Year: 	  	         Calendar Year	  	
		
	2.	  	The property that is the subject of this election (the “Property”) is                     
common shares, par value $0.01 per share, in Reata Pharmaceuticals, Inc.
		
	3.	  	The Property was transferred to the Taxpayer on                     .
		
	4.	  	The Property is subject to the following restrictions: Pursuant to the terms of the Reata Pharmaceuticals, Inc. Amended and Restated 2007 Long Term Incentive Plan and the Restricted Stock Agreement and related Notice
of Grant of Restricted Sock (the “Agreement”) between Reata Pharmaceuticals, Inc. and the Taxpayer, the common stock will not be transferable and will be subject to a substantial risk of forfeiture as set forth in the Agreement and the
Reata Pharmaceuticals, Inc. Amended and Restated 2007 Long Term Incentive Plan. The restrictions on the common stock will expire and the shares will become transferable and non-forfeitable according to the following schedule:
                                        ;
provided, however, that such restrictions will expire on such dates only if the Taxpayer continues to provide services to Reata Pharmaceuticals, Inc. or its subsidiaries continuously from the Date of Grant through the vesting date. All unvested
common stock shall be forfeited upon the termination of the Taxpayer’s employment or service relationship with the Company or its subsidiaries for any reason except as otherwise provided in the Taxpayer’s employment agreement.
		
	5.	  	The fair market value of the Property at the time of transfer (determined without regard to any restriction other than a nonlapse restriction as defined in Section 1.83-3(h) of the Income Tax Regulations) is
$             per common share x                  shares =
$            .
		
	6.	  	The amount paid by the Taxpayer for the Property is $             per common share x
                 shares = $            .
		
	7.	  	The amount to include in gross income is $            .

 The undersigned taxpayer will file this election with the Internal Revenue Service office with which the taxpayer files his
or her annual income tax return not later than 30 days after the date of transfer of the 

  
 4 

 
Property. A copy of the election also will be furnished to the person for whom the services were performed. Additionally, the undersigned will include a copy of the election with his or her
income tax return for the taxable year in which the Property is transferred. The undersigned is the person performing the services in connection with which the Property was transferred. 

 

							
	Dated:	 	  
	 		 	  

		 		 		 	Taxpayer’s Signature

  
 5 

 Appendix D 

Eighth Amended and Restated Investors’ 

Rights Agreement, dated December 6, 2011 

 Exhibit 10.2f 

[TO BE PLACED ON REATA LETTERHEAD] 

            , 20     

 

	
	  

	  

	  

 NOTICE OF GRANT OF RESTRICTED STOCK UNIT 

(Director/Consultant) 

Pursuant to the terms and conditions of the Reata Pharmaceuticals, Inc. Amended and Restated 2007 Long Term Incentive Plan, attached as
Appendix A (the “Plan”), and the associated Restricted Stock Unit Agreement, attached as Appendix B (the “Agreement”), you are hereby granted an award to receive the number of Restricted
Stock Units set forth below whereby each Restricted Stock Unit represents the right to receive one share of Stock, plus rights to certain Dividend Equivalents described in Section 4 of the Agreement, subject to certain restrictions thereon, and
under the terms and conditions set forth below, in the Agreement, and in the Plan (the “Restricted Stock Units”). Capitalized terms used but not defined herein shall have the meanings set forth in the Plan. 

 

			
	Grantee:	  	
		
	Date of Grant:	  	                     (“Date of Grant”)
		
	Number of Restricted Stock Units:	  	
		
	Vesting Schedule:	  	 The Forfeiture Restrictions on the Restricted Stock Units granted pursuant to the Agreement will expire and the Restricted Stock Units
will vest and become nonforfeitable, as set forth in Section 6 of the Agreement, as follows: [                    ] provided,
however, that, except as otherwise provided in the Agreement, such Restricted Stock Units will vest on such dates only if you remain a director or employee of or a service provider to the Company or its Subsidiaries continuously from the Date
of Grant through the applicable vesting date.
  
 Notwithstanding the foregoing, in the
event of (i) a Change in Control, (ii) a separation from service by reason of death, or (iii) a separation from service by reason of Disability (as defined below), any Restricted Stock Units that are unvested on the date of such event shall become
vested on such date.
  
 “Disability” means, as determined by the
Board or the Committee, in its sole discretion exercised in good faith, a physical or mental impairment of sufficient severity that you are either unable to 

 <Name> 

Page 2 
 <Date> 

 

			
		  	perform the essential functions of your position, with or without a reasonable accommodation for your disability, or to perform the essential functions of your position without an accommodation that would be an undue hardship for
the Company or a Subsidiary to provide.
		
	Settlement Event:	  	Stock will become issuable (which Stock will be fully transferable when issued, except to the extent provided in Section 14 of the Agreement) and Dividend Equivalents payable on the date elected by the Grantee on a timely
submitted Settlement Election Form and, if no such form is timely submitted by the Grantee, then on the date of vesting of the Restricted Stock Units. Absent a provision in the Agreement or the Plan to the contrary, Stock and Dividend Equivalents
with respect to vested Restricted Stock Units will be delivered to you no later than 45 days following the Settlement Event.

 By your signature and the signature of the Company’s representative below, you and the Company hereby
acknowledge receipt of the Restricted Stock Units issued on the Date of Grant indicated above, which have been granted under the terms and conditions of this Notice of Grant of Restricted Stock Units (the “Notice of Grant”),
the Plan and the Agreement. 
 You acknowledge and agree that (a) you are not relying upon any written or oral statement or
representation of the Company, its affiliates, or any of their respective employees, directors, officers, attorneys or agents (collectively, the “Company Parties”) regarding the tax effects associated with your execution of
this Notice of Grant and your receipt and holding of and the vesting of the Restricted Stock Units, and (b) in deciding to enter into this Agreement, you are relying on your own judgment and the judgment of the professionals of your choice with
whom you have consulted. You hereby release, acquit and forever discharge the Company Parties from all actions, causes of actions, suits, debts, obligations, liabilities, claims, damages, losses, costs and expenses of any nature whatsoever, known or
unknown, on account of, arising out of, or in any way related to the tax effects associated with your execution of the Agreement and your receipt and holding of and the vesting of the Restricted Stock Units. In addition, you are consenting to
receive documents from the Company and any plan administrator by means of electronic delivery, provided that such delivery complies with applicable law. This consent shall be effective for the entire time that you are a participant in the Plan. 

By signing this Notice you will become a party to the Eighth Amended and Restated Investors’ Rights Agreement, dated December 6,
2011, as it may be amended from time-to-time (the “Investors’ Rights Agreement”), attached as Appendix C. You further acknowledge receipt of a copy of the Plan, the Agreement and the Investors’ Rights Agreement and
agree to all of the terms and conditions of this Notice of Grant and of the Plan, the Agreement and the Investors’ Rights Agreement, which are incorporated in this Notice of Grant by reference. 

Note: To accept the grant of these Restricted Stock Units, you must execute this form and return an executed copy to
[                    ] (the “Designated Recipient”) by
[                    ]. Failure to return the executed copy to the Designated Recipient by such date will render this Restricted Stock Unit
invalid.  

 <Name> 

Page 3 
 <Date> 

 

			
	REATA PHARMACEUTICALS, INC.,
	a Delaware corporation
		
	By:	 	  

	Name:	 	[                                ]
	Title:	 	[                                ]
	
	Accepted by:
	
	  

	[GRANTEE]
		
	Date:	 	  

	
	  

	
[                        
        ]

	
	Date Received:                                 
                            

 Attachments: 

Appendix A – Reata Pharmaceuticals, Inc. Amended and Restated 2007 Long Term Incentive Plan 

Appendix B – Restricted Stock Unit Agreement 

Appendix C – Investors’ Rights Agreement 

 Appendix A 

Reata Pharmaceuticals, Inc. 

Amended and Restated 

2007 Long Term Incentive Plan 

 Appendix B 

Restricted Stock Unit Agreement 

 Appendix C 

Eighth Amended and Restated Investors’ 

Rights Agreement, dated December 6, 2011 

 Exhibit 10.2g 

[TO BE PLACED ON REATA LETTERHEAD] 

            , 20     

 

	
	  

	  

	  

 NOTICE OF GRANT OF RESTRICTED STOCK UNIT 

(Employee) 
 Pursuant to
the terms and conditions of the Reata Pharmaceuticals, Inc. Amended and Restated 2007 Long Term Incentive Plan, attached as Appendix A (the “Plan”), and the associated Restricted Stock Unit Agreement, attached as
Appendix B (the “Agreement”), you are hereby granted an award to receive the number of Restricted Stock Units set forth below whereby each Restricted Stock Unit represents the right to receive one share of Stock, plus
rights to certain Dividend Equivalents described in Section 4 of the Agreement, subject to certain restrictions thereon, and under the terms and conditions set forth below, in the Agreement, and in the Plan (the “Restricted Stock
Units”). Capitalized terms used but not defined herein shall have the meanings set forth in the Plan. 
  

			
	Grantee:	  	
		
	Date of Grant:	  	                    (“Date of Grant”)
		
	Number of Restricted Stock Units:	  	
		
	Vesting Schedule:	  	 The Forfeiture Restrictions on the Restricted Stock Units granted pursuant to the Agreement will expire and the Restricted Stock Units
will vest and become nonforfeitable, as set forth in Section 6 of the Agreement, as follows: [                    ] Restricted Stock Units will vest
on the date that is the one year anniversary of the Date of Grant, following which [                    ] Restricted Stock Units will vest every
three months, such that 100% of the Restricted Stock Units will be vested as of the [                    ] year anniversary of the Date of Grant;
provided, however, that, except as otherwise provided in the Agreement, such Restricted Stock Units will vest on such dates only if you remain in the employ of or a service provider to the Company or its Subsidiaries continuously from
the Date of Grant through the applicable vesting date.
  
 Notwithstanding the foregoing,
following a Change in Control, any Restricted Stock Units that are unvested on the date of the Change in Control shall vest with respect to
[                    ] of all such unvested Restricted Stock Units on the one month anniversary of the Change in Control and thereafter with respect
to an additional [                    ] of

 <Name> 

Page 2 
 <Date> 

 

			
		  	all such unvested Restricted Stock Units at the time of the Change in Control on each subsequent month anniversary of the Change in Control such that the Restricted Stock Units will be 100% vested on the
[                    ] month anniversary of the Change in Control, in each case, so long as you remain in the employ of or a service provider to the
Company or its Subsidiaries continuously from the Date of Grant through the applicable vesting date; provided, however, that if 100% of the Restricted Stock Units would otherwise become vested pursuant to the vesting rules set forth in
the preceding paragraph prior to the [                    ] month anniversary of the date of the Change in Control, then the Restricted Stock Units
will become vested in accordance with such vesting rules.
		
	Settlement Event:	  	Stock will become issuable (which Stock will be fully transferable when issued, except to the extent provided in Section 14 of the Agreement) and Dividend Equivalents payable on the date of vesting of the Restricted Stock Units.
Absent a provision in the Agreement or the Plan to the contrary, Stock and Dividend Equivalents with respect to vested Restricted Stock Units will be delivered to you no later than 45 days following the Settlement Event.

 By your signature and the signature of the Company’s representative below, you and the Company hereby
acknowledge receipt of the Restricted Stock Units issued on the Date of Grant indicated above, which have been granted under the terms and conditions of this Notice of Grant of Restricted Stock Units (the “Notice of Grant”),
the Plan and the Agreement. 
 You acknowledge and agree that (a) you are not relying upon any written or oral statement or
representation of the Company, its affiliates, or any of their respective employees, directors, officers, attorneys or agents (collectively, the “Company Parties”) regarding the tax effects associated with your execution of
this Notice of Grant and your receipt and holding of and the vesting of the Restricted Stock Units, and (b) in deciding to enter into this Agreement, you are relying on your own judgment and the judgment of the professionals of your choice with
whom you have consulted. You hereby release, acquit and forever discharge the Company Parties from all actions, causes of actions, suits, debts, obligations, liabilities, claims, damages, losses, costs and expenses of any nature whatsoever, known or
unknown, on account of, arising out of, or in any way related to the tax effects associated with your execution of the Agreement and your receipt and holding of and the vesting of the Restricted Stock Units. In addition, you are consenting to
receive documents from the Company and any plan administrator by means of electronic delivery, provided that such delivery complies with applicable law. This consent shall be effective for the entire time that you are a participant in the Plan. 

By signing this Notice you will become a party to the Eighth Amended and Restated Investors’ Rights Agreement, dated December 6,
2011, as it may be amended from time-to-time (the “Investors’ Rights Agreement”), attached as Appendix C. You further acknowledge receipt of a copy of the Plan, the Agreement and the Investors’ Rights Agreement and
agree to all of the terms and conditions of this Notice of Grant and of the Plan, the Agreement and the Investors’ Rights Agreement, which are incorporated in this Notice of Grant by reference. 

 <Name> 

Page 3 
 <Date> 

 

 Note: To accept the grant of these Restricted Stock Units, you must execute this form and return an
executed copy to [                    ] (the “Designated Recipient”) by
[                    ]. Failure to return the executed copy to the Designated Recipient by such date will render this Restricted Stock Unit
invalid.  

 <Name> 

Page 4 
 <Date> 

 

			
	REATA PHARMACEUTICALS, INC.,
	a Delaware corporation
		
	By:	 	  

	Name:	 	[                                ]
	Title:	 	[                                ]
	
	Accepted by:
	
	  

[GRANTEE]

			
		
	Date:	 	  

			
	
	  

	[                                ]
		
	Date Received:	 	  

 Attachments: 

Appendix A – Reata Pharmaceuticals, Inc. Amended and Restated 2007 Long Term Incentive Plan 

Appendix B – Restricted Stock Unit Agreement 

Appendix C – Investors’ Rights Agreement 

 Appendix A 

Reata Pharmaceuticals, Inc. 

Amended and Restated 

2007 Long Term Incentive Plan 

 Appendix B 

Restricted Stock Unit Agreement 

 Appendix C 

Eighth Amended and Restated Investors’ 

Rights Agreement, dated December 6, 2011 

 Exhibit 10.2h 

Reata Pharmaceuticals, Inc. Amended and Restated 2007 Long Term Incentive Plan (the “Plan”) 

Notice of Stock Option Exercise 
  

									
	OPTIONEE INFORMATION:	 		    		  	
					
	Name:	 	  
	 		    	 Employee Number:	  	  

	Address:	 	  
	 		    		  	
		 	  
	 		    		  	

 OPTION INFORMATION: 

 

					
	Date of Grant:         ,     , 20    	 		 	Type of Option:     ̈  Nonstatutory (NSO) or
		 		 	                              
 ̈  Incentive (ISO)
	Exercise Price per share: $            	 		 	
			
	Total number of shares of common stock (“Stock”) of Reata Pharmaceuticals, Inc. (the “Company”) covered by option:	 		 	                 shares

 EXERCISE INFORMATION: 

 

	1.	Number of shares of Stock of the Company for which option is being exercised now: 

                 (These shares are referred to below as the
“Purchased Shares.”) 
  

	2.	Total Exercise Price for the Purchased Shares: $             

  

	3.	Total tax withholding associated with Purchased Shares: $             

(Please contact                      at
                     to obtain this information.) 
  

	4.	Form of payment of exercise price (enclosed, as applicable) [check all that apply]: 

  

							
	 ̈  a.	    	Check for $            , made payable to “Reata Pharmaceuticals, Inc.”	  	 ̈  c.	    	I elect for the Company to withhold from the number shares of Stock set forth in Item 1 above a number of shares with a Fair Market Value (as defined in the Plan) equal to the Exercise Price set forth in my Notice
of Grant of Stock Option. (These shares will be valued as of the date this notice is received by the Company.)
	  
  ̈  b.
	    	  
 Certificate(s) for
                 shares of Stock of the Company that I have owned for at least six months. (These shares will be valued as of the date this notice is received by the
Company.)
	  	    

 Note that the forms of payment described in Items 4.b. and 4.c. require approval by the committee appointed by the Board of
Directors of the Company to administer the Plan (the “Committee”). 
  

	5.	Form of payment of tax withholding (enclosed, as applicable) [check all that apply]: 

  

							
	 ̈  a.	    	Check for $            , made payable to “Reata Pharmaceuticals, Inc.”	  	 ̈  c.	    	I elect for the Company to withhold from the number shares of Stock set forth in Item 1 above the number of shares with a Fair Market Value (as defined in the Plan) equal to the amount necessary to satisfy the
Company’s tax withholding obligations. (These shares will be valued as of the date this notice is received by the Company.)
	  
  ̈  b.
	    	  
 Certificate(s) for
                 shares of Stock of the Company that I have owned for at least six months. (These shares will be valued as of the date this notice is received by the
Company.)
	  		    

 Note that the forms of payment described in Items 5.b. and 5.c. require approval by the Committee. 

	6.	Names in which the Purchased Shares should be registered [you must check one]: 

  

							
	 ̈  a.	    	In my name only	 		  	
				
	 ̈  b.	    	In the names of my spouse and myself as community 	 		  	My spouse’s name (if applicable):
		    	property	 		  	  

			
	 ̈  c.	    	In the names of my spouse and myself as joint tenants with the right of survivorship	 	
			
	7.	    	If certificated shares are issued, the	 	  

		    	Purchased Shares should be sent to the	 	  

		    	following address:	 	  

 You must sign this Notice on the third page before submitting it to the Company. 

  
 2 

 REPRESENTATIONS AND ACKNOWLEDGMENTS OF
THE OPTIONEE: 
  

	1.	I represent and warrant to the Company that I am acquiring and will hold the Purchased Shares for investment for my account only, and not with a view to, or for resale in connection with, any “distribution” of
the Purchased Shares within the meaning of the Securities Act of 1933, as amended (the “Securities Act”). 

  

	2.	I understand that the Purchased Shares have not been registered under the Securities Act by reason of a specific exemption therefrom and that the Purchased Shares must be held indefinitely, unless they are subsequently
registered under the Securities Act or I obtain an opinion of counsel (in form and substance satisfactory to the Company and its counsel) that registration is not required. 

 

	3.	I acknowledge that the Company is under no obligation to register the Purchased Shares. 

  

	4.	I am aware of the adoption of Rule 144 by the Securities and Exchange Commission under the Securities Act, which permits limited public resales of securities acquired in a non-public offering, subject to the
satisfaction of certain conditions. These conditions include (without limitation) that certain current public information about the issuer is available, that the resale occurs only after the holding period required by Rule 144 has been satisfied,
that the sale occurs through a “riskless principal transaction,” an unsolicited “broker’s transaction” or directly with a “market maker” and that the amount of securities being sold during any three month period
does not exceed specified limitations. I understand that the conditions for resale set forth in Rule 144 have not been satisfied and that the Company has no plans to satisfy these conditions in the foreseeable future. 

 

	5.	I will not sell, transfer or otherwise dispose of the Purchased Shares in violation of the Securities Act, the Securities Exchange Act of 1934, or the rules promulgated thereunder, including Rule 144 under the
Securities Act. 

  

	6.	I acknowledge that I have received and have had access to such information as I consider necessary or appropriate for deciding whether to invest in the Purchased Shares and that I have had an opportunity to ask
questions and receive answers from the Company regarding the terms and conditions of the issuance of the Purchased Shares. 

  

	7.	I am aware that my investment in the Company is a speculative investment which has limited liquidity and is subject to the risk of complete loss. I am able, without impairing my financial condition, to hold the
Purchased Shares for an indefinite period and to suffer a complete loss of my investment in the Purchased Shares. 

  

	8.	I acknowledge that the Purchased Shares remain subject to the Company’s right of first refusal and purchase option and may remain subject to the Company’s right of repurchase at the exercise price, all in
accordance with the Plan, and the applicable Notice of Grant of Stock Option and Stock Option Agreement (the “Agreement”). 

  

	9.	I acknowledge that the Purchased Shares remain subject to, and I remain a party to, the Eighth Amended and Restated Investors’ Rights Agreement, dated December 6, 2011, as amended from time-to-time, by and
among the Company and certain other individuals listed therein (the “Investors’ Rights Agreement”). 

  

	10.	I acknowledge that I am acquiring the Purchased Shares subject to all other terms of the Notice of Grant of Stock Option, the Agreement and the Investors’ Rights Agreement. 

 

	11.	I agree to seek the consent of my spouse to the extent required by the Company to enforce the foregoing. 

  

			
	By:	 	  

	Name:	 	  

	Date:	 	  

  
 3 

 Exhibit 10.2i 

REATA PHARMACEUTICALS, INC. 

AMENDED AND RESTATED 

2007 LONG TERM INCENTIVE PLAN 

RESTRICTED STOCK AGREEMENT 

This Agreement is made and entered into as of the Date of Grant set forth in the Notice of Grant of Restricted Stock (“Notice of
Grant”) by and between Reata Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and you; 

WHEREAS, the Company in order to induce you to enter into and to continue and dedicate service to the Company and to materially
contribute to the success of the Company agrees to grant you this restricted stock award; 
 WHEREAS, the Company adopted the Reata
Pharmaceuticals, Inc. Amended and Restated 2007 Long Term Incentive Plan as it may be amended from time to time (the “Plan”) under which the Company is authorized to grant restricted stock awards to certain employees and
service providers of the Company and certain Affiliates; 
 WHEREAS, a copy of the Plan has been furnished to you and shall be deemed
a part of this restricted stock award agreement (“Agreement”) as if fully set forth herein and the terms capitalized but not defined herein shall have the meanings set forth in the Plan or the Notice of Grant; and 

WHEREAS, you desire to accept the restricted stock award made pursuant to this Agreement. 

NOW, THEREFORE, in consideration of and mutual covenants set forth herein and for other valuable consideration hereinafter set forth,
the parties agree as follows: 
 1. The Grant. Subject to the conditions set forth below, the Company hereby grants you effective as
of the Date of Grant set forth in the Notice of Grant, as a matter of separate inducement but not in lieu of any salary or other compensation for your services for the Company, an award (the “Award”) consisting of the
aggregate number of shares of Stock set forth in the Notice of Grant (the “Restricted Shares”) in accordance with the terms and conditions set forth herein and in the Plan. 

2. Escrow of Restricted Shares. The Company shall evidence the Restricted Stock in the manner that it deems appropriate, including,
without limitation, certificating the Restricted Stock or evidencing the Restricted Stock in book entry form, electronic or otherwise. The Company may issue in your name a certificate or certificates representing the Restricted Stock and retain that
certificate or those certificates until the restrictions on such Award expire as contemplated in Section 5 of this Agreement or the Award is forfeited as described in Sections 4 and 6 of this Agreement. If the Company certificates the
Restricted Stock, you shall execute one or more stock powers in blank for those certificates and deliver those stock powers to the Company. The Company shall hold the Restricted Stock and the related stock powers pursuant to the terms of this
Agreement, if applicable, until such time as (a) a certificate or certificates for the Restricted Stock are delivered to you, (b) the Restricted Stock is otherwise transferred to you free of restrictions, or (c) the Restricted Stock
is canceled and forfeited pursuant to this Agreement. 

 3. Ownership of Restricted Shares. From and after the Date of Grant, you will be entitled
to all the rights of absolute ownership of the Restricted Stock granted under this Agreement, including the right to vote those shares; provided, however, that any dividends paid by the Company with respect to the Restricted Stock prior to the
expiration of the Forfeiture Restrictions (as defined below) shall be held in escrow by the Company and paid to you, if at all, at the time the Forfeiture Restrictions expire on the Restricted Stock for which the dividend accrued; provided, further,
that in no event shall dividends be settled later than 45 days following the date on which the Forfeiture Restrictions expire with respect to the Restricted Stock for which the dividends were accrued. For purposes of clarity, if the Restricted Stock
is forfeited by you pursuant to the terms of this Agreement then you shall also forfeit the dividends, if any, accrued with respect to such forfeited Restricted Stock. No interest will accrue on the dividends between the declaration and settlement
of the dividends. 
 4. Restrictions; Forfeiture. The Restricted Stock under the Award is restricted in that it may not be sold,
transferred or otherwise alienated or hypothecated until the restrictions enumerated in this Agreement and the Plan are removed or expire as contemplated in Section 5 or 6 of this Agreement. The Restricted Stock is also restricted in the sense
that it may be forfeited to the Company (the “Forfeiture Restrictions”). You hereby agree that if the Restricted Stock is forfeited, as provided in Section 6, the Company shall have the right to deliver the Restricted
Stock to the Company’s transfer agent for, at the Company’s election, cancellation or transfer to the Company. 
 5. Expiration
of Restrictions and Risk of Forfeiture. The restrictions on the Restricted Shares granted pursuant to this Agreement of this Agreement will expire and the Restricted Shares will become transferable, except to the extent provided in
Section 14 of this Agreement, and nonforfeitable as set forth in the Notice of Grant, provided that you remain in the employ of, or a service provider to, the Company or its Subsidiaries until the applicable dates set forth therein. 

6. Termination of Services. Subject to Section 34, if your service relationship with the Company or any of its Subsidiaries is
terminated for any reason, then those Restricted Shares for which the restrictions have not lapsed as of the date of termination shall become null and void and those Restricted Shares shall be forfeited to the Company. The Restricted Shares for
which the restrictions have lapsed as of the date of such termination shall not be forfeited to the Company. 
 7. Leave of Absence.
With respect to the Award, the Company may, in its sole discretion, determine that if you are on leave of absence for any reason you will be considered to still be in the employ of, or providing services for, the Company, provided that rights to the
Restricted Shares during a leave of absence will be limited to the extent to which those rights were earned or vested when the leave of absence began. 

  
 2 

 8. Delivery of Stock. Promptly following the expiration of the restrictions on the
Restricted Shares as contemplated in Section 5 of this Agreement, the Company shall cause to be issued and delivered to you or your designee a certificate or other evidence of the number of Restricted Shares as to which restrictions have
lapsed, free of any restrictive legend relating to the lapsed restrictions, upon receipt by the Company of any tax withholding as may be requested pursuant to Section 9. The value of such Restricted Shares shall not bear any interest owing to
the passage of time. 
 9. Payment of Taxes. The Company may require you to pay to the Company (or the Company’s Subsidiary if
you are an employee of a Subsidiary of the Company), an amount the Company deems necessary to satisfy its (or its Subsidiary’s) current or future obligation to withhold federal, state or local income or other taxes that you incur as a result of
the Award. With respect to any required tax withholding, you may (a) direct the Company to withhold from the shares of Stock to be issued to you under this Agreement the number of shares necessary to satisfy the Company’s obligation to
withhold taxes, which determination will be based on the shares’ Fair Market Value at the time such determination is made; (b) deliver to the Company shares of Stock sufficient to satisfy the Company’s tax withholding obligations,
based on the shares’ Fair Market Value at the time such determination is made; (c) deliver cash to the Company sufficient to satisfy its tax withholding obligations; or (d) satisfy such tax withholding through any combination of (a),
(b) and (c). If you desire to elect to use the stock withholding option described in subparagraph (a), you must make the election at the time and in the manner the Company prescribes. If such tax obligations are satisfied under subparagraph
(a) or (b), the maximum number of shares of Stock that may be so withheld or surrendered shall be the number of shares of Stock that have an aggregate Fair Market Value on the date of withholding or repurchase equal to the aggregate amount of
such tax liabilities determined based on the greatest withholding rates for federal, state, foreign and/or local tax purposes, including payroll taxes, that may be utilized without creating adverse accounting treatment with respect to such Award The
Company, in its discretion, may deny your request to satisfy its tax withholding obligations using a method described under subparagraph (a), (b), or (d). In the event the Company determines that the aggregate Fair Market Value of the shares of
Stock withheld as payment of any tax withholding obligation is insufficient to discharge that tax withholding obligation, then you must pay to the Company, in cash, the amount of that deficiency immediately upon the Company’s request. 

10. Compliance with Securities Law. Notwithstanding any provision of this Agreement to the contrary, the issuance of Stock (including
Restricted Shares) will be subject to compliance with all applicable requirements of federal, state, or foreign law with respect to such securities and with the requirements of any stock exchange or market system upon which the Stock may then be
listed. No Stock will be issued hereunder if such issuance would constitute a violation of any applicable federal, state, or foreign securities laws or other law or regulations or the requirements of any stock exchange or market system upon which
the Stock may then be listed. In addition, Stock will not be issued hereunder unless (a) a registration statement under the Securities Act, is at the time of issuance in effect with respect to the shares issued or (b) in the opinion of
legal counsel to the Company, the shares issued may be issued in accordance with the terms of an applicable exemption from the registration requirements of the Securities Act. YOU ARE CAUTIONED THAT ISSUANCE OF UNRESTRICTED STOCK UPON THE VESTING OF
RESTRICTED STOCK GRANTED PURSUANT TO THIS AGREEMENT 

  
 3 

 
MAY NOT OCCUR UNLESS THE FOREGOING CONDITIONS ARE SATISFIED. The inability of the Company to obtain from any regulatory body having jurisdiction the authority, if any, deemed by the
Company’s legal counsel to be necessary to the lawful issuance and sale of any shares subject to the Award will relieve the Company of any liability in respect of the failure to issue such shares as to which such requisite authority has not
been obtained. As a condition to any issuance hereunder, the Company may require you to satisfy any qualifications that may be necessary or appropriate to evidence compliance with any applicable law or regulation and to make any representation or
warranty with respect to such compliance as may be requested by the Company. From time to time, the Board and appropriate officers of the Company are authorized to take the Securities Actions necessary and appropriate to file required documents with
governmental authorities, stock exchanges, and other appropriate Persons to make shares of Stock available for issuance. 
 11.
Adjustments. The terms of the Award shall be subject to adjustment in accordance with Section 8 of the Plan. 
 12. Right of
First Refusal. Stock acquired pursuant hereto is subject to the provisions of Section 9(b) of the Plan. 
 13. Purchase
Option. Stock acquired pursuant hereto is subject to the provisions of Section 9(c) of the Plan. 
 14. Lock-Up Period. You
agree not sell or otherwise transfer any Stock or other securities of the Company during any applicable Market Standoff Period, as described in Section 9(d) of the Plan. 

15. Investors’ Rights Agreement. Stock acquired pursuant hereto is subject to the Investors’ Rights Agreement. 

16. Legends. The Company may at any time place legends referencing any restrictions imposed on the shares pursuant to this Agreement on
all certificates representing shares issued with respect to this Award. 
 17. Right of the Company and Subsidiaries to Terminate
Services. Nothing in this Agreement confers upon you the right to continue in the employ of or performing services for the Company or any Subsidiary, or interferes in any way with the rights of the Company or any Subsidiary to terminate your
employment or service relationship at any time. 
 18. Furnish Information. You agree to furnish to the Company all information
requested by the Company to enable it to comply with any reporting or other requirements imposed upon the Company by or under any applicable statute or regulation. 

19. Remedies. The parties to this Agreement shall be entitled to recover from each other reasonable attorneys’ fees incurred in
connection with the successful enforcement of the terms and provisions of this Agreement whether by an action to enforce specific performance or for damages for its breach or otherwise. 

  
 4 

 20. No Liability for Good Faith Determinations. The Company and the members of the Board
shall not be liable for any act, omission or determination taken or made in good faith with respect to this Agreement or the Restricted Shares granted hereunder. 

21. Execution of Receipts and Releases. Any payment of cash or any issuance or transfer of shares of Stock or other property to you, or
to your legal representative, heir, legatee or distributee, in accordance with the provisions hereof, shall, to the extent thereof, be in full satisfaction of all claims of such Persons hereunder. The Company may require you or your legal
representative, heir, legatee or distributee, as a condition precedent to such payment or issuance, to execute a release and receipt therefor in such form as it shall determine. 

22. No Guarantee of Interests. The Board and the Company do not guarantee the Stock of the Company from loss or depreciation. 

23. Company Records. Records of the Company or its Subsidiaries regarding your period of service, termination of service and the
reason(s) therefor, and other matters shall be conclusive for all purposes hereunder, unless determined by the Company to be incorrect. 

24. Notice. All notices required or permitted under this Agreement must be in writing and personally delivered or sent by mail and
shall be deemed to be delivered on the date on which it is actually received by the person to whom it is properly addressed or if earlier the date it is sent via certified United States mail. 

25. Waiver of Notice. Any person entitled to notice hereunder may waive such notice in writing. 

26. Successors. This Agreement shall be binding upon you, your legal representatives, heirs, legatees and distributees, and upon the
Company, its successors and assigns. 
 27. Severability. If any provision of this Agreement is held to be illegal or invalid for any
reason, the illegality or invalidity shall not affect the remaining provisions hereof, but such provision shall be fully severable and this Agreement shall be construed and enforced as if the illegal or invalid provision had never been included
herein. 
 28. Company Action. Any action required of the Company shall be by resolution of the Board or by a person or entity
authorized to act by resolution of the Board. 
 29. Headings. The titles and headings of Sections are included for convenience of
reference only and are not to be considered in construction of the provisions hereof. 
 30. Governing Law. All questions arising
with respect to the provisions of this Agreement shall be determined by application of the laws of Delaware, without giving any effect to any conflict of law provisions thereof, except to the extent Delaware state law is preempted by federal law.
The obligation of the Company to sell and deliver Stock hereunder is subject to applicable laws and to the approval of any governmental authority required in connection with the authorization, issuance, sale, or delivery of such Stock. 

  
 5 

 31. Consent to Texas Jurisdiction and Venue. You hereby consent and agree that state
courts located in Dallas County, Texas and the United States District Court for the Northern District of Texas each shall have personal jurisdiction and proper venue with respect to any dispute between you and the Company arising in connection with
the Restricted Shares or this Agreement. In any dispute with the Company, you will not raise, and you hereby expressly waive, any objection or defense to such jurisdiction as an inconvenient forum. 

32. Amendment. This Agreement may be amended the Board or by the Committee at any time (a) without your consent, so long as the
amendment does not materially and adversely affect your rights under the Award, or (b) with your consent. For purposes of clarity, any adjustment made to the Award pursuant to Section 8 of the Plan will be deemed not to materially and
adversely affect your rights under this Award. 
 33. Clawback. This Agreement and your Award is subject to any written clawback
policies of the Company, whether in effect on the Date of Grant or adopted, with the approval of the Board, following the Date of Grant. Any such policy may subject your Award and amounts paid or realized with respect to your Award to reduction,
cancelation, forfeiture or recoupment if certain specified events or wrongful conduct occur, including but not limited to an accounting restatement due to the Company’s material noncompliance with financial reporting regulations or other events
or wrongful conduct specified in any such clawback policy adopted to conform to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 and rules promulgated thereunder by the Securities and Exchange Commission and that the Company
determines should apply to this Award. 
 34. The Plan. This Agreement and the Notice of Grant are subject to all the terms,
conditions, limitations and restrictions contained in the Plan. In the event of any conflict or inconsistency between any terms and conditions of this Agreement, the Notice of Grant, and the terms and provisions of an employment agreement,
consulting agreement, severance or change in control agreement, if any, between you and the Company or any Subsidiary or other Affiliate (the “Employment Agreement”), the terms and conditions of the Employment Agreement shall
be controlling. Taking into account the provisions of Section 6(a) of the Plan, if there is any conflict or inconsistency between the Plan and the Notice of Grant, this Agreement, or the Employment Agreement, then you acknowledge and agree that
those terms of the Plan shall control and, if necessary, the applicable terms of the Notice of Grant, this Agreement, or the Employment Agreement shall be deemed amended so as to carry out the purpose and intent of the Plan. 

[Remainder of page intentionally left blank] 

  
 6 

 Exhibit 10.2j 

REATA PHARMACEUTICALS, INC. 

AMENDED AND RESTATED 

2007 LONG TERM INCENTIVE PLAN 

RESTRICTED STOCK UNIT AGREEMENT 

This Agreement is made and entered into as of the Date of Grant set forth in the Notice of Grant of Restricted Stock Unit (“Notice
of Grant”) by and between Reata Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and you; 

WHEREAS, the Company in order to induce you to enter into and to continue and dedicate service to the Company and to materially
contribute to the success of the Company agrees to grant you this restricted stock unit award; 
 WHEREAS, the Company adopted the
Reata Pharmaceuticals, Inc. Amended and Restated 2007 Long Term Incentive Plan, as it may be amended from time to time (the “Plan”), under which the Company is authorized to grant restricted stock units to certain employees,
directors and other service providers of the Company and certain Affiliates; 
 WHEREAS, a copy of the Plan has been furnished to you
and shall be deemed a part of this Restricted Stock Unit Agreement (“Agreement”) as if fully set forth herein and the terms capitalized but not defined herein shall have the meanings set forth in the Plan or the Notice of
Grant; and 
 WHEREAS, you desire to accept the restricted stock unit award made pursuant to this Agreement. 

NOW, THEREFORE, in consideration of and mutual covenants set forth herein and for other valuable consideration hereinafter set forth,
the parties agree as follows: 
 1. The Grant. Subject to the conditions set forth below, the Company hereby grants you, effective as
of the Date of Grant set forth in the Notice of Grant, an award consisting of an aggregate number of Restricted Stock Units, whereby each Restricted Stock Unit represents the right to receive one share of Stock, plus the additional rights to
Dividend Equivalents set forth in Section 3, in accordance with the terms and conditions set forth herein and in the Plan (the “Award”). 

2. No Shareholder Rights. The Restricted Stock Units granted pursuant to this Agreement do not and shall not entitle you to any rights
of a holder of Stock prior to the date shares of Stock are issued to you in settlement of the Award. 
 3. Dividend Equivalents. In
the event that the Company declares and pays a dividend in respect of its outstanding shares of Stock and, on the record date for such dividend, you hold Restricted Stock Units granted pursuant to this Agreement that have not been settled, the
Company will record the amount of such dividend in a bookkeeping account under your name. No later than 45 days following the Settlement Event set forth in the Notice of Grant, the Company will pay to you an amount in cash equal to the cash
dividends accumulated in the 

 
bookkeeping account for that Restricted Stock Unit. For purposes of clarity, if the Restricted Stock Units are forfeited by you pursuant to the terms of this Agreement then you shall also forfeit
the Dividend Equivalents, if any, accrued with respect to such forfeited Restricted Stock Unit. No interest will accrue on the Dividend Equivalents between the declaration and settlement of the dividends. 

4. Restrictions; Forfeiture. The Restricted Stock Units are restricted in that they (i) may not be sold, transferred or otherwise
alienated or hypothecated until these restrictions are removed or expire as contemplated in Section 6 of this Agreement and as described in the Notice of Grant and (ii) may be forfeited to the Company (the “Forfeiture
Restrictions”). Your rights with respect to the Restricted Stock Units shall remain forfeitable at all times prior to the date on which the Forfeiture Restrictions lapse. 

5. Issuance of Stock. No shares of Stock shall be issued to you prior to the Settlement Event, as set forth in your Notice of Grant.
After the Settlement Event, the Company shall, promptly and within 45 days of such Settlement Event, cause to be issued Stock registered in your name in payment of such vested Restricted Stock Units upon receipt by the Company of any required tax
withholding. The Company shall evidence the Stock to be issued in payment of such vested Restricted Stock Units in the manner it deems appropriate. The value of any fractional Restricted Stock Units shall be rounded down at the time Stock is issued
to you in connection with the Restricted Stock Units. No fractional shares of Stock, nor the cash value of any fractional shares of Stock, will be issuable or payable to you pursuant to this Agreement. The value of such shares of Stock shall not
bear any interest owing to the passage of time. Neither this Section 5 nor any action taken pursuant to or in accordance with this Section 5 shall be construed to create a trust or a funded or secured obligation of any kind. 

6. Expiration of Restrictions and Risk of Forfeiture. The restrictions on the Restricted Stock Units granted pursuant to this
Agreement, including the Forfeiture Restrictions, will expire as set forth in the Notice of Grant and shares of Stock that are nonforfeitable and transferable, except to the extent provided in Section 14 of this Agreement, will be issued to you
in payment of your vested Restricted Stock Units as set forth in Section 5, provided that you remain in the employ of, or a service provider to, the Company or its Subsidiaries until the applicable dates set forth in the Notice of Grant. 

7. Termination of Services. Subject to Section 35, if your service relationship with the Company or any of its Subsidiaries is
terminated for any reason, then those Restricted Stock Units for which the restrictions have not lapsed as of the date of termination shall become null and void and those Restricted Stock Units shall be forfeited to the Company. The Restricted Stock
Units for which the restrictions have lapsed as of the date of such termination, including Restricted Stock Units for which the restrictions lapsed in connection with such termination, shall not be forfeited to the Company and shall be settled as
set forth in Section 6. 
 8. Leave of Absence. With respect to the Award, the Company may, in its sole discretion, determine
that if you are on leave of absence for any reason you will be considered to still be in the employ of, or providing services for, the Company, provided that rights to the Restricted Stock Units during a leave of absence will be limited to the
extent to which those rights were earned or vested when the leave of absence began. 

  
 2 

 9. Payment of Taxes. The Company may require you to pay to the Company (or the
Company’s Subsidiary if you are an employee of a Subsidiary of the Company) an amount the Company deems necessary to satisfy its (or its Subsidiary’s) current or future obligation to withhold federal, state or local income or other taxes
that you incur as a result of the Award. With respect to any required tax withholding, you may (a) direct the Company to withhold from the shares of Stock to be issued to you under this Agreement the number of shares necessary to satisfy the
Company’s obligation to withhold taxes, which determination will be based on the shares’ Fair Market Value at the time such determination is made; (b) deliver to the Company shares of Stock sufficient to satisfy the Company’s tax
withholding obligations, based on the shares’ Fair Market Value at the time such determination is made; (c) deliver cash to the Company sufficient to satisfy its tax withholding obligations; or (d) satisfy such tax withholding through
any combination of (a), (b) and (c). If you desire to elect to use the stock withholding option described in subparagraph (a), you must make the election at the time and in the manner the Company prescribes. If such tax obligations are
satisfied under subparagraph (a) or (b), the maximum number of shares of Stock that may be so withheld or surrendered shall be the number of shares of Stock that have an aggregate Fair Market Value on the date of withholding or repurchase equal
to the aggregate amount of such tax liabilities determined based on the greatest withholding rates for federal, state, foreign and/or local tax purposes, including payroll taxes, that may be utilized without creating adverse accounting treatment
with respect to such Award. The Company, in its discretion, may deny your request to satisfy its tax withholding obligations using a method described under subparagraph (a), (b), or (d). In the event the Company determines that the aggregate Fair
Market Value of the shares of Stock withheld as payment of any tax withholding obligation is insufficient to discharge that tax withholding obligation, then you must pay to the Company, in cash, the amount of that deficiency immediately upon the
Company’s request. 
 10. Compliance with Securities Law. Notwithstanding any provision of this Agreement to the contrary, the
issuance of Stock will be subject to compliance with all applicable requirements of federal, state, or foreign law with respect to such securities and with the requirements of any stock exchange or market system upon which the Stock may then be
listed. No Stock will be issued hereunder if such issuance would constitute a violation of any applicable federal, state, or foreign securities laws or other law or regulations or the requirements of any stock exchange or market system upon which
the Stock may then be listed. In addition, Stock will not be issued hereunder unless (a) a registration statement under the Securities Act is, at the time of issuance, in effect with respect to the shares issued or (b) in the opinion of
legal counsel to the Company, the shares issued may be issued in accordance with the terms of an applicable exemption from the registration requirements of the Securities Act. YOU ARE CAUTIONED THAT ISSUANCE OF STOCK UPON THE VESTING OF RESTRICTED
STOCK UNITS GRANTED PURSUANT TO THIS AGREEMENT MAY NOT OCCUR UNLESS THE FOREGOING CONDITIONS ARE SATISFIED. The inability of the Company to obtain from any regulatory body having jurisdiction the authority, if any, deemed by the Company’s legal
counsel to be necessary to the lawful issuance and sale of any shares subject to the Award will relieve the Company of any liability in respect of the failure to issue such shares as to which such requisite authority has not been obtained. As a
condition to any issuance hereunder, the Company may require you to satisfy any qualifications that may be necessary or appropriate to evidence compliance with any applicable law or regulation and to make any representation or warranty with respect
to such compliance as may be requested by the 

  
 3 

 
Company. From time to time, the Board and appropriate officers of the Company are authorized to take the actions necessary and appropriate to file required documents with governmental
authorities, stock exchanges, and other appropriate Persons to make shares of Stock available for issuance. 
 11. Adjustments. The
terms of the Award, including the number and type of shares subject to the Award, shall be subject to adjustment in accordance with Section 8 of the Plan. 

12. Right of First Refusal. Stock that may be acquired pursuant hereto is subject to the provisions of Section 9(b) of the Plan.

 13. Purchase Option. Stock that may be acquired pursuant hereto is subject to the provisions of Section 9(c) of the Plan.

 14. Lock-Up Period. You agree not sell or otherwise transfer any Stock or other securities of the Company during any applicable
Market Standoff Period, as described in Section 9(d) of the Plan. 
 15. Investors’ Rights Agreement. Any Stock that may be
acquired pursuant hereto is subject to the Investors’ Rights Agreement. 
 16. Legends. The Company may at any time place
legends referencing any restrictions imposed on the shares pursuant to this Agreement on all certificates representing shares issued with respect to this Award. 

17. Right of the Company and Subsidiaries to Terminate Services. Nothing in this Agreement confers upon you the right to continue in
the employ of or performing services for the Company or any Subsidiary, or interferes in any way with the rights of the Company or any Subsidiary to terminate your employment or service relationship at any time. 

18. Furnish Information. You agree to furnish to the Company all information requested by the Company to enable it to comply with any
reporting or other requirements imposed upon the Company by or under any applicable statute or regulation. 
 19. Remedies. The
parties to this Agreement shall be entitled to recover from each other reasonable attorneys’ fees incurred in connection with the successful enforcement of the terms and provisions of this Agreement whether by an action to enforce specific
performance or for damages for its breach or otherwise. 
 20. No Liability for Good Faith Determinations. The Company and the
members of the Board shall not be liable for any act, omission or determination taken or made in good faith with respect to the Plan, this Agreement or the Restricted Stock Units granted hereunder. 

21. Execution of Receipts and Releases. Any payment of cash or any issuance or transfer of shares of Stock or other property to you, or
to your legal representative, heir, legatee or distributee, in accordance with the provisions hereof, shall, to the extent thereof, be in full satisfaction of all claims of such Persons hereunder. The Company may require you or your legal
representative, heir, legatee or distributee, as a condition precedent to such payment or issuance, to execute a release and receipt therefor in such form as it shall determine. 

  
 4 

 22. No Guarantee of Interests. The Board and the Company do not guarantee the Stock of the
Company from loss or depreciation. 
 23. Company Records. Records of the Company or its Subsidiaries regarding your period of
service, termination of service and the reason(s) therefor, and other matters shall be conclusive for all purposes hereunder, unless determined by the Company to be incorrect. 

24. Notice. All notices required or permitted under this Agreement must be in writing and personally delivered or sent by mail and
shall be deemed to be delivered on the date on which it is actually received by the person to whom it is properly addressed or if earlier the date it is sent via certified United States mail. 

25. Waiver of Notice. Any person entitled to notice hereunder may waive such notice in writing. 

26. Successors. This Agreement shall be binding upon you, your legal representatives, heirs, legatees and distributees, and upon the
Company, its successors and assigns. 
 27. Severability. If any provision of this Agreement is held to be illegal or invalid for any
reason, the illegality or invalidity shall not affect the remaining provisions hereof, but such provision shall be fully severable and this Agreement shall be construed and enforced as if the illegal or invalid provision had never been included
herein. 
 28. Company Action. Any action required of the Company shall be by resolution of the Board or by a person or entity
authorized to act by resolution of the Board. 
 29. Headings. The titles and headings of Sections are included for convenience of
reference only and are not to be considered in construction of the provisions hereof. 
 30. Governing Law. All questions arising
with respect to the provisions of this Agreement shall be determined by application of the laws of Delaware, without giving any effect to any conflict of law provisions thereof, except to the extent Delaware state law is preempted by federal law.
The obligation of the Company to sell and deliver Stock hereunder is subject to applicable laws and to the approval of any governmental authority required in connection with the authorization, issuance, sale, or delivery of such Stock. 

31. Consent to Texas Jurisdiction and Venue. You hereby consent and agree that state courts located in Dallas County, Texas and the
United States District Court for the Northern District of Texas each shall have personal jurisdiction and proper venue with respect to any dispute between you and the Company arising in connection with the Restricted Stock Units or this Agreement.
In any dispute with the Company, you will not raise, and you hereby expressly waive, any objection or defense to such jurisdiction as an inconvenient forum. 

  
 5 

 32. Amendment. This Agreement may be amended the Board or by the Committee at any time
(a) without your consent, so long as the amendment does not materially and adversely affect your rights under the Award, or (b) with your consent. For purposes of clarity, any adjustment made to the Award pursuant to Section 8 of the
Plan will be deemed not to materially and adversely affect your rights under this Award. 
 33. Clawback. This Agreement and your
Award is subject to any written clawback policies of the Company, whether in effect on the Date of Grant or adopted, with the approval of the Board, following the Date of Grant. Any such policy may subject your Award and amounts paid or realized
with respect to your Award to reduction, cancelation, forfeiture or recoupment if certain specified events or wrongful conduct occur, including but not limited to an accounting restatement due to the Company’s material noncompliance with
financial reporting regulations or other events or wrongful conduct specified in any such clawback policy adopted to conform to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 and rules promulgated thereunder by the Securities
and Exchange Commission and that the Company determines should apply to this Award. 
 34. Nonqualified Deferred Compensation Rules.

 (a) Notwithstanding any provision of this Agreement to the contrary, all provisions of this Agreement are intended to comply with the
Nonqualified Deferred Compensation Rules or an exemption therefrom and shall be construed and administered in accordance with such intent. Any payments under this Agreement that may be excluded from the Nonqualified Deferred Compensation Rules
either as separation pay due to an involuntary separation from service or as a short-term deferral shall be excluded from the Nonqualified Deferred Compensation Rules to the maximum extent possible. Any payments to be made under this Agreement upon
a termination of your employment shall only be made if such termination of employment constitutes a “separation from service” under the Nonqualified Deferred Compensation Rules. 

(b) Notwithstanding any provision in this Agreement to the contrary, if any payment or benefit provided for herein would be subject to
additional taxes and interest under the Nonqualified Deferred Compensation Rules if your receipt of such payment or benefit is not delayed until the earlier of (i) your death or (ii) the date that is six months after the date of your
separation from service (such date, the “Section 409A Payment Date”), then such payment or benefit shall not be provided to you (or your estate, if applicable) until the Section 409A Payment Date. Notwithstanding the
foregoing, the Company makes no representations that the payments and benefits provided under this Agreement are exempt from, or compliant with, the Nonqualified Deferred Compensation Rules and in no event shall the Company or its Affiliates be
liable for all or any portion of any taxes, penalties, interest or other expenses that may be incurred by you on account of non-compliance with the Nonqualified Deferred Compensation Rules. 

35. The Plan. This Agreement and the Notice of Grant are subject to all the terms, conditions, limitations and restrictions contained
in the Plan. In the event of any conflict or inconsistency between any terms and conditions of this Agreement, the Notice of Grant, and the terms and provisions of an employment agreement, consulting agreement, severance or change in

  
 6 

 
control agreement, if any, between you and the Company or any Subsidiary or other Affiliate (the “Employment Agreement”), the terms and conditions of the Employment
Agreement shall be controlling. Taking into account the provisions of Section 6(a) of the Plan, if there is any conflict or inconsistency between the Plan and the Notice of Grant, this Agreement, or the Employment Agreement, then you
acknowledge and agree that those terms of the Plan shall control and, if necessary, the applicable terms of the Notice of Grant, this Agreement, or the Employment Agreement shall be deemed amended so as to carry out the purpose and intent of the
Plan. 
 [Remainder of page intentionally left blank] 

  
 7 

 Exhibit 10.2k 

INITIAL ELECTION 
 REATA
PHARMACEUTICALS, INC. 
 AMENDED AND RESTATED 

2007 LONG TERM INCENTIVE PLAN 

RESTRICTED STOCK UNIT 

TIME OF SETTLEMENT ELECTION FORM 
 Please
complete this Time of Settlement Election Form (this “Form”) and return a signed copy to the [                    ] of Reata
Pharmaceuticals, Inc. (the “Company”). Any capitalized terms used but not defined in this Form shall have the meaning set forth in the Reata Pharmaceuticals, Inc. Amended and Restated 2007 Long Term Incentive Plan (the
“Plan”), the Restricted Stock Unit Agreement (the “Award Agreement”), or the Notice of Grant (the “Notice of Grant”). 

 

			
	Name:	 	  

 NOTE: This Form relates to your initial award of Restricted Stock Units (the “Initial
Award”). You will become eligible to participate in the non-qualified deferred compensation plan (within the meaning of the Nonqualified Deferred Compensation Rules) pursuant to which you may defer the settlement of Restricted Stock
Units as of the Date of Grant (as defined in the applicable Notice of Grant and currently estimated to be [                    ]1) of the Initial Award. You may complete and return this Form any time prior to
[                    ]2; however, if you wish to defer the settlement of the entire Initial
Award you must return the Form no later than the Date of Grant of the Initial Award. If you return this Form after the Date of Grant of the Initial Award but prior to
[                    ]3 you may only defer a pro-rata portion of the Initial Award calculated by
multiplying the number of Restricted Stock Units included in the Initial Award by a fraction, the numerator of which is the number of days from the date of your election through the last vesting date for the Initial Award and the denominator of
which is the total number of days from the Date of Grant of the Initial Award until the last vesting date for the Initial Award. If you do not wish to make a deferral election, no action is required on your part and the Initial Award will be settled
at the time specified in your Award Agreement and Notice of Grant. 
  

	1.	Settlement of Restricted Stock Units 

 Irrespective of your election below, the Restricted Stock
Units will continue to be subject to the terms of the Plan, the Award Agreement, and the Notice of Grant for the Initial Award in addition to this Form. In order to defer the settlement of the Initial Award you must select a settlement date below as
of which you will receive the shares of Stock in settlement of the Restricted Stock Units granted as the Initial Award and any Dividend Equivalents that accrued with respect to the Initial Award, if any. 

Recognizing that such election is contingent in all respects upon the prior vesting of the Initial Award, I hereby irrevocably elect to
receive the Stock and any Dividend Equivalents issuable pursuant to the Initial Award upon the earliest to occur of (i) a separation from service by reason of my death, (ii) a Change in Control (as defined in the Plan and subject to any
limitations described in my Notice of Grant or Award Agreement), (iii) a separation from service by reason of my Disability (as defined in the Notice of Grant), or (select one or both of the following): 

 

	 	 ̈	Upon              ,         , or if such date is not a business day, the first business day following such date.

  
  

	1 	[NTD: Insert estimated Date of Grant.] 

	2 	[NTD: Insert date that is 30 days following Date of Grant.] 

	3 	[NTD: Insert date that is 30 days following Date of Grant.] 

	 	 ̈	The one year anniversary of my date of retirement, resignation or removal from the Board of Directors (or, if later, the one year anniversary of the date I incur a separation from service with the Company, determined in
accordance with the Nonqualified Deferred Compensation Rules), or if such date is not a business day, the first business day following such date. 

  

	2.	Signature 

 I understand that my right to settlement of the Stock and Distribution Equivalents
pursuant to the Award Agreement and Notice of Grant is subject to the rights of the Company’s creditors in the event of the Company’s insolvency. I further understand that this Form will be effective upon the later of (i) the Date of
Grant of the Initial Award and (ii) receipt of this Form by the Company and, once effective, shall be irrevocable. 
 By executing this
Form, I hereby acknowledge my understanding of and agreement with the terms and provisions set forth in this Form, the Plan, the Award Agreement, and the Notice of Grant. 
  

									
	DIRECTOR	 		 	REATA PHARMACEUTICALS, INC.
					
	By:	 	  
	 		 	By:	 	  

	Name:	 	  
	 		 	Name:	 	  

	Date:	 	  
	 		 	Title:	 	  

		 		 		 	Date:	 	  

  
 2 

 Exhibit 10.2l 

REATA PHARMACEUTICALS, INC. 

AMENDED AND RESTATED 

2007 LONG TERM INCENTIVE PLAN 

STOCK OPTION AGREEMENT 

This Agreement is made and entered into as of the Date of Grant set forth in the Notice of Grant of Stock Option (“Notice of
Grant”) by and between Reata Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and you: 

WHEREAS, the Company, in order to induce you to enter into and continue in dedicated service to the Company and to materially
contribute to the success of the Company, agrees to grant you an option to acquire an interest in the Company through the purchase of shares of stock of the Company; 

WHEREAS, the Company adopted the Reata Pharmaceuticals, Inc. Amended and Restated 2007 Long Term Incentive Plan, as it may be amended
from time to time (the “Plan”), under which the Company is authorized to grant stock options to certain employees and service providers of the Company; 

WHEREAS, a copy of the Plan has been furnished to you and shall be deemed a part of this stock option agreement (the
“Agreement”) as if fully set forth herein and terms capitalized but not defined herein shall have the meaning set forth in the Plan; and 

WHEREAS, you desire to accept the option created pursuant to the Agreement. 

NOW, THEREFORE, in consideration of the mutual covenants set forth herein and for other valuable consideration hereinafter set forth,
the parties agree as follows: 
 1. The Grant. Subject to the conditions set forth below, the Company hereby grants to you, effective
as of the Date of Grant set forth in the Notice of Grant, as a matter of separate inducement and not in lieu of any salary or other compensation for your services for the Company, the right and option to purchase (the
“Option”), in accordance with the terms and conditions set forth herein and in the Plan, an aggregate of the number of shares of Stock set forth in the Notice of Grant (the “Option Shares”), at the
Exercise Price set forth in the Notice of Grant. 
 2. Exercise. 

(a) Option Shares shall be deemed “Nonvested Shares” unless and until they have become “Vested
Shares,” as defined in the Notice of Grant. The Option shall in all events terminate at the close of business on the Expiration Date set forth in the Notice of Grant. Subject to other terms and conditions set forth herein, including,
but not limited to, Section 3(d) of this Agreement, the Option may be exercised in cumulative installments in accordance with the vesting schedule set forth in the Notice of Grant, provided that you remain in the employ of or a service provider
to the Company or its Subsidiaries until the applicable dates set forth therein. 
 (b) Subject to the relevant provisions and limitations
contained herein and in the Plan, you may exercise the Option to purchase all or a portion of the applicable number of 

 
Vested Shares at any time prior to the termination of the Option pursuant to this Option Agreement. No less than 100 Vested Shares may be purchased at any one time unless the number purchased is
the total number of Vested Shares at that time purchasable under the Option. In no event shall you be entitled to exercise the Option for any Nonvested Shares or for a fraction of a Vested Share. 

(c) Any exercise by you of the Option shall be in writing addressed to the Secretary of the Company at its principal place of business.
Exercise of the Option shall be made by delivery to the Company by you (or other person entitled to exercise the Option as provided hereunder) of (i) an executed Notice of Stock Option Exercise in the form provided by the Company, and
(ii) payment of the aggregate purchase price for shares purchased pursuant to the exercise. 
 (d) Payment of the Exercise Price may be
made, at your election, with the approval of the Committee, (i) in cash, by certified or official bank check or by wire transfer of immediately available funds, (ii) by delivery to the Company of a number of shares of Stock having a Fair
Market Value as of the date of exercise equal to the Exercise Price, (iii) by net issue exercise, pursuant to which the Company will issue to you a number of shares of Stock as to which the Option is exercised, less a number of shares with a
Fair Market Value as of the date of exercise equal to the Exercise Price, (iv) if the Stock is readily tradable on a national securities market, through a “cashless exercise” in accordance with a Company-established policy or program
for the same, or (v) any combination of the foregoing. No fraction of a share of Stock shall be accepted by the Company in payment of the Exercise Price. 

(e) If you are on leave of absence for any reason, the Company may, in its sole discretion, determine that you will be considered to still be
in the employ of or providing services for the Company, provided that rights to the Option will be limited to the extent to which those rights were earned or vested when the leave of absence began. Notwithstanding the preceding sentence, if the
Option is intended to be an incentive stock option designed pursuant to section 422 of the Code, then in addition to being approved by the Company, such leave must also meet the requirements of Treasury Regulation Section 1.421-1(h)(2), as
applicable. 
 3. Effect of Termination of Service on Exercisability. Except as provided in Sections 6 and 7 or an Employment
Agreement, this Option may be exercised only while you continue to perform services for the Company or any Subsidiary and will terminate and cease to be exercisable upon termination of your service, except as follows: 

(a) Termination on Account of Disability. 

(i) If your service with the Company or any Subsidiary terminates by reason of Disability (as defined below), this Option may be exercised by
you (or your estate or the person who acquires this Option by will or the laws of descent and distribution or otherwise by reason of your death, or by a Permitted Transferee who acquires this Option in compliance with Section 7(a) of the Plan)
at any time during the period ending on the earlier to occur of (A) the date that is one year following such termination, or (B) the Expiration Date, but only to the extent this Option was exercisable for Vested Shares as of the date your
service so terminates. 

  
 2 

 (ii) As used in this Agreement, “Disability” shall have the meaning set
forth in your Employment Agreement (as defined in Section 2(f) above), or if no such Employment Agreement exists or such Employment Agreement does not define “Disability,” “Disability” means, as determined by the Board or
the Committee, in its sole discretion exercised in good faith, a physical or mental impairment of sufficient severity that you are either unable to perform the essential functions of your position, with or without a reasonable accommodation for your
disability, or to perform the essential functions of your position without an accommodation that would be an undue hardship for the Company or a Subsidiary to provide. 

(b) Termination on Account of Death. If you cease to perform services for the Company or any Subsidiary due to your death or die within
30 days of your termination of employment (or termination of your service relationship) with the Company or a Subsidiary, your estate, the person who acquires this Option by will or the laws of descent and distribution or otherwise by reason of your
death, or a Permitted Transferee who acquires this Option in compliance with Section 7(a) of the Plan, may exercise this Option at any time during the period ending on the earlier to occur of (i) the date that is one year following your
death, or (ii) the Expiration Date, but only to the extent this Option was exercisable for Vested Shares as of the date of your death. 

(c) Termination not for Cause. 

(i) If your service with the Company or any Subsidiary terminates for any reason other than as described in Sections 3(a) or (b) of this
Agreement, unless such service is terminated for Cause (as defined below), this Option may be exercised by you (or by a Permitted Transferee who acquires this Option in compliance with Section 7(a) of the Plan) at any time during the period
ending on the earlier to occur of (A) the date that is three months following your termination, or (B) the Expiration Date, but only to the extent this Option was exercisable for Vested Shares as of the date of your termination. 

(ii) As used in this Agreement, “Cause” means your (A) commission of a willful criminal act, such as fraud,
embezzlement or theft, provided that it is proven that you committed such willful criminal act, (B) conviction, plea of no contest or nolo contendere, deferred adjudication or unadjudicated probation for any felony or any crime involving moral
turpitude, or (C) unlawful use or unlawful possession of alcohol or illegal drugs (however, for purposes of this Agreement, unlawful use and possession of alcohol shall be limited to a conviction of any alcohol-related crime, including driving
while intoxicated); and provided that in no event shall the termination of your employment or service relationship as a result of bad judgment or negligence on your part be considered a termination for Cause. 

(d) Termination in Connection with a Change in Control. 

(i) If (A) your service with the Company or any Subsidiary is terminated for a reason described in Section 3(a) or
(b) following a Change in Control or is terminated by the Company for a reason other than Cause in anticipation of or following a Change in Control, or (B) following a Change in Control, you terminate your employment or service
relationship with the Company for Good Reason (as defined below), then any Option Shares that are Nonvested Shares on the date of the Change in Control shall become Vested Shares immediately prior to the termination of your employment or service
relationship. 

  
 3 

 (ii) As used in this Agreement, “Good Reason” shall mean (A) any
reduction in your annual cash base salary or cash bonus compensation from the level of such compensation immediately prior to the Change in Control, (B) any termination or reduction of a material benefit under any benefit plan in which you
participate unless there is substituted a comparable benefit that is economically substantially equivalent to the terminated or reduced benefit prior to the Change in Control, (C) any requirement that you relocate away from the Dallas/Fort
Worth metropolitan area, or (D) without limiting the generality of the foregoing, any material breach by the Company of this Agreement or any other agreement between you and the Company. 

(e) Miscellaneous Post-Termination Exercise Provisions. This Option will not be exercisable following your termination of employment,
or the termination of your service relationship, with the Company, except as provided in this Section 3. The purchase price of shares as to which this Option is exercised shall be paid in full at the time of exercise, pursuant to
Section 2(c) of this Agreement. 
 4. Transferability. The Option, and any rights or interests therein will be transferable by
you only to the extent approved by the Committee in conformance with Section 7(a) of the Plan. If this Option is intended to be an incentive stock option designed pursuant to section 422 of the Code, then such option shall not be transferable
by you other than by will or the laws of descent and distribution and shall be exercisable during your lifetime only by you, in each case, unless otherwise specifically permitted pursuant to section 422 of the Code or the regulations issued
thereunder. If Following the transfer of this Option, as permitted by the Committee in its complete discretion, (a) this Option shall continue to be subject to the same terms and conditions as were applicable immediately prior to transfer,
provided that the terms “you,” “your,” and “Participant,” as used in this Agreement, the Plan, and the Notice of Grant, shall be deemed to refer to the Permitted Transferee, the recipient under a qualified domestic
relations order, your estate or heirs if you are deceased, or other transferee, as applicable, to the extent appropriate to enable the holder to exercise this Option in accordance with the terms of the Plan and applicable law and (b) the
provisions of this Option relating to exercisability shall continue to be applied with respect to the original holder and, following the occurrence of any such events described herein, this Option shall be exercisable by the Permitted Transferee,
the recipient under a qualified domestic relations order, your estate or heirs if you are deceased, or other transferee, as applicable, only to the extent and for the periods that would have been applicable in the absence of the transfer. 

5. Compliance with Securities Law. Notwithstanding any provision of this Agreement to the contrary, the grant of the Option and the
issuance of Stock will be subject to compliance with all applicable requirements of federal, state, and foreign securities laws and with the requirements of any stock exchange or market system upon which the Stock may then be listed. The Option may
not be exercised if the issuance of shares of Stock upon exercise would constitute a violation of any applicable federal, state, or foreign securities laws or other law or regulations or the requirements of any stock exchange or market system upon
which the Stock may then be listed. In addition, the Option may not be exercised unless (a) a registration statement under the Securities Act is in effect at the time of exercise of the Option with respect to the shares issuable upon exercise
of the Option or (b) in the opinion of legal counsel to the Company, the shares issuable upon exercise of the Option may be issued in accordance with the 

  
 4 

 
terms of an applicable exemption from the registration requirements of the Securities Act. YOU ARE CAUTIONED THAT THE OPTION MAY NOT BE EXERCISED UNLESS THE FOREGOING CONDITIONS ARE SATISFIED.
ACCORDINGLY, YOU MAY NOT BE ABLE TO EXERCISE THE OPTION WHEN DESIRED EVEN THOUGH THE OPTION IS VESTED. The inability of the Company to obtain from any regulatory body having jurisdiction the authority, if any, deemed by the Company’s legal
counsel to be necessary to the lawful issuance and sale of any shares subject to the Option will relieve the Company of any liability in respect of the failure to issue or sell such shares as to which such requisite authority has not been obtained.
As a condition to the exercise of the Option, the Company may require you to satisfy any qualifications that may be necessary or appropriate to evidence compliance with any applicable law or regulation and to make any representation or warranty with
respect to such compliance as may be requested by the Company. 
 6. Extension if Exercise Prevented by Law. Notwithstanding
Section 3, if the exercise of the Option within the applicable time periods set forth in Section 3 is prevented by the provisions of Section 5, the Option will remain exercisable until 30 days after the date you are notified by the
Company that the Option is exercisable, but in any event no later than the Expiration Date. The Company makes no representation as to the tax consequences of any such delayed exercise. You should consult with your own tax advisor as to the tax
consequences of any such delayed exercise. 
 7. Extension if You are Subject to Section 16(b). Notwithstanding Section 3,
if a sale within the applicable time periods set forth in Section 3 of shares acquired upon the exercise of the Option would subject you to suit under Section 16(b) of the Securities Exchange Act of 1934, as amended, the Option will remain
exercisable until the earliest to occur of (a) the 10th day following the date on which a sale of such shares by you would no longer be subject to such suit, (b) the 190th day after your termination of service with the Company and any
Subsidiary, or (c) the Expiration Date. The Company makes no representation as to the tax consequences of any such delayed exercise. You should consult with your own tax advisor as to the tax consequences of any such delayed exercise. 

8. Withholding Taxes. The Committee may, in its discretion, require you to pay to the Company at the time of the exercise of an Option
or thereafter, the amount that the Committee deems necessary to satisfy the Company’s current or future obligation to withhold federal, state or local income or other taxes that you incur by exercising an Option. In connection with such an
event requiring tax withholding, you may (a) direct the Company to withhold from the shares of Stock to be issued to you the number of shares necessary to satisfy the Company’s obligation to withhold taxes, that determination to be based
on the shares’ Fair Market Value as of the date of exercise; (b) deliver to the Company sufficient shares of Stock (based upon the Fair Market Value as of the date of such delivery) to satisfy the Company’s tax withholding obligation;
or (c) deliver sufficient cash to the Company to satisfy its tax withholding obligations. If you elect to use a Stock withholding feature you must make the election at the time and in the manner that the Committee prescribes and the maximum
number of shares of Stock that may be so withheld or surrendered shall be the number of shares of Stock that have an aggregate Fair Market Value on the date of withholding or repurchase equal to the aggregate amount of such tax liabilities
determined based on the greatest withholding rates for federal, state, foreign and/or local tax purposes, including payroll taxes, that may be utilized 

  
 5 

 
without creating adverse accounting treatment with respect to such Award. The Committee may, at its sole option, deny your request to satisfy withholding obligations through shares of Stock
instead of cash. In the event the Committee subsequently determines that the aggregate Fair Market Value (as determined above) of any shares of Stock withheld or delivered as payment of any tax withholding obligation is insufficient to discharge
that tax withholding obligation, then you shall pay to the Company, immediately upon the Committee’s request, the amount of that deficiency in the form of payment requested by the Committee. 

9. Status of Stock. With respect to the status of the Stock, at the time of execution of this Agreement you understand and agree to all
of the following: 
 (a) If the shares of Stock to be issued upon exercise of this Option have not been registered under the Securities Act
or any state securities law as of such date, then in the event exemption from registration under the Securities Act is available upon an exercise of this Option, you (or such other person permitted to exercise this Option if applicable), if
requested by the Company to do so, will execute and deliver to the Company in writing an agreement containing such provisions as the Company may require to ensure compliance with applicable securities laws. 

(b) You agree that the shares of Stock that you may acquire by exercising this Option will be acquired for investment without a view to
distribution, within the meaning of the Securities Act, and will not be sold, transferred, assigned, pledged, or hypothecated in the absence of an effective registration statement for the shares under the Securities Act and applicable state
securities laws or an applicable exemption from the registration requirements of the Securities Act and any applicable state securities laws. You also agree that the shares of Stock that you may acquire by exercising this Option will not be sold or
otherwise disposed of in any manner that would constitute a violation of any applicable securities laws, whether federal or state. 
 (c)
You agree that (i) the Company may refuse to register the transfer of the shares of Stock purchased under this Option on the stock transfer records of the Company if such proposed transfer would, in the opinion of counsel satisfactory to the
Company, constitute a violation of the terms and provisions of any stockholder or investors’ rights agreement, Sections 7(a) or 9(b) of the Plan, or any applicable securities law and (ii) the Company may give related instructions to its
transfer agent, if any, to stop registration of the transfer of the shares of Stock purchased under this Option. 
 10. Adjustments.
The terms of the Option, including the number and type of shares subject to the Option and the option price shall be subject to adjustment in accordance with Section 8 of the Plan. 

11. Right of First Refusal. Stock that may be acquired pursuant hereto is subject to the provisions of Section 9(b) of the Plan.

 12. Purchase Option. Stock that may be acquired pursuant hereto is subject to the provisions of Section 9(c) of the Plan.

  
 6 

 13. Lock-Up Period. You agree not sell or otherwise transfer any Stock or other securities
of the Company during any applicable Market Standoff Period, as described in Section 9(d) of the Plan. 
 14. Investors’ Rights
Agreement. Any Stock that may be acquired pursuant hereto is subject to the Investors’ Rights Agreement. 
 15. Legends. The
Company may at any time place legends, referencing any restrictions imposed on the shares pursuant to this Agreement, and any applicable federal, state or foreign securities law restrictions, on all certificates representing shares of Stock subject
to the provisions of this Agreement. 
 16. Notice of Sales Upon Disqualifying Disposition of ISO. If the Option is designated as an
Incentive Stock Option in the Notice of Grant, you must comply with the provisions of this Section 16. You must promptly notify the Chief Financial Officer of the Company if you dispose of any of the shares acquired pursuant to the Option
within one year after the date you exercise all or part of the Option or within two years after the Date of Grant. Until such time as you dispose of such shares in a manner consistent with the provisions of this Agreement, unless otherwise expressly
authorized by the Company, you must hold all shares acquired pursuant to the Option in your name (and not in the name of any nominee) for the one-year period immediately after the exercise of the Option and the two-year period immediately after the
Date of Grant. At any time during the one-year or two-year periods set forth above, the Company may place a legend on any certificate representing shares acquired pursuant to the Option requesting the transfer agent for the Company’s stock to
notify the Company of any such transfers. Your obligation to notify the Company of any such transfer will continue notwithstanding that a legend has been placed on the certificate pursuant to the preceding sentence. 

17. Right to Terminate Services. Nothing contained in this Agreement shall confer upon you the right to continue in the employ of, or
performing services for, the Company or any Subsidiary, or interfere in any way with the rights of the Company or any Subsidiary to terminate your employment or service relationship at any time. 

18. Furnish Information. You agree to furnish to the Company all information requested by the Company to enable it to comply with any
reporting or other requirement imposed upon the Company by or under any applicable statute or regulation. 
 19. Remedies. The
Company shall be entitled to recover from you reasonable attorneys’ fees incurred in connection with the enforcement of the terms and provisions of this Agreement whether by an action to enforce specific performance or for damages for its
breach or otherwise. 
 20. No Liability for Good Faith Determinations. The Company and the members of the Committee and the Board
shall not be liable for any act, omission or determination taken or made in good faith with respect to this Agreement or the Option granted hereunder and all members of the Board or the Committee and each and any officer or employee of the Company
acting on their behalf shall, to the extent permitted by law, be fully indemnified and protected by the Company in respect of any such action, determination, or interpretation. 

  
 7 

 21. Execution of Receipts and Releases. Any payment of cash or any issuance or transfer of
shares of Stock or other property to you, or to your legal representative, heir, legatee or distributee, in accordance with the provisions hereof, shall, to the extent thereof, be in full satisfaction of all claims of such persons hereunder. The
Company may require you or your legal representative, heir, legatee or distributee, as a condition precedent to such payment or issuance, to execute a release and receipt therefore in such form as it shall determine. 

22. No Guarantee of Interests. The Board and the Company do not guarantee the Stock of the Company from loss or depreciation. 

23. Company Records. Records of the Company regarding your service and other matters shall be conclusive for all purposes hereunder,
unless determined by the Company to be incorrect. 
 24. Notice. Each notice required or permitted under this Agreement must be in
writing and personally delivered or sent by mail and shall be deemed to be delivered on the date on which such notice is actually received by the person to whom it is properly addressed or if earlier the date sent via certified mail. 

25. Waiver of Notice. Any person entitled to notice hereunder may, by written form, waive such notice. 

26. Successors. This Agreement shall be binding upon you, your legal representatives, heirs, legatees and distributees, and upon the
Company, its successors and assigns. 
 27. Severability. If any provision of this Agreement is held to be illegal or invalid for any
reason, the illegality or invalidity shall not affect the remaining provisions hereof, but such provision shall be fully severable and this Agreement shall be construed and enforced as if the illegal or invalid provision had never been included
herein. 
 28. Company Action. Any action required of the Company shall be by resolution of the Board or by a person authorized to
act by resolution of the Board. 
 29. Headings. The titles and headings of Sections are included for convenience of reference only
and are not to be considered in construction of the provisions hereof. 
 30. Governing Law. All questions arising with respect to
the provisions of this Agreement shall be determined by application of the laws of Delaware, without giving any effect to any conflict of law provisions thereof, except to the extent Delaware state law is preempted by federal law. The obligation of
the Company to sell and deliver Stock hereunder is subject to applicable laws and to the approval of any governmental authority required in connection with the authorization, issuance, sale, or delivery of such Stock. 

31. Consent to Texas Jurisdiction and Venue. You hereby consent and agree that state courts located in Dallas County, Texas and the
United States District Court for the Northern District of Texas each shall have personal jurisdiction and proper venue with respect to any dispute between you and the Company arising in connection with the Option or this Agreement. In any dispute
with the Company, you will not raise, and you hereby expressly waive, any objection or defense to any such jurisdiction as an inconvenient forum. 

  
 8 

 32. Word Usage. Words used in the masculine shall apply to the feminine where applicable,
and wherever the context of this Agreement dictates, the plural shall be read as the singular and the singular as the plural. 
 33. No
Assignment. You may not assign this Agreement or any of your rights under this Agreement without the Company’s prior written consent, and any purported or attempted assignment without such prior written consent shall be void. 

34. Clawback. This Agreement and your Award is subject to any written clawback policies of the Company, whether in effect on the Date
of Grant or adopted, with the approval of the Board, following the Date of Grant. Any such policy may subject your Option and amounts paid or realized with respect to your Option to reduction, cancelation, forfeiture or recoupment if certain
specified events or wrongful conduct occur, including but not limited to an accounting restatement due to the Company’s material noncompliance with financial reporting regulations or other events or wrongful conduct specified in any such
clawback policy adopted to conform to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 and rules promulgated thereunder by the Securities and Exchange Commission and that the Company determines should apply to this Option. 

35. Miscellaneous. 
 (a)
This Agreement and the Notice of Grant are subject to all the terms, conditions, limitations and restrictions contained in the Plan. In the event of any conflict or inconsistency between any terms and conditions of this Agreement, the Notice of
Grant, and the terms and provisions of an employment agreement, consulting agreement, severance or change in control agreement, if any, between you and the Company or any Subsidiary or other Affiliate (the “Employment
Agreement”), the terms and conditions of the Employment Agreement shall be controlling. Taking into account the provisions of Section 6(a) of the Plan, if there is any conflict or inconsistency between the Plan and the Notice of
Grant, this Agreement, or the Employment Agreement, then you acknowledge and agree that those terms of the Plan shall control and, if necessary, the applicable terms of the Notice of Grant, this Agreement, or the Employment Agreement shall be deemed
amended so as to carry out the purpose and intent of the Plan. 
 (b) This Agreement and the Notice of Grant may be amended the Board or by
the Committee at any time (a) without your consent, so long as the amendment does not materially and adversely affect your rights under the Option, or (b) with your consent. For purposes of clarity, any adjustment made to the Award
pursuant to Sections 8(b) through 8(h) of the Plan will be deemed not to materially and adversely affect your rights under this Award. 

(c) If this Option is intended to be an incentive stock option designed pursuant to section 422 of the Code, then in the event the Option
Shares (and all other options designed pursuant to section 422 of the Code granted to you by the Company or any parent of the Company or Subsidiary) that first become exercisable in any calendar year have an aggregate fair market value (determined
for each Option Share as of the Date of Grant) that exceeds $100,000, the Option Shares in excess of $100,000 shall be treated as subject to a Nonstatutory Stock Option. 

  
 9 

 [Remainder of page intentionally left blank] 

  
 10EX-10.3

 Exhibit 10.3 

EMPLOYMENT AGREEMENT 

by and between 
 Reata
Pharmaceuticals, Inc. 
 and 

J. Warren Huff 
 THIS
EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into as of the 23rd day of September of 2015, by and between Reata Pharmaceuticals, Inc., a Delaware corporation (together with its successors and assigns permitted
hereunder, the “Company”), and J. Warren Huff (the “Executive”). 
 The Board of Directors of the Company
(the “Board”) has determined that it is in the best interests of the Company and its stockholders to assure that the Company will continue to enjoy the services of the Executive, and in order to accomplish this objective, the Board
has caused the Company to enter into this Agreement. 
 NOW, THEREFORE, IT IS HEREBY AGREED AS FOLLOWS: 

1. Employment Period. Subject to earlier termination pursuant to Section 3, the Company hereby agrees to employ the
Executive, and the Executive hereby agrees to be employed by the Company, in accordance with the terms and provisions of this Agreement, for the period commencing on the date of this Agreement (the “Effective Date”) and ending at
the close of business on September 22, 2019 (the “Employment Period”). Thereafter, such term of employment shall be extended automatically for successive one-year periods (such extended term, the “Additional Employment
Period”) unless the Company or Executive provides the other with written notice no less than 30 days prior to the date the Employment Period or the Additional Employment Period, as applicable, would otherwise end either (i) declining
to extend such term of employment, or (ii) requesting that the terms of this Agreement are renegotiated prior to the Agreement’s renewal. If the parties fail to enter into the renegotiation process within 30 days of receipt of such notice,
this Agreement will be extended automatically as if such notice was not given. 
 2. Terms of Employment. 

(a) Position and Duties. 

(i) During the Employment Period, or any Additional Employment Period, the Executive shall serve as the Chief Executive Officer
of the Company and as a President of the Company and, in so doing, shall report to the Board. The Executive shall have supervision and control over, and responsibility for, such management and operational functions of the Company currently assigned
to such positions, and shall have such other powers and duties (including holding officer positions with one or more subsidiaries of the Company) as may from time to time be prescribed by the Board, so long as such powers and duties are reasonable
and customary for the Chief Executive Officer or President of an enterprise comparable to the Company. 
 (ii) During the
Employment Period, or any Additional Employment Period, and excluding any periods of vacation and sick leave to which the Executive is 

 
entitled, the Executive agrees to devote full business time to the business and affairs of the Company and, to the extent necessary to discharge the responsibilities assigned to the Executive
hereunder, to use the Executive’s reasonable best efforts to perform faithfully and efficiently such responsibilities. During the Employment Period, or any Additional Employment Period, it shall not be a violation of this Agreement for the
Executive to (A) serve on corporate, civic or charitable boards or committees, (B) deliver lectures, fulfill speaking engagements or teach at educational institutions, or (C) manage personal investments, so long as such activities do
not significantly interfere with the performance of the Executive’s responsibilities as an employee of the Company in accordance with this Agreement. 

(b) Compensation. 

(i) Base Salary. During the Employment Period, or any Additional Employment Period, the Executive shall receive an
annual base salary of $450,000 (the “Annual Base Salary”), which shall be paid on a semi-monthly basis in accordance with the customary payroll terms, conditions and practices of the Company. During the Employment Period, or any
Additional Employment Period, the Annual Base Salary may be reviewed and may be increased from time to time in accordance with the compensation practices and guidelines of the Company for its executives. Any increase in Annual Base Salary shall not
serve to limit or reduce any other obligation to the Executive under this Agreement. The term Annual Base Salary as utilized in this Agreement shall refer to the Executive’s Annual Base Salary as so increased. 

(ii) Bonus. In addition to Annual Base Salary, the Executive shall be eligible to receive during the Employment Period,
or any Additional Employment Period, an annual bonus (the “Bonus”), such Bonus to be awarded only upon the Company’s attainment of certain milestones to be determined by the Board (or a committee of the Board). The Bonus, if
any, shall be payable annually to the Executive consistent with the practices for executives of the Company. The Executive’s target bonus (“Target Bonus”) will be 50% of the Executive’s Annual Base Salary. 

(iii) Incentive, Savings and Retirement Plans. During the Employment Period, or any Additional Employment Period, the
Executive shall be entitled to participate in all incentive, savings and retirement plans, practices, policies and programs applicable generally to other executives of the Company (the “Investment Plans”). 

(iv) Welfare Benefit Plans. During the Employment Period, or any Additional Employment Period, the Executive and/or the
Executive’s family, as the case may be, shall be eligible for participation in and shall receive all benefits under welfare benefit plans, practices, policies and programs (the “Welfare Plans”) provided generally to other
executives of the Company. In the event of a Change in Control, for a period of two years following the occurrence of the Change in Control, the Company, or its successor, will continue to provide the Executive and/or the Executive’s family, as
the case may be, benefits that are not materially diminished, taken as a whole, from the benefits provided to the Executive and/or the Executive’s family, as the case may be, under the Welfare Plans in effect immediately prior to the Change in
Control. 

  
 2 

 (v) Expenses. During the Employment Period, or any Additional Employment
Period, the Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by the Executive on behalf of the Company in accordance with the policies, practices and procedures of the Company, which provide an
objectively determinable nondiscretionary definition of the expenses eligible for reimbursement. Notwithstanding any provision of this Agreement to the contrary, (A) the amount of expenses eligible to receive reimbursement during any calendar
year shall not affect the amount of expenses for which the Executive is eligible to receive reimbursement during any other calendar year within the Employment Period, or any Additional Employment Period, (B) the reimbursement of expenses under
this Section 2(b)(v) shall be made on or before the last day of the calendar year following the calendar year in which the expense was incurred and (C) the Executive will not receive a payment or other benefit in lieu of
reimbursement under this Section 2(b)(v). 
 (vi) Vacation and Holidays. During the Employment Period, or
any Additional Employment Period, the Executive shall be entitled to paid vacation and paid holidays in accordance with the plans, policies, programs and practices of the Company for its executives. 

3. Termination of Employment. 

(a) Death or Disability. The Executive’s employment shall terminate automatically upon the Executive’s death during the
Employment Period, or any Additional Employment Period. If a Disability (as defined below) of the Executive has occurred during the Employment Period, or any Additional Employment Period, and subject to Executive’s rights, if any, under the
Family Medical Leave Act, Americans with Disabilities Act or similar local, state or federal law, the Company may give to the Executive written notice of its intention to terminate the Executive’s employment. In such event, the Executive’s
employment with the Company shall terminate effective on the 30th day after receipt of such notice by the Executive (the “Disability Effective Date”), provided, that, within the 30 days after such receipt, the Executive shall
not have returned to full-time performance of the Executive’s duties. For purposes of this Agreement, “Disability” shall mean that the Executive is unable to engage in any substantial gainful activity by reason of any medically
determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than 12 months. 

(b) Cause. The Company may terminate the Executive’s employment during the Employment Period, or any Additional Employment Period,
for Cause or without Cause. For purposes of this Agreement, “Cause” shall mean: 
 (i) commission by the
Executive of an act of fraud upon, or willful misconduct toward, the Company; 
 (ii) a material breach by the Executive of
the noncompetition provisions of Section 5 or of the Employee Confidentiality, Nondisclosure, Intellectual Property and Nonsolicitation Agreement described in Section 6; 

  
 3 

 (iii) the conviction of the Executive of any felony (or a plea of nolo
contendere thereto); or 
 (iv) the Executive’s addiction to alcohol, drugs or any other controlled substance. 

Upon the occurrence of any event described in Section 3(b), the Company may terminate Executive’s employment hereunder for Cause by giving
Executive a Notice of Termination to that effect as provided in Section 3(d) within 30 days after the occurrence of the event giving rise to Cause that specifies the date of Executive’s termination (which may be the date the Notice
of Termination is delivered) and describes in reasonable detail the facts or circumstances giving rise to the Company’s right to terminate Executive’s employment for Cause (and, if applicable, the action required to cure same). If the
effect of the occurrence of the event described in Section 3(b) may be cured, Executive shall have the opportunity to cure any such effect for a period of 30 days following receipt of the Company’s Notice of Termination. If, within
30 days following Executive’s receipt of a Notice of Termination for Cause, (A) Executive delivers written notice to the Company denying that Cause exists, the question of the existence or nonexistence of Cause will be subject to the
dispute resolution procedure set forth in Section 9(f); or (B) Executive has not cured the facts or circumstances giving rise to the Company’s right to terminate Executive’s employment for Cause and shall not have
delivered a notice pursuant to clause (A) herein, then Executive’s termination for Cause shall be effective as of the date specified in the Company’s Notice of Termination (which date may not be earlier than the date the Notice of
Termination is delivered to Executive). If the Company does not give a Notice of Termination to Executive within 30 days after learning of the occurrence of an event giving rise to Cause, then this Agreement will remain in effect, and Executive may
not be terminated for Cause based on the occurrence of the event that gave rise to Cause; provided, however, that the failure of the Company to terminate the Executive’s employment for Cause shall not be deemed a waiver of the Company’s
right to terminate Executive’s employment for Cause upon the occurrence of a subsequent event described in Section 3(b) in accordance with the terms of this Agreement. Notwithstanding the foregoing, the right of the Company to
terminate Executive’s employment for Cause under this Section 3(b) shall not limit Executive’s right to terminate his employment for Good Reason under Section 3(c) if Good Reason is determined to exist prior to the
time Cause is determined to exist. 
 (c) Good Reason. The Executive’s employment may be terminated during the Employment
Period, or any Additional Employment Period, by the Executive for Good Reason or without Good Reason. For purposes of this Agreement, “Good Reason” shall mean, without the express written consent of the Executive, the occurrence of
any of the following: 
 (i) a material diminution in the Executive’s base compensation; 

(ii) a material diminution in the Executive’s authority, duties or responsibilities; provided, however, following a Change
in Control, the Executive’s authority, duties and responsibilities shall be deemed to have been materially diminished (even though his authority, duties and responsibilities have not actually been materially diminished) if, within two years
after the Change in Control, the Executive is required to report to an executive of the parent company of the Company, or its successor, who is not serving as the chief executive officer of such parent company; 

  
 4 

 (iii) the appointment of an officer or employee of the Company or any of its
subsidiaries to serve as Chairman of the Board; 
 (iv) a change in the geographic location at which the Executive must
perform services of more than 50 miles in radius from such location as of the date of this Agreement; or 
 (v) any other
action or inaction that constitutes a material breach by the Company of this Agreement. 
 In the case of the Executive’s allegation of Good Reason,
(A) the Executive shall provide notice to the Company of the event alleged to constitute Good Reason within 90 days after the occurrence of such event (such notice the “Notice of Good Reason,”) and (B) the Company shall
have the opportunity to remedy the alleged Good Reason event within 30 days after receipt of notice of such allegation (the “Cure Period”). If, within the Cure Period, the Company delivers written notice to the Executive denying
that Good Reason exists, the question of the existence or nonexistence of Good Reason will be subject to the dispute resolution procedure set forth in Section 9(f). In the event the Company has not cured the facts or circumstances giving
rise to the Executive’s right to terminate the Executive’s employment for Good Reason during the Cure Period and shall not have delivered a notice pursuant to the preceding sentence, then the Executive’s employment hereunder will be
terminated for Good Reason on the 31st day following the Cure Period. If the Executive does not give a Notice of Good Reason to the Company within 90 days after learning of the occurrence of an
event giving rise to Good Reason, then this Agreement will remain in effect, and Executive may not terminate his employment for Good Reason based on the occurrence of the event that gave rise to Good Reason; provided, however, that the failure of
the Executive to provide a Notice of Good Reason or terminate the Executive’s employment for Good Reason shall not be deemed a waiver of the Executive’s right to terminate the Executive’s employment for Good Reason upon the occurrence
of a subsequent event described in Section 3(c) in accordance with the terms of this Agreement. Notwithstanding anything to the contrary contained herein, any isolated, insubstantial and inadvertent action not taken in bad faith and that
is remedied by the Company promptly after receipt of notice thereof given by the Executive shall not be or constitute Good Reason. 
 (d)
Notice of Termination. Any termination by the Company for Cause or without Cause, or by the Executive for Good Reason or without Good Reason, shall be communicated by a Notice of Termination to the other party hereto. For purposes of this
Agreement, a “Notice of Termination” means a written notice that (i) indicates the specific termination provision in this Agreement relied upon, (ii) to the extent applicable, sets forth in reasonable detail the facts and
circumstances claimed to provide a basis for termination of the Executive’s employment under the provision so indicated, and (iii) other than with respect to a termination by the Executive for Good Reason, if the Date of Termination (as
defined below) is other than the date of receipt of such notice, specifies the termination date (which date, except for a termination of Executive’s employment due to a Disability, shall not be more than 15 days after the giving of such notice
or the date the applicable cure period expires, whichever is later). 

  
 5 

 
The failure by the Executive or the Company to set forth in the Notice of Termination any fact or circumstance which contributes to a showing of Good Reason or Cause shall not waive any right of
the Executive or the Company hereunder or preclude the Executive or the Company from asserting such fact or circumstance in enforcing the Executive’s or the Company’s rights hereunder. 

(e) Date of Termination. “Date of Termination” means (i) if the Executive’s employment is terminated by the
Company for Cause, or by the Executive without Good Reason, the date of receipt of the Notice of Termination or any later date specified therein, (ii) if the Executive’s employment is terminated by the Executive for Good Reason, the 31st day following receipt by the Company of the Notice of Good Reason (provided the Company does not otherwise remedy the alleged Good Reason event within the Cure Period), (iii) if the
Executive’s employment is terminated by the Company without Cause, the date on which the Company notifies the Executive of such termination (unless a later date is specified in the Notice of Termination, in which case the Executive’s
employment will be terminated on such later date), and (iv) if the Executive dies or incurs a Disability, the date of death of the Executive or the Disability Effective Date, as the case may be. If the Executive is a member of the Board, any
continuation of the Executive’s service to the Company as a member of the Board on or after the Executive’s termination of employment shall not result in any deferral of the Date of Termination. 

4. Obligations of the Company upon Termination. 

(a) Termination by the Company for Cause or by the Executive other than for Good Reason. If, during the Employment Period, or any
Additional Employment Period, the Executive’s employment with the Company is terminated by the Company for Cause or by the Executive other than for Good Reason (and not due to death or Disability), the Company shall have no further payment
obligations to the Executive or his legal representatives under this Agreement, other than for: 
 (i) to the extent not
theretofore paid, the sum of (w) the Executive’s Annual Base Salary earned through the Date of Termination, (x) the Bonus for the fiscal year ending immediately prior to the Date of Termination, (y) compensation previously
deferred by the Executive (together with any accrued interest or earnings thereon), and (z) any accrued and unused vacation pay through the Date of Termination (the “Accrued Obligations”), which sum shall be paid within 15 days
following the Date of Termination; and 
 (ii) to the extent not theretofore paid or provided, the Company shall timely pay
or provide to the Executive and/or the Executive’s family any other amounts or benefits required to be paid or provided or which the Executive and/or the Executive’s family is eligible to receive pursuant to this Agreement and under any
plan, program, policy or practice or contract or agreement of the Company (“Other Benefits”). 
 (b) Death or Disability
prior to, or more than two years after, a Change in Control. Upon the Executive’s death or Disability during the Employment Period, or any Additional Employment Period, but prior to the occurrence of a Change in Control or more than

  
 6 

 
two years after the occurrence of a Change in Control, the Company shall have no further payment obligations to the Executive or his legal representatives under this Agreement, other than for
(i) payment of the Accrued Obligations (within 15 days following the Date of Termination) and Other Benefits; (ii) payment of a lump sum cash amount equal to the Executive’s current Annual Base Salary, payable on the next payroll date
immediately following the eighth day following the delivery to the Company of a properly executed Release in accordance with Section 4(f) of this Agreement; (iii) Welfare Benefit Continuation as defined, and pursuant to the terms
and in the manner described, in Section 4(d)(ii) up to the 12 month, rather than the 24 month, anniversary of the Date of Termination; and (iv) subject to Section 4(f), all equity awards granted by the Company to, or
otherwise held by, the Executive shall immediately vest in full and any repurchase provisions (other than fair market value repurchase provisions) shall lapse and may be exercised and/or settled in accordance with the terms of the applicable plan or
award agreement; provided, however, the Executive may elect, and the Company will allow, the payment of the exercise price of any outstanding stock options, and the satisfaction of any required tax withholding with respect to any outstanding stock
option or other equity award, through the withholding of shares otherwise issuable to the Executive pursuant to the stock option or other equity award. 

(c) Certain Terminations more than six months prior to, or more than two years after, a Change in Control by the Company other than for
Cause or by Executive for Good Reason. If, during the Employment Period, or any Additional Employment Period, but more than six months prior to, or more than two years after, the occurrence of a Change in Control, the Executive’s employment
with the Company is terminated by the Company for any reason other than for Cause (and not due to death or Disability) or by the Executive for Good Reason, the Executive will be entitled to (i) the Accrued Obligations and Other Benefits,
payable in accordance with Section 4(a)(i) and (ii); (ii) subject to Sections 4(f) and (h), a lump sum cash amount equal to the Executive’s then current Annual Base Salary, payable on the next payroll date
immediately following the eighth day following the Executive’s delivery to the Company of a properly executed Release in accordance with Section 4(f) of this Agreement; and (iii) Welfare Benefit Continuation as defined, and
pursuant to the terms and in the manner described, in Section 4(d)(ii) up to the 12 month, rather than the 24 month, anniversary of the Date of Termination; and (iv) subject to Section 4(f), all equity awards granted by
the Company to, or otherwise held by the Executive shall immediately vest in full and any repurchase provisions (other than fair market value repurchase provisions) shall lapse and may be exercised and/or settled in accordance with the applicable
plan or award agreement; provided, however, the Executive may elect, and the Company will allow, the payment of the exercise price of any outstanding vested stock options, and the satisfaction of any required tax withholding with respect to any
vested outstanding stock option or other equity award, through the withholding of shares otherwise issuable to the Executive pursuant to the stock option or other equity award. 

(d) Certain Terminations within six months prior to, or within two years following, a Change in Control. In the event that the
Executive’s employment is terminated by the Company for any reason other than Cause or by the Executive for Good Reason or the Executive dies or incurs a Disability, in each case, during the Employment Period, or any Additional Employment
Period, and such termination occurs within six months prior to (excluding death or Disability), or within two years after, a Change in Control, the following 

  
 7 

 
provisions shall apply and Sections 4(b) and (c) shall not be applicable until Section 4(d) is no longer applicable: 

(i) The Company shall pay to the Executive (A) the Accrued Obligations within 15 days following the Date of Termination,
and (B) subject to Sections 4(f) and 4(h), a lump sum cash amount equal to two times the Executive’s then current Annual Base Salary, such sum to be paid on the next payroll date immediately following the eighth day following
the Executive’s delivery to the Company of a properly executed Release in accordance with Section 4(f) of this Agreement. 

(ii) Until the earlier to occur of (A) the 24 month anniversary of the Date of Termination or (B) the
Executive’s acceptance of full-time employment with another entity, the Company shall continue benefits provided under Welfare Plans to the Executive and/or the Executive’s family at least equal to those that would have been provided to
them if the Executive’s employment had not been terminated (“Welfare Benefit Continuation”) pursuant to an in-kind benefit arrangement that satisfies the requirements of Treasury Regulation § 1.409A-3(i)(1)(iv)(A),
and the Company-provided costs of such Welfare Benefit Continuation will be imputed as income to the Executive and reported on Form W-2; provided, that in the event the Company is unable to provide the Welfare Benefit Continuation under its
Welfare Plans or to the extent such Welfare Benefit Continuation would subject the Company to negative tax consequences, the Company will reimburse the Executive for amounts necessary to enable the Executive to obtain similar benefits, and any such
reimbursement will be made in accordance with the provisions of Treasury Regulation § 1.409A-3(i)(1)(iv). Such Welfare Benefit Continuation provided in this Section 4(d)(ii) is in addition to any rights Executive may have to
continue such coverages under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”). The COBRA continuation period shall begin on the day following the end of the Welfare Benefit Continuation period
provided in this Section 4(d)(ii). 
 (iii) Subject to Section 4(f), notwithstanding the provisions
of any applicable plan or agreement, all equity awards granted by the Company to, or otherwise held by, the Executive shall immediately vest in full and any repurchase provisions (other than fair market value repurchase provisions) will lapse and
such awards may be exercised and/or settled in accordance with the terms of the applicable plan or award agreement; provided, however, the Executive may elect, and the Company will allow, the exercise of any outstanding stock options, and the
satisfaction of any required tax withholding with respect to any outstanding stock option or other equity award, through the withholding of shares otherwise issuable to the Executive pursuant to the stock option or other equity award. 

(iv) To the extent not theretofore paid or provided, the Company shall timely pay or provide to the Executive and/or the
Executive’s family the Other Benefits. 
 (v) If the Executive’s employment is terminated within six months prior
to a Change in Control and the provisions of Section 4(d) apply, but the provisions of Section 4(b) or 4(c) were initially applied, then, subject to Section 4(f), upon the

  
 8 

 
Change in Control, the Company shall pay, no later than the first payroll date following such Change in Control, additional payments and provide additional benefits in order to provide the
Executive the payments and benefits as set forth in Section 4(d). The post employment exercise period for stock options under the Equity Documents shall be measured from the date of the Change in Control. 

In addition, upon a Change in Control, whether or not the Executive’s employment with the Company (or its successor) ceases for any
reason upon or following a Change in Control or continues following the Change in Control, notwithstanding any other provision of this Agreement or the provisions of any applicable plan or agreement, all equity awards granted by the Company to, or
otherwise held by, the Executive shall immediately vest in full and any repurchase provisions (other than fair market value repurchase provisions) will lapse and such awards may be exercised and/or settled in accordance with the terms of the
applicable plan or award agreement; provided, however, the Executive may elect, and the Company will allow, the exercise of any outstanding stock options, and the satisfaction of any required tax withholding with respect to any outstanding stock
option or other equity award, through the withholding of shares otherwise issuable to the Executive pursuant to the stock option or other equity awards. The parties hereto agree that in the event of any conflict or inconsistency between this
Agreement and the terms of any equity award agreement, this Agreement shall govern and shall supersede the terms of the equity award agreement. 

(e) For purposes of this Agreement, “Change in Control” means the occurrence of any of the following events: 

(i) The Company is not the surviving entity in any merger or consolidation (or survives only as a subsidiary of an entity other
than a previously wholly owned subsidiary of the Company) and as a result of such merger or consolidation, stockholders of the Company immediately prior to such merger cease to own more than 50% of the outstanding capital stock of the surviving
corporation determined on a fully diluted basis; 
 (ii) The Company sells, leases, or exchanges or agrees to sell, lease, or
exchange more than 50% of its assets to any other person or entity (other than a wholly owned subsidiary of the Company); 

(iii) The Company is to be dissolved and liquidated (in a dissolution taxed under Section 331 of the Internal Revenue Code
of 1986, as amended (the “Code”)); 
 (iv) Any person or entity, including a “group” as
contemplated by Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, acquires or gains ownership or control (including, without limitation, power to vote), directly , by merger or otherwise, of more than 50% of the outstanding
shares of the Company’s voting stock (based upon voting power) and as a result of such acquisition, the stockholders holding a majority of the capital stock of the Company receive cash or marketable securities for their shares of capital stock;
or 

  
 9 

 (v) As a result of or in connection with a contested election of directors, the
persons who were directors before such election will cease to constitute a majority of the Board. 
 Notwithstanding the foregoing definition of Change in
Control (other than clause (iii) of such definition), a Change in Control shall only be deemed to occur upon a “change in the ownership or effective control of the Company, or in the ownership of a substantial portion of the assets of the
Company” under Section 409A of the Code. 
 (f) Release. Notwithstanding any other provision in this Agreement to the
contrary, in consideration for receiving the accelerated vesting described in Sections 4(b), 4(c) or 4(d) and the payments described in Section 4(b)(ii), Section 4(c)(ii) or Section 4(d)(i)(B), the
Executive hereby agrees to execute (and not revoke) a release agreement in the form attached hereto as Exhibit A (the “Release”) within 60 days of the Date of Termination. If the Executive fails to properly execute and
timely deliver the Release (or revokes the Release), the Executive agrees that the Executive shall not be entitled to receive the accelerated vesting described in Sections 4(b), 4(c) or 4(d) and the payments described in
Section 4(b)(ii), Section 4(c)(ii) or Section 4(d)(i)(B). For purposes of this Agreement, the Release shall be considered to have been executed by the Executive if it is signed by the Executive’s legal
representative (in the case of the Executive’s incapacity due to physical or mental illness) or on behalf of the Executive’s estate (in the case of the Executive’s death). 

(g) Gross-Up for Certain Taxes. In the event that it is determined that any payment (other than the Gross-Up payment provided for in
this Section 4(g)) or distribution by the Company (or any of its Affiliates) to or for the benefit of Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise pursuant to or
by reason of any other agreement, policy, plan, program or arrangement, including without limitation any stock option or similar right, or the lapse or termination of any restriction on or the vesting or exercisability of any of the foregoing (a
“Payment”), would be subject to the excise tax imposed by Section 4999 of the Code (or any successor provision thereto) by reason of being considered “contingent on a change in ownership or control” of the Company,
within the meaning of Section 280G of the Code or any successor provision thereto (such tax being hereafter referred to as the “Excise Tax”), then the Executive will be entitled to receive an additional payment or payments (a
“Gross-Up Payment”). The Gross-Up Payment will be in an amount such that, after payment by the Executive of all taxes, penalties and interest, including any Excise Tax imposed upon the Gross-Up Payment, the Executive retains an
amount of the Gross-Up Payment equal to the Excise Tax imposed upon the Payment. For purposes of determining the amount of the Gross-Up Payment, the Executive will be considered to pay (A) federal income taxes at the highest rate in effect in
the year in which the Gross-Up Payment will be made and (B) state and local income taxes at the highest rate in effect in the state or locality in which the Gross-Up Payment would be subject to state or local tax, net of the maximum reduction
in federal income tax that could be obtained from deduction of such state and local taxes. The determination of whether an Excise Tax would be imposed, the amount of such Excise Tax, and the calculation of the amounts referred to in this
Section 4(g) will be made at the expense of the Company by the Company’s regular independent accounting firm (the “Accounting Firm”), which shall provide detailed supporting calculations. Any determination by the
Accounting Firm will be binding upon the Company and the Executive. The Gross-Up 

  
 10 

 
Payment will be paid to the Executive as soon as administratively practicable following the later of (i) the date Executive is required to pay the excise tax imposed by Section 4999 of
the Code, or (ii) in the event the Executive is determined, in accordance with the methods specified in the regulations issued under Section 409A of the Code, to be a “specified employee” (within the meaning of
Section 409A(a)(2)(B)(i) of the Code) of the Company at the time of the Executive’s “separation from service” (within the meaning of Section 409A(a)(2)(A)(i) of the Code and the applicable regulations and administrative
guidance issued thereunder), the first day of the seventh month after the date of the Executive’s “separation from service” or, if earlier, the date of death of Executive. In the event that the Excise Tax is later determined by the
Accounting Firm or pursuant to any proceeding or negotiations with the Internal Revenue Service to exceed the Gross-Up Payment at the time the payment is made under this Section 4(g) (including, but not limited to, by reason of any
payment the existence or amount of which cannot be determined at the time of such payment), the Company shall make an additional payment in respect of such excess (plus any interest or penalty payable with respect to such excess) at the time that
the amount of such excess is finally determined. In the event that the Excise Tax is subsequently determined by the Accounting Firm or pursuant to any proceeding or negotiations with the Internal Revenue Service to be less than the Gross-Up Payment
at the time payment is made under this Section 4(g), the Executive shall repay to the Company, at the time that the amount of such reduction in the Excise Tax is finally determined, the portion of such prior payment that would not have
been paid if such Excise Tax had been applied in initially calculating such payment, plus interest on the amount of such repayment at the rate provided in section 1274(b)(2)(B) of the Code. Notwithstanding the foregoing, in the event that any
portion of the payment made hereunder that is to be refunded to the Company has been paid to any Federal, state or local tax authority, repayment thereof shall not be required until actual refund or credit of such portion has been made to the
Executive, and interest payable to the Company shall not exceed interest received or credited to the Executive by such tax authority for the period it held such portion. The Gross-Up Payment will be made in a manner that complies with Treasury
Regulation § 1.409A-3(i)(1)(v). 
 (h) Specified Employee Provisions. For purposes of determining the time of payment of any
severance payable pursuant to Section 4(b)(ii), Section 4(c)(ii) and Section 4(d)(i)(B), and the timely return of the Release in accordance with Section 4(f), the Date of Termination shall be the date
that the Executive incurs a “separation from service” within the meaning of Treasury Regulation § 1.409A-1(h). To the extent the Executive’s “separation from service” is within the 60 day period ending on
December 31 of any calendar year, the severance payable pursuant to Section 4(b)(ii), Section 4(c)(ii) and Section 4(d)(i)(B) will be paid no earlier than the first business day of the following calendar
year. In the event the Executive is determined, in accordance with the methods specified in the regulations issued under Section 409A of the Code, to be a “specified employee” (within the meaning of Section 409A(a)(2)(B)(i) of
the Code) of the Company at the time of the Executive’s “separation from service” (within the meaning of Section 409A(a)(2)(A)(i) of the Code and the applicable regulations and administrative guidance issued thereunder) then,
in-lieu of providing Welfare Benefit Continuation pursuant to this Section 4 with respect to benefits that would not constitute medical expenses deductible under section 213 of the Code (disregarding the requirement of section 213(a) of
the Code that the deduction is available only to the extent that such expenses exceed 7.5 percent of adjusted gross income) (“Non-Medical Continuation Benefits”), during the six month period following Executive’s
“separation from service,” the Company shall pay to the 

  
 11 

 
Executive an amount equal to the Company-provided costs of such Non-Medical Continuation Benefits in a single lump sum payment on the first day of the seventh month following the Executive’s
“separation from service.” Nothing in this Section 4(h) will impact the obligation of the Company to provide Welfare Benefit Continuation as provided in this Section 4 with respect to Welfare Benefits other than
Non-Medical Continuation Benefits or to provide Non-Medical Continuation Benefits following the six month period following Executive’s “separation from service.” This Section 4(h) will have no effect with respect to
benefits payable pursuant to this Agreement due to the Executive’s Disability. 
 5. Restrictive Covenants. 

(a) Confidential Information; Assignment of Rights to Intellectual Property. 

(i) The Executive hereby recognizes and acknowledges that the business of the Company and its Affiliates is highly competitive
and that certain information related to their business, including, without limitation, their plans, strategies, research and development, testing methods, clinical trial results, costs, prices, business methods, customer names and needs, prospect
names and needs, names of referral sources, identity of contact persons, marketing plans, reports, manuals, methods, costing procedures, information relating to the services provided, developed, used or in the process of development, their services,
customer-related lists and other customer information, formatting and programming concepts and plans, computer programs, simulations, data bases, pricing policies, financial information, methods of doing business, policy and/or procedure manuals,
training and recruiting procedures, accounting procedures, the status and content of their contracts with their customers, the identity and performance of their employees, their business philosophy, and servicing methods and techniques at any time
used, developed, or investigated by them, which are not generally known by or available to the public or which are maintained as confidential by them, comprises confidential or proprietary business information that is a valuable, special, and unique
asset of the Company and its Affiliates, that such confidential or proprietary information has been developed through their expenditure of substantial time and money, and that all such confidential or proprietary information could be used by the
Executive and others to compete unfairly with them (all such information is jointly referred to herein as “Confidential Information and Trade Secrets”). The Executive hereby agrees that the Confidential Information and Trade Secrets
shall constitute trade secrets, and further agrees not to use or disclose such information except as required to do so by subpoena or other legal process (after the Company has been given reasonable notice and opportunity to seek relief from such
subpoena or other legal process). The Executive also agrees to maintain in confidence any confidential or proprietary information of third parties that the Executive received during the course of and as a result of the Executive’s employment
with the Company and its Affiliates. No information otherwise in the public domain (other than by an act of the Executive in violation hereof) shall be considered Confidential Information and Trade Secrets. The Executive understands that the
restrictions set forth in this Section 5(a)(i) shall continue to apply following the Executive’s termination of employment with the Company, regardless of the reason for such termination. 

  
 12 

 (ii) All documents, records, tapes and other media of every kind and description
relating to the business, present or otherwise, of the Company and any copies, in whole or in part, thereof (“Documents”), whether or not prepared by the Executive, shall be the sole and exclusive property of the Company. The
Executive shall safeguard all Documents and shall surrender to the Company all Documents in Executive’s possession or control at the time Executive’s employment terminates, or at such earlier time or times as the Company may specify. 

(iii) The Executive shall promptly and fully disclose all Intellectual Property to the Company. “Intellectual
Property” means all information, ideas, concepts, improvements, discoveries and inventions, whether patentable or not, and whether or not reduced to practice, that are conceived, developed, made or acquired by the Company, either
individually or jointly with others, and that relate to the past, present or anticipated business of the Company, irrespective of whether the Executive utilized the Company’s time or facilities and irrespective of whether such information,
ideas, concepts, improvements, discoveries and inventions were conceived, developed, discovered or acquired by the Executive on the job, at home or elsewhere. The Executive hereby assigns and agrees to assign to the Company (or as otherwise directed
by the Company) Executive’s full right, title and interest in and to all Intellectual Property. The Executive agrees to execute any and all applications for domestic and foreign patents, copyrights or other proprietary rights (including,
without limitation, the execution and delivery of instruments of further assurance or confirmation) requested by the Company to assign the Intellectual Property to the Company and to permit the Company to enforce any patents, copyrights or other
proprietary rights to the Intellectual Property. The Executive will not charge the Company for time spent in complying with any such obligation to execute. The Executive will, at the Company’s expense, take such other actions as the Company may
reasonably request to so assign or enforce such Intellectual Property. All copyrightable Intellectual Property that Executive created during Executive’s employment is considered “work made for hire.” 

(b) Non-Competition; Non-Solicitation. 

(i) The Company hereby makes a binding promise not conditioned upon continued employment to provide the Executive with
Confidential Information and Trade Secrets above and beyond any Confidential Information and Trade Secrets the Executive may have previously received. In order in part to protect the Confidential Information and Trade Secrets, and as part of the
consideration for the payments described in Section 4 of this Agreement, the Company and the Executive agree to the provisions of this Section 5(b). As a part of the employment relationship, the Executive learned of and the
Company disclosed to the Executive Confidential Information and Trade Secrets. Accordingly, the Executive hereby agrees that, for one year after the Executive ceases to provide services to the Company, the Executive will not: 

A. directly or indirectly, individually or as an officer, director, employee, stockholder, consultant, contractor, partner,
joint venturer, agent, equity owner or in any capacity whatsoever, (1) engage in any Competing Business (as hereinafter defined) or (2) divert or take away any customers of the 

  
 13 

 
Company or its Affiliates. Notwithstanding the foregoing, the Company agrees that the Executive may own less than five percent of the outstanding voting securities of any publicly traded company
that is a Competing Business so long as the Executive does not otherwise participate in such Competing Business in any way prohibited by the preceding clause; 

B. use Executive’s access to, knowledge of, or application of Confidential Information and Trade Secrets to perform any
duty for any Competing Business; it being understood and agreed to that this Section 5(b)(i)(B) shall be in addition to and not be construed as a limitation upon the covenants in Section 5(a); 

C. directly or indirectly, for Executive or for others, recruit, solicit or induce any employee of the Company or its
Affiliates to terminate his or her employment with the Company or its Affiliates, or hire or assist in the hiring of any such employee by a Person not affiliated with the Company or its Affiliates; or 

D. induce or attempt to induce any customer, client, supplier, service provider, researcher, scientist or other business
relation of the Company or its Affiliates to cease doing business with the Company or its Affiliates, or in any way interfere with the relationship between the Company and any such Person. 

(ii) The restrictions in this Section 5(b) shall be in addition to any restrictions imposed upon the Executive by
statute or at common law. 
 (iii) “Competing Business” means any business that researches, develops,
manufactures, markets, licenses or sells (A) antioxidant inflammation modulators that target Keap 1 and activate Nrf2 or have similar mechanisms of action or (B) any other product, compound, or agent having the same or similar mechanisms
of action as any product, compound or agent that is being actively developed, manufactured, marketed, licensed or sold by the Company at the Date of Termination. 

(iv) “Affiliate” means, with respect to the Company or any other specified Person, any other Person directly
or indirectly controlling, controlled by or under common control with the Company or such other specified Person, where control may be by management authority, equity interest or other means. 

(v) “Person” means any person or entity of any nature whatsoever, specifically including an individual, a
firm, a company, a corporation, a partnership, a limited liability company, a trust or other entity. 
 (c) Scope of Prohibited
Activities. The parties hereby acknowledge that the restrictions in this Section 5 have been specifically negotiated and agreed to by the parties hereto and are limited only to those restrictions necessary to protect the Company from
unfair competition and to protect the Confidential Information and Trade Secrets and the business and goodwill of the Company and its Affiliates. The parties hereby agree that if the scope or enforceability of any provision, paragraph or
subparagraph of this Section 5 is in any way 

  
 14 

 
disputed at any time, and should a court find that such restrictions are overly broad, the court may modify and enforce the covenant to the extent that it believes to be reasonable under the
circumstances. Each provision, paragraph and subparagraph of the Section 5 is separable from every other provision, paragraph, and subparagraph and constitutes a separate and distinct covenant. Nevertheless, the Executive agrees that the
enforcement of the restrictions in this Section 5 would not cause the Executive any undue hardship or unreasonably interfere with Executive’s ability to earn a livelihood. 

(d) Non-Disparagement. The Executive and the Company each agree to refrain from engaging in any conduct, or from making any comments or
statements, which have the purpose or effect of harming the Executive’s reputation or goodwill, on the one hand, or the reputation or goodwill of the Company or any of its Affiliates, employees, directors or stockholders, on the other hand.

 6. Full Settlement. The Company’s obligation to make the payments provided for in this Agreement and otherwise to perform its
obligations hereunder shall not be affected by any set-off, counterclaim, recoupment, defense or other claim, right or action which the Company may have against the Executive or others. In no event shall the Executive be obligated to seek other
employment or take any other action by way of mitigation of the amounts payable to the Executive under any of the provisions of this Agreement. Neither the Executive nor the Company shall be liable to the other party for any damages in addition to
the amounts payable under Section 4 hereof arising out of the termination of the Executive’s employment prior to the end of the Employment Period, or any Additional Employment Period; provided, however, that the
Company shall be entitled to seek damages for any breach of the noncompetition provisions of Section 5 hereof or of the Employee Confidentiality, Nondisclosure, Intellectual Property and Nonsolicitation Agreement, dated
September 27, 2002, by and between the Executive and the Company. 
 7. Successors. 

(a) This Agreement is personal to the Executive and, without the prior written consent of the Company, shall not be assignable by the Executive
otherwise than by will or the laws of descent and distribution. This Agreement shall inure to the benefit of and be enforceable by the Executive’s legal representatives. 

(b) This Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns. 

(c) The Company will require any successor (whether direct or indirect, by purchase, merger, consolidation, pursuant to a Change in Control or
otherwise) to all or substantially all of the business and/or assets of the Company to assume expressly and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such
succession had taken place. As used in this Agreement, “Company” shall mean the Company as hereinbefore defined and any successor to its business and/or assets as aforesaid which assumes and agrees to perform this Agreement by
operation of law, or otherwise. 

  
 15 

 8. Effect of Agreement on Other Benefits. The existence of this Agreement shall not
prohibit or restrict the Executive’s entitlement to full participation in the executive compensation, executive benefit and other plans or programs in which executives of the Company are eligible to participate. 

9. Miscellaneous. 
 (a)
This Agreement shall be governed by and construed in accordance with the laws of the State of Texas, without reference to principles of conflict of laws. The captions of this Agreement are not part of the provisions hereof and shall have no force or
effect. This Agreement may not be amended or modified otherwise than by a written agreement executed by the parties hereto or their respective successors and legal representatives. 

(b) All notices and other communications hereunder shall be in writing and shall be given by hand delivery to the other party or sent by
registered or certified mail, return receipt requested, postage prepaid, addressed as follows: 
  

			
	If to the Executive:	  	J. Warren Huff
		  	4506 Watauga Road
		  	Dallas, Texas 75209
		
	If to the Company:	  	Reata Pharmaceuticals, Inc.
		  	2801 Gateway Drive, Suite 150
		  	Irving, Texas 75063
		  	Attention: Chief Financial Officer

 or to such other address as either party shall have furnished to the other in writing in accordance herewith. Notice and
communications shall be effective when actually received by the addressee. 
 (c) If any provision of this Agreement is held to be illegal,
invalid or unenforceable under present or future laws effective during the term of this Agreement, such provision shall be fully severable; this Agreement shall be construed and enforced as if such illegal, invalid or unenforceable provision had
never comprised a portion of this Agreement; and the remaining provisions of this Agreement shall remain in full force and effect and shall not be affected by the illegal, invalid or unenforceable provision or by its severance from this Agreement.
Furthermore, in lieu of such illegal, invalid or unenforceable provision there shall be added automatically as part of this Agreement a provision as similar in terms to such illegal, invalid or unenforceable provision as may be possible and be
legal, valid and enforceable. 
 (d) The Company may withhold from any amounts payable under this Agreement such Federal, state or local
taxes as shall be required to be withheld pursuant to any applicable law or regulation. 
 (e) The Executive’s or the Company’s
failure to insist upon strict compliance with any provision of this Agreement or the failure to assert any right the Executive or the Company may have hereunder, including, without limitation, the right of the Executive to terminate employment for
Good Reason, shall not be deemed to be a waiver of such provision or right or of any other provision or right of this Agreement. 

  
 16 

 (f) If any dispute arises out of this Agreement, the “complaining party” shall give the
“other party” written notice of such dispute. The other party shall have 10 business days to resolve the dispute to the complaining party’s satisfaction. If the dispute is not resolved by the end of such period, either disputing party
may require the other to submit to non-binding mediation with the assistance of a neutral, unaffiliated mediator. If the parties encounter difficulty in agreeing upon a neutral unaffiliated mediator, they shall seek the assistance of the American
Arbitration Association in the selection process. If mediation is unsuccessful or if mediation has not commenced, in either case within 30 days after the other party received the notice of dispute, the complaining party may by written notice (the
“Notice”) demand arbitration of the dispute as set out below, and each party hereto expressly agrees to submit to, and be bound by, such arbitration. 

(i) Each party will, within 10 business days of the Notice, nominate an arbitrator, who shall be a non-neutral arbitrator. Each
nominated arbitrator must be someone experienced in dispute resolution and of good character without moral turpitude and not within the employ or direct or indirect influence of the nominating party. The two nominated arbitrators will, within 10
business days of nomination, agree upon a third arbitrator, who shall be neutral. If the two appointed arbitrators cannot agree on a third arbitrator within such period, the parties may seek such an appointment through any permitted court proceeding
or by the American Arbitration Association (“AAA”). The three arbitrators will set the rules and timing of the arbitration, but will generally follow the rules of the AAA and this Agreement where same are applicable and shall
provide for a reasoned opinion. 
 (ii) The arbitration hearing will in no event take place more than 180 days after the
appointment of the third arbitrator. 
 (iii) The mediation and the arbitration will take place in Irving, Texas unless
otherwise unanimously agreed to by the parties. 
 (iv) The results of the arbitration and the decision of the arbitrators
will be final and binding on the parties and each party agrees and acknowledges that these results shall be enforceable in a court of law. 

(v) All costs and expenses of the mediation and arbitration shall be born equally by the Company and the Executive. The
Arbitrator shall award the prevailing party its reasonable attorneys fees incurred in connection with the dispute. 
 (g) The Company and
the Executive hereby agree that Sections 4, 5, 6, 7, 8 and 9, shall survive the expiration of the Employment Period, and any Additional Employment Period, in accordance with their terms. 

(h) The parties hereto intend that any amounts payable hereunder comply with or are exempt from Section 409A of the Code
(“Section 409A”) (including under Treasury Regulation §§ 1.409A-1(b)(4) (“short-term deferrals”) and (b)(9) (“separation pay plans,” 

  
 17 

 
including the exceptions under subparagraph (iii) and subparagraph (v)(D)) and other applicable provisions of Treasury Regulation §§ 1.409A-1 through A-6). For purposes
of Section 409A, each of the payments that may be made under this Agreement shall be deemed to be a separate payment for purposes of Section 409A. This Agreement shall be administered, interpreted and construed in a manner that does not
result in the imposition of additional taxes, penalties or interest under Section 409A. The Company and the Executive agree to negotiate in good faith to make amendments to the Agreement, as the parties mutually agree are necessary or desirable
to avoid the imposition of taxes, penalties or interest under Section 409A. Neither the Company nor the Executive shall have the right to accelerate or defer the delivery of any such payments or benefits except to the extent specifically
permitted or required by Section 409A. 
 (i) The parties hereto agree that, in the event of any conflict or inconsistency between this
Agreement and the terms of any equity award agreement, this Agreement shall govern and shall supersede the terms of the equity award agreement. The parties hereto agree that, in the event of any conflict or inconsistency between this Agreement and
the plan document governing any equity award, the terms of the plan document shall control and, if necessary, this Agreement shall be deemed amended so as to carry out the purpose and intent of the plan document. In the event of any inconsistency
between any provision of this Agreement and any provision of any employee handbook, personnel manual, program, policy, or arrangement of the Company or any of its Affiliates, or any provision of any agreement, plan, or corporate governance document
of any of them (other than the terms of the plan document governing any equity award), the provisions of this Agreement shall control unless the Executive otherwise agrees in a signed writing that expressly refers to the provision whose control the
Executive is waiving. The Company agrees not to impose any restrictions, enforceable by injunction, on Executive’s post-employment activities, other than those expressly set forth in this Agreement. 

(j) Each party hereto agrees with the other party hereto that it will cooperate with such other party and will execute and deliver, or cause
to be executed and delivered, all such other instruments and documents, and will take such other actions, as such other party may reasonably request from time to time to effectuate the provisions and purpose of this Agreement. 

(k) The provisions of this Agreement constitute the complete understanding and agreement among the parties with respect to the subject matter
hereof. This Agreement supersedes any prior employee agreement between the Company and the Executive. 
 (l) This Agreement may be executed
in two or more counterparts. 
 [SIGNATURE PAGE FOLLOWS] 

  
 18 

 IN WITNESS WHEREOF, the Executive has hereunto set the Executive’s hand and, pursuant to the
authorization from its Board, the Company has caused this Agreement to be executed in its name on its behalf, as of the date first written above. 
  

			
	EXECUTIVE
	
	 /s/ J. Warren Huff

	J. Warren Huff
	
	REATA PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Jason D. Wilson

	Name:	 	Jason D. Wilson
	Title:	 	Chief Financial Officer

  
 S-1 

 EXHIBIT A 

RELEASE 
 This Release
(“Release”) is entered into between you, the undersigned employee, and Reata Pharmaceuticals, Inc., a Delaware corporation (the “Company”), in connection with the Employment Agreement between you and the Company
dated             , 2015 (the “Employment Agreement”). You have      days to consider this Release, which you agree is a reasonable amount of time. In
order to receive the consideration set forth in Section 2 below, you must return this Release to the Company on or before             ,
        . 
 10. Definitions. 

(a) “Released Parties” means the Company and its past, present and future parents, subsidiaries, divisions, successors,
predecessors, employee benefit plans and affiliated or related companies, and also each of the foregoing entities’ past, present and future owners, officers, directors, stockholders, investors, partners, managers, principals, members,
committees, administrators, sponsors, executors, trustees, fiduciaries, employees, agents, assigns, representatives and attorneys, in their personal and representative capacities. Each of the Released Parties is an intended beneficiary of this
Release. 
 (b) “Claims” means all theories of recovery of whatever nature, whether known or unknown, recognized by the law
or equity of any jurisdiction. It includes but is not limited to any and all actions, causes of action, lawsuits, claims, complaints, petitions, charges, demands, liabilities, indebtedness, losses, damages, rights and judgments in which you have had
or may have an interest. It also includes but is not limited to any claim for wages, benefits or other compensation; provided, however that nothing in this Release will affect your entitlement to any of the following, none of which shall be deemed
to be a Claim: (i) benefits pursuant to the terms of any employee benefit plan (as defined in the Employee Retirement Income Security Act of 1974, as amended) sponsored by the Company in which you are a participant; (ii) outstanding equity
compensation awards previously granted to you pursuant to any equity compensation plan sponsored by the Company (the “Equity Plan and Equity Awards”); (iii) to enforce your rights to receive the consideration set forth in
Section 2 below and any other rights under the Employment Agreement; or (iv) indemnification and D&O insurance (as set forth in the Employment Agreement, any other agreement to which you and the Company are a party, or the charter or
bylaws of the Company) (the “Indemnification Rights”). The term Claims also includes but is not limited to claims asserted by you or on your behalf by some other person, entity or government agency. 

11. Consideration. The Company agrees to provide the accelerated vesting described in [Section 4(b)] [Section 4(d)] and to pay
you the consideration set forth in [Section 4(b)(ii)] [Section 4(c)(ii)] [Section 4(d)(i)(B)] of the Employment Agreement. The Company will make the payment(s) to you on the first pay date of the Company occurring at least eight (8) days
following the date you sign this Release (and return it to the Company). You acknowledge that any payment that the Company makes to you under this Release is in addition to anything else of value to which you are entitled and that the Company is not
otherwise obligated to make such payment to you. 

  
 1 

 12. Release of Claims. 

(a) You — on behalf of yourself and your heirs, executors, administrators, legal representatives, successors, beneficiaries, and assigns
— unconditionally release and forever discharge the Released Parties from, and waive, any and all Claims that you have or may have against any of the Released Parties arising from your employment with the Company, the termination thereof, and
any other acts or omissions occurring on or before the date you sign this Release. 
 (b) The release set forth in Paragraph 3(a) includes,
but is not limited to, any and all Claims under (i) the common law (tort, contract or other) of any jurisdiction; (ii) the Rehabilitation Act of 1973, the Age Discrimination in Employment Act of 1967 and the Older Worker’s Benefit
Protection Act of 1990, as amended, the Americans with Disabilities Act, Title VII of the Civil Rights Act of 1964, and any other federal, state and local statutes, ordinances, employee orders and regulations prohibiting discrimination or
retaliation upon the basis of age, race, sex, national original, religion, disability, or other unlawful factor; (iii) the National Labor Relations Act; (iv) the Employee Retirement Income Security Act; (v) the Family and Medical
Leave Act; (vi) the Fair Labor Standards Act; (vii) the Equal Pay Act; (viii) the Worker Adjustment and Retraining Notification Act; and (ix) any other federal, state or local law. 

(c) In furtherance of this Release, you promise not to bring any Claims against any of the Released Parties in or before any court or arbitral
authority. 
 13. Acknowledgment. You acknowledge that, by entering into this Release, the Company does not admit to any
wrongdoing in connection with your employment or termination, and that this Release is intended as a compromise of any Claims you have or may have against the Released Parties. You acknowledge that you continue to be subject to the Employee
Confidentiality, Nondisclosure, Intellectual Property and Nonsolicitation Agreement by and between you and the Company. 
 14. ADEA
Rights. You further acknowledge that: 
 (a) You have been advised that you have the right to seek legal counsel before signing this
Release and you have had adequate opportunity to do so. You warrant that you are executing this Release voluntarily and of your own free will, after having a reasonable period of time to review and deliberate regarding its meaning and effect. 

(b) [You have been provided with, and attached to this Release as Annex A is, a listing of: (i) the job titles and ages of all
employees selected for termination and offered a payment in exchange for entering into an agreement and release; (ii) the ages of all employees in the same job classification or organizational unit who were not selected for termination and not
eligible to receive a payment in exchange for entering into an agreement and release; and (iii) information about coverage, eligibility factors and time limits associated with such terminations and related agreements and releases.] [To be
included as applicable.] 
 (c) You have been given at least [            ]
days to review this Release and you understand that if you do not accept this Release by returning an executed copy to the Company on or before             ,
        , this offer will expire. 

  
 2 

 (d) You have seven (7) days after signing this Release to revoke it. This Release will not
become effective or enforceable until the revocation period has expired. Any notice of revocation of the Release is effective only if received by the Chief Financial Officer, in care of the Company at 2801 Gateway Drive, Suite 150, Irving, Texas,
75063, in writing by the close of business at 5:00 p.m. Central Time on the seventh day after your signing of this Release. If you revoke your acceptance of this Release pursuant to this Section 5(d), the Company will not provide you with any
of the consideration described in Section 2 above and all other terms of this Release will become null and void. 
 15.
Applicable Law. This Release shall be construed and interpreted pursuant to the laws of the State of Texas without regard to its choice of law rules. 

16. Severability. Each part, term, or provision of this Release is severable from the others. Notwithstanding any possible
future finding by a duly constituted authority that a particular part, term, or provision is invalid, void, or unenforceable, this Release has been made with the clear intention that the validity and enforceability of the remaining parts, terms and
provisions shall not be affected thereby. If any part, term, or provision is so found invalid, void or unenforceable, the applicability of any such part, term or provision shall be modified to the minimum extent necessary to make it or its
application valid and enforceable. 
 17. Litigation Assistance and Cooperation. You acknowledge and affirm that you may be a
witness in litigation, arbitrations, government or other administrative proceedings involving the Company of which you have specific knowledge. In connection therewith, you covenant and agree, upon reasonable prior notice and during normal business
hours, to make yourself reasonably available to and otherwise reasonably assist and cooperate with the Company, and with its respective attorneys and advisors in connection with any such litigation, arbitrations, government or other administrative
proceeding; provided, that, in connection with so making yourself available to, assisting or cooperating with such parties (i) the Company shall pay you a mutually agreeable per diem rate, bi-weekly in arrears, (ii) the Company shall bear,
and reimburse you for, all out-of-pocket expenses reasonably incurred by you in connection with such services, and (iii) you shall not be required to devote an amount of time that would materially interfere with your other professional
responsibilities or services provided to any other person or entity. 
 18. Other Agreements. The Company and you acknowledge
and agree that each party has continuing obligations to the other party under the Employment Agreement, the Indemnification Rights, and Equity Plan and Equity Agreements. Accordingly, the Company and you acknowledge and agree that, to the extent
expressly provided in each agreement, the Employment Agreement, Indemnification Rights and Equity Plan and Equity Agreements shall remain in full force and effect in accordance with their respective terms. 

  
 3 

 I ACKNOWLEDGE THAT I HAVE CAREFULLY READ THE FOREGOING AGREEMENT, UNDERSTAND ALL OF ITS TERMS,
UNDERSTAND THAT IT CONTAINS A COMPLETE RELEASE OF ALL KNOWN AND UNKNOWN CLAIMS, AND AM ENTERING INTO IT VOLUNTARILY. 
  

							
	 	 	 	 	  

	 	 	 	 	J. Warren Huff
			
	 	 	 	 	  

		 		 	Date:
				
	Accepted and Agreed:	 		 		 	
			
		 		 	REATA PHARMACEUTICALS, INC.
				
		 		 	By:	 	  

		 		 	Name:	 	  

		 		 	Title:	 	  

				
		 		 	Date:	 	

  
 4 

 ANNEX A 

ATTACHMENT TO SEVERANCE AGREEMENT AND GENERAL RELEASE OF CLAIMS 

The decisional unit was all employees of Reata Pharmaceuticals, Inc. (the “Company”). Employees were selected for termination on the basis of
business necessity. All persons whose employment was selected for termination in conjunction with the current layoffs are eligible to receive a payment in exchange for entering into an agreement and release. 

The following is a listing of employees (by job title and age) in the above-referenced decisional unit who have been selected for termination and offered a
payment in exchange for entering into an agreement and release: 
 [INSERT LIST OF EMPLOYEES] 

The above-selected employees must sign the agreement and release and return it to the Company within the 45-day period prescribed in the agreement and release
if they wish to receive the payment set forth in the agreement and release. For employees receiving this Exhibit, once the agreement is signed, the employee has 7 days to revoke the agreement. 

The following is a listing of employees (by age) in the above-referenced decisional unit who have not been selected for termination and are not eligible for a
payment in exchange for entering into an agreement and release: 
 [INSERT LIST OF EMPLOYEES] 

  
 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}]]